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Chapter 1 
Introduction 
The sympathetic nervous system plays a key role in the regulation of cardiovascular 
homeostasis. Reflex-induced adjustments in sympathetic activity are required to main-
tain arterial blood pressure in several physiological conditions like change of body 
position or exercise [1]. Without rapid constriction of resistance vessels by increments 
in sympathetic nerve activity, upright posture would not be possible for the human 
being. Since the hallmark of primary hypertension is an increased total peripheral 
vascular resistance, it is presumed that increased sympathetic activity contributes to the 
pathogenesis of hypertension. Numerous studies have tried to define the pathogenetic 
role of the sympathetic nervous system in primary hypertension. The activity and 
reactivity of the sympathetic nervous system are very difficult to assess quantitatively 
because of its high variability and its non-uniform outflow to the different organs. 
The sympathetic nervous system 
The sympathetic nervous system consists of nerve networks that entwine blood vessels, 
especially arterioles, throughout the body and that invade organs like heart, viscera and 
endocrine glands. The sympathetic outflow to these effector organs is controlled by the 
central nervous system, whose activity is continuously modulated by information 
received from an array of peripheral sensors. The sensors in the carotid sinus and aortic 
arch are referred to as arterial baroreceptors, whereas the sensors in the atria, ventricles 
and lungs are called cardiopulmonary baroreceptors. Nerve pulses from baroreceptors 
inhibit tonically sympathetic outflow to restrain the blood pressure and heart rate 
between certain values. When the arterial pressure in the carotid sinus or in the aortic 
arch increases, the resulting increase in afferent nerve activity leads to a decrease of 
sympathetic outflow to the heart and blood vessels and an increase in vagal outflow to 
the heart. A decrease in heart rate and cardiac contractility ensue together with dilation 
of the resistance vessels in muscles, kidneys, and splanchnic vascular bed. The decrease 
in cardiac output and peripheral vascular resistance restores the arterial blood pressure 
level. In contrast, a reduction of blood pressure at the site of the arterial baroreceptors 
deactivates the baroreceptors with a subsequent increase of blood pressure to its original 
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level. The cardiopulmonary baroreceptors are activated or deactivated by an increase or 
decrease in intrathoracic blood volume that is sufficient to alter the cardiac filling 
pressures but insufficient to change mean arterial or pulse pressure. This results in 
decreased or increased sympathetic outflow respectively, with ensuing reflex vasodilata-
tion or vasoconstriction of the resistance vessels, thus restoring the cardiac filling 
pressures. Experimental studies concerning the baroreflex commonly employ head-up 
tilt and lower body negative pressure (LBNP). Selective unloading of cardiopulmonary 
baroreceptors can be achieved by application of LBNP at less then -20 mmHg, which 
decreases cardiac filling pressure without detectable changes in arterial blood pressure 
[2]. LBNP exceeding the -20 mmHg decreases arterial blood pressure, resulting in 
combined arterial and cardiopulmonary baroreceptor unloading. Efferent sympathetic 
nerve impulses cause exocytotic release of the neurotransmitter norepinephrine (NE) 
from the prejunctional sympathetic nerve terminals into the neuroeffector junctions of 
arteriolar walls and heart, where it exerts its effect through postjunctional adrenoceptors 
on the effector cells. A small proportion of the released NE spills over into the circulation. 
The adrenal medulla, being specialized sympathetic nervous tissue where NE is meta-
bolized to epinephrine (EPI), releases EPI and NE directly into the circulation [3] 
Measurement of sympathetic activity: plasma catecholamine concentrations 
The plasma concentration of NE is dependent on the rate of its spillover into the 
circulation and on the rate of its clearance from the circulation. When sympathetic nerve 
pulses arrive at the nerve terminal, NE is released from intraneuronal vesicles into the 
synaptic cleft. A substantial proportion of the released NE is inactivated intrasynapti-
cally, mainly by neuronal reuptake. Only a small fraction spills over from the synaptic 
cleft into the venous drainage of the organ. Since in most vascular beds NE spillover 
rate exceeds the clearance rate, there is usually an arteriovenous increment in the plasma 
NE concentration of an organ. The venous plasma NE concentration in a particular 
organ is not only determined by the NE spillover rate in that organ but also by the NE 
concentration of the inflowing arterial blood and by the extraction of NE during passage 
of blood through the organ. Therefore it is not surprising that the antecubital forearm 
venous plasma NE concentration is only a moderately reliable measure of sympathetic 
activity. Actually it merely reflects regional forearm sympathetic activity than global 
sympathetic activity of the entire body. For the latter purpose, arterial sampling is 
preferred over venous sampling [4,5]. 
EPI is directly released into the circulation from the adrenal medulla. The EPI concen-
tration in mixed venous blood reflects sympathetic outflow to the adrenal medulla. The 
antecubital venous plasma EPI concentration is unreliable for the determination of 
sympathetic activity to the adrenal medulla because EPI is subject to extraction in the 
forearm [6]. Changes in the arterial plasma EPI level can be due to alterations in the 
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release of EPI from the adrenal medulla but also from alterations in clearance in several 
vascular beds. 
Measurement of sympathetic activity: catechoUmine kinetic studies 
In order to unravel the contributions of spillover and clearance to the resulting plasma 
catecholamine concentration, kinetic techniques using radiotracers have been devel­
oped. The catecholamine tracer dilution method permits measurement of spillover and 
clearance rates of NE and EPI [7]. Total body as well as regional kinetics of NE and EPI 
in particular vascular beds can be measured. For the assessment of catecholamine 
kinetics, tritiated NE or EPI are infused at a constant rate to achieve steady state 
radiotracer concentrations in plasma. Under steady state conditions, the total body 
catecholamine spillover rate of a catecholamine can be calculated as the quotient of the 
radiotracer infusion rate and specific radioactivity of the catecholamine in plasma. 
Catecholamine clearance rate of a catecholamine from the body can be calculated from 
the quotient of radiotracer infusion rate and the plasma catecholamine radiotracer 
concentration. An important underlying assumption is that a well-mixed central plasma 
pool exists for the endogenous catecholamines and the radiotracers. Another relevant 
assumption is that any rerelease of the radiotracer from sympathetic nerves is negligible 
in comparison to the radiotracer infusion rate. 
Total body spillover of EPI provides an estimation of adrenal medullary sympathetic 
activity or more specifically of the adrenomedullary EPI secretion. Total body NE 
spillover rate provides a measure of overall sympathetic tone but does not indicate the 
source of the released NE. Because organ-specific increases in sympathetic outflow can 
occur, methods for estimation of regionalized increments in NE release have been 
developed. The assessment of sympathetic activity in specific organs is complicated by 
the fact that all organs release NE into and remove NE from the circulation in a variable 
manner, depending on sympathetic activity in the organ and the proportion of cardiac 
output to that organ. NE spillover in an organ can be estimated by the following 
equation: organ NE spillover = [(C
v
 - C J + Ο , ( Ν Ε Ε ) ] X plasma flow, where Q, is the 
venous plasma NE concentration, C
a
 is the arterial plasma NE concentration and N E E 
is the fractional extraction of tritiated NE. It should be emphasized that the spillover of 
NE into the circulation is not identical with the rate of release of NE from the 
sympathetic nerve terminals into the synaps. Thus, with the tracer dilution method, the 
NE spillover rate but not the neuronal NE release rate can be measured [8,9]. The rate 
of release and the rate of spillover of NE can differ for several reasons. The neuronal NE 
release can be modulated by several endogenous compounds, including NE and EPI 
themselves or other cotransmitters like peptides, purines and dopamine. All these 
compounds may act at specific presynaptic receptors at the nerve terminal, affecting 
intrasynaptic neuronal release of NE [10,11]. The neuronal NE spillover rate can also 
be influenced by intrinsic factors like the width of the neuronal cleft, the efficacy of 
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intrasynaptic inactivation mechanisms such as neuronal or extraneuronal NE clearance 
rates and local blood flow [10-12]. 
Measurement of sympathetic activity: microneurography 
Prejunctional sympathetic nervous activity can be recorded intraneuronally by mi-
croneurography of peripheral nerves [13]. This technique permits direct observation of 
the exact timing of sympathetic nerve traffic to skeletal muscles. Moreover, nerve activity 
can be separated from effects of hormonal or local actions at the receptor site. However, 
small changes in intraneuronal discharge frequency are difficult to quantify whereas they 
may have large effects at the target site. Finally, sympathetic outflow, measured in one 
nerve of the skeletal muscles of one arm or leg, does not automatically represent 
sympathetic nerve activity to other organs in the body, especially during sympathetic 
stimulation. 
Measurement of sympathetic activity: plethysmography and heart rate variability 
The effects of the sympathetic nervous system on the cardiovascular system at the 
postjunctional level can be assessed by measuring forearm blood flow to skeletal muscles 
with venous occlusion mercury-in-strain gauge plethysmography [14] or by measuring 
'heart rate variability by spectral analysis. Heart rate variability measurement is a method 
to estimate indirectly cardiac sympathetic and parasympathetic activity [15]. The 
responsiveness of a target organ for a given nerve impulse rate is influenced by neural, 
local or circulating vasoactive factors, such as the type and density of the adrenoceptors 
and their affinity for NE, the locally operating uptake mechanisms, the rate of enzymatic 
degradation of NE, the synthesis and release of interfering metabolites, the vasomotor 
effects of locally synthesised substances like prostaglandins, histamine, adenine nucleo-
tides, 5-hydroxytryptamine and effects of circulating substances like EPI and angiotensin 
II. Intrinsic factors like vascular size and structure also play a role. 
The sympathetic nervous system in primary hypertension 
No consensus exists on the role of the sympathetic nervous system in the pathophysiol-
ogy of primary hypertension. Increased sympathetic nerve activity is suggested by the 
increased cardiac output and increased heart rate in the early phase of hypertension and 
by the increased vascular resistance in the later phase of established hypertension. When 
hypertension has reached this later phase, structural cardiovascular abnormalities have 
developed and predominate in the maintenance of high blood pressure. They can 
possibly mask an eventual sympathetic dysfunction. The exact nature of a sympathetic 
defect in primary hypertension remains unknown. The methods nowadays available for 
the assessment of sympathetic activity can only measure a part of the system. It seems 
impossible to measure overall sympathetic activity of this extremely differentiated and 
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highly variable system. Because of the capacity of the sympathetic nervous system to 
adapt very rapidly, it still remains difficult to unravel causes and consequences. 
Several abnormalities in the sympathetic nervous system at different levels have been 
described. Shortly after the discovery of the carotid sinus baroreflex, it was suggested 
that dysfunction of the baroreflex might play a role in the pathogenesis of primary 
hypertension in humans. Hypertension in humans appears to be related to a depression 
of the arterial baroreceptor reflex sensitivity for heart rate control [16], and to a lesser 
degree for peripheral resistance control [ 17]. On the other hand, the responses of forearm 
vascular resistance and sympathetic nerve traffic (microneurography) to cardiopulmon-
ary baroreceptor deactivation in borderline hypertension, were shown to be augmented 
[18,19]. The reflexive responses in vascular resistance in established hypertensives were 
similar to the responses in normotensives [20]. The cardiac responses to arterial 
baroreflex stimulation with head-up tilt seem also to be impaired, whereas sympathetic 
nerve traffic to skeletal muscles is preserved in early hypertension [21]. It is however still 
unknown, whether impaired baroreflexes cause hypertension, or vice versa. Irrespective 
of what is cause or consequence, it was shown that baroreceptor endings are reset to a 
higher blood pressure level in the hypertensive patient. After resetting, the receptor 
endings have lower peak firing frequencies and also lower increases in firing rate for 
stepwise increments in distending pressure. This means that although the receptors are 
reset to the higher arterial pressure, they are less sensitive to changes of blood pressure 
and presumably less efficient in buffering further rises in pressure [22]. Resetting of the 
baroreflex may occur at the local baroreceptor level or at the central nervous system level. 
It may be related to physical changes at the baroreceptor site, such as reduced elasticity 
in the arterial wall of the carotid sinus and aorta. Other mechanisms may be an altered 
central processing of afferent baroreflex information. 
Many efforts have been spent to the measurement of the sympathetic neurotransmitter 
NE. Venous plasma NE concentrations however, were not found to be increased in the 
majority of studies. Younger patient groups, with probably more recent onset hyperten-
sion than older patients, seem to have higher plasma NE concentrations, though 
controversial data have been published [23]. After development of the radiotracer 
dilution method, more precise measurements of sympathetic activity in human hyper-
tension were possible. Assessment of organ-specific sympathetic outflow suggests that 
the increased sympathetic outflow is regionalized mainly to the heart and kidneys in 
young hypertensive patients [24,25], and not to the lungs or hepatosplanchnic complex 
[24]. The demonstrated increased muscle sympathetic nerve activity (MSNA) in skeletal 
muscles of the forearm of young borderline hypertensives [26] would imply an increased 
regional forearm NE spillover but this has never been demonstrated convincingly. The 
important difference between NE spillover and neuronal NE release is underlined by 
the finding that neuronal reuptake (uptake-1) may be impaired in primary hypertension. 
When uptake-1 is indeed decreased, this would result in increased spillover of NE into 
the circulation despite the absence of increased sympathetic nerve traffic and neuronal 
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NE release. Additional important factors to be taken into account are the duration of 
the hypertension and the gender of the subjects. The increased MSNA in borderline or 
mild hypertension could not be demonstrated anymore in established hypertension. 
Previous reports on gender-related effects on plasma catecholamine levels have not been 
followed by studies on gender-dependent differences in NE and EPI kinetics [27]. 
Several lines of evidence suggest that increased release of adrenomedullary EPI may be 
the primary abnormality in primary hypertension. Small repetitive increases in circulat-
ing EPI by an increased release of adrenomedullary EPI might stimulate presynaptic 
ß2-adrenoceptors. This would facilitate NE release from sympathetic nerve terminals 
with a subsequent increase in peripheral vasculature resistance and blood pressure. EPI 
can possibly also act as a cotransmitter after neuronal uptake. In addition to these actions 
at the neuroeffector junction, stimulation of ß2-adrenoceptors by EPI also facilitates 
hypothalamic and adrenal catecholamine release. This might even cause a positive 
feedback loop, through which even a small increase in circulating EPI can sustain 
amplification of neurotransmission at the central and peripheral level [28]. Plasma EPI 
concentrations are slightly elevated in many but not all young subjects with borderline 
or mild hypertension [23] but are mostly measured in antecubital venous blood. Since 
venous plasma EPI concentrations do not reflect adrenomedullary EPI secretion because 
of the major extraction of EPI through the forearm, it would be more interesting to 
know whether patients with hypertension have increased arterial plasma EPI levels. 
Mechanisms of postsynaptic hyperresponsiveness include altered adrenoceptor number 
and function or altered cardiovascular structure. The increased heart rate, cardiac output 
and forearm blood flow, as described in many young patients with borderline hyperten-
sion, could be a consequence of increased postjunctional ßj- and ß2-adrenoceptor 
responsiveness. In some studies an increase in mononuclear leucocyte ß2-adrenoceptor 
number has been described, but the majority of studies in older patients and those with 
established hypertension have demonstrated a decreased number of postjunctional 
ß2-adrenoceptors [29]. Besides alterations in receptor density, an attenuation of the 
coupling between ß2-adrenoceptors and Gç-proteins was observed in primary hyperten-
sion, suggesting a defect in ß2-adrenergic signal transducton in hypertension. A difficulty 
in the interpretation of these studies is that the lymphocyte ß-adrenoceptor numbers 
and ß-adrenoceptor-stimulated adenylate cyclase activity are themselves subject to 
modification by catecholamines. 
Sympathetic activity during antihypertensive treatment 
Many effective antihypertensive agents exert their action by interfering with sympathetic 
neurotransmission, blocking cardiac or vascular adrenoceptors or stimulating central 
neural adrenoceptors. 
Alpha]-adrenoceptor antagonists like doxazosin lower blood pressure by blocking 
postjunctional aj-adrenoceptors, causing vasodilation without tachycardia [30,31]. 
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During chronic (X] -blockade the arterial plasma NE level is increased, which could be 
due to vasodilation-induced baroreflex stimulation [32] or to decreased clearance of NE 
due to decreased extraction by the vasodilation. The absence of tachycardia suggests that 
no sympathetic counterregulation occurs and the unchanged heart rate has been attrib-
uted to absence of antagonism of prejunctional O^-adrenoceptors [33]. 
Betaj-adrenoceptor antagonists like atenolol are effective antihypertensive drugs. The 
antihypertensive action has been ascribed to blockade of sympathetic activity, either in 
the central nervous system or through presynaptic modulation of NE release. Resetting 
of baroreflex control of blood pressure has also been considered [34]. Previous reports 
have described variable effects of different ß-adrenoceptor antagonists on plasma NE 
and EPI levels [34] in hypertension, despite similar antihypertensive effects. No NE and 
EPI kinetic data are available during longterm treatment with β!-adrenoceptor antago­
nists but inconsistent results were found in acute [12,35,36] and chronic [37] studies 
with ßi-selective [36] and non-selective [12,35-37] ß-adrenoceptor antagonists. These 
results can not be generalized, since ßj-selective and non-selective ß-antagonists can 
affect NE release differently through presynaptic ß2-adrenoceptors [34], whereas short 
and longterm treatment have different effects on organ blood flow and may differently 
affect NE clearance [34]. 
Outline of this thesis 
This thesis focuses on the assessment of sympathetic nervous activity in primary 
hypertension by the isotope dilution technique. We measured sympathoneural and 
adrenomedullary activities by using steady state infusions of tritiated catecholamines in 
a large group of patients with mild primary hypertension. For this purpose we needed 
a sensitive assay for the simultaneous quantification of endogenous plasma catecho-
lamine concentrations and its radiotracers. Catecholamine kinetics were determined at 
rest and during sympathetic stimulation by lower body negative pressure (LBNP). In 
chapter 2 is described how the HPLC method with fluorometric detection allows 
simultaneous sensitive measurement of the radiolabeled and endogenous catecholamines 
in the same eluted HPLC fraction. In chapter 3, the effects of prolonged low-intensity 
and high-intensity LBNP on NE and EPI kinetics in normotensives are described. Since 
some subjects are prone to a vasodepressor syncope during prolonged high-intensity 
LBNP, we studied the neurohumoral regulation during low-intensity LBNP in those 
subjects who developed a syncope during high-intensity LBNP. This is described in 
chapter 4. Chapter 5 contains a study on NE and EPI kinetics in a large group of mildly 
hypertensive patients, both at rest and during sympathetic stimulation. Chapter 6 and 
7 deal with catecholamine kinetics during longterm treatment with the selective OC]-ad-
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renoceptor antagonist doxazosin or with the β ι -adrenoceptor antagonist atenolol in 
subjects with primary hypertension. 
References 
1. Abboud FM, Heistad DD, Mark AL, Schmid PG. Reflex control of the peripheral circulation. Progr 
Cardiovasc Dis 1976;13:371-403 
2. Mark AL, Mancia G. Cardiopulmonary baroreflexes in humans. In: Handbook of Physiology. The 
cardiovascular system. Eds Shepherd JT, Abboud FM. Bethesda: American Physiological Society 
1983;3(part2):795-813 
3. Weiner N. Control of the biosynthesis of adrenal catecholamines by the adrenal medulla. In: Geiger 
SR (Ed). Handbook of physiology. A critical, comprehensive presentation of physiological knowledge 
and concepts. Section 7 Endocrinology. Volume 6 Adrenal gland. 1975, 357-366 
4. Esler M, Jennings G, Körner Ρ, Blombery Ρ, Sacharías Ν, Leonard P. Measurement of total and 
organ-specific norepinphrine kinetics in humans. Am J Physiol 247 (Endocrinol Metab 10):E21-E28, 
1984 
5. Hjemdahl P. Physiological aspects on catecholamine sampling. Life Sci 1987;41:841-844 
6. Kjeldsen SE, Westheim A, Aakesson I, Eide I, Leren P. Plasma adrenaline and noradrenaline during 
onhostasis in man: The importance of arterial sampling. Scand J Clin Lab Invest 1986;46:397-401 
7. Esler M, Leonard P, O'Dea K, Jackman G, Jennings G, Körner P. Biochemical quantification of 
sympathetic nervous activity in humans using radiotracer methodology: Fallibility of plasma norad-
renaline measurements. J Cardiovasc Pharmacol 1982;4:S152-S157 
8. Eisenhofer G, Esler MD, Meredith IT, Dan A, Cannon RO, Quyyumi AA, Lambert G, Chin J, 
Jennings GL, Goldstein DS. Sympathetic nervous function in human heart as assessed by cardiac 
spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 1992;85:1775-1785 
9. Chang PC, Kriek E, van der Krogt JA, van Brummelen P. Does regional norepinephrine spillover 
represent local sympathetic activity? Hypertension 1991;18:56-66 
10. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981;32;337-362 
11. Langer SZ, Caverò I, Massingham R. Recent developments in noradrenergic neurotransmission and 
its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 1980;2:372-
382 
12. Rosen SG, Supiano MA, Perry TJ, Linares OA, Hogikyan RV, Smith MJ, Halter JB. ß-Adrenergic 
blockade decreases norepinephrine release. Am J Physiol 1990;258 (Endocrinol Metab 21):E999-
E1005 
13. Hagbarth KE, Vallbo AB. Pulse and respiratory grouping of sympathetic impulses in human muscle 
nerves. Acta Physiol Scand 1968;74:96-108 
14. Brakkee AJM, Vendrik AJH. Strain gauge plethysmography, theoretical and practical notes on a new 
design. J Appi Physiol 1966;21:701-704 
15. Pagani M, Lombardi F, Guzetti S, Rimoldi О, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, 
Dell'Orto S, Piccaluga S, Turil M, Baselli G, Cerutti S, Malliani A. Power spectral analysis of heart 
rate and arterial blood pressure variabilities as a marker of sympathovagal interaction in man and 
conscious dog. Circ Res 1986;59:178-193 
16. Gribbin B, Pickering TG, Sleight P, Peto R, Effect of age and high blood pressure on baroreflex 
sensitivity in man. Circ Res 1971;29:424-431 
17. Duprez D, de Pue Ν, Clement DL. Peripheral vascular responses during carotid baroreceptor 
stimulation in normotensive and hypertensive subjects. Clin Sci 1987;73:635-640 
Introduct ion I 17 
18 Mark AL, Kerber RE Augmentation of cardiopulmonary baroreflex control of forearm vascular 
resistance in borderline hypertension Hypertension 1982,4 39-46 
19. Rea RF, Hamdan M Baroreflex control of muscle sympathetic nerve activity in borderline hyperten­
sion Circulation 1990,82 856-862 
20 Grassi G, Giannattasio С, Cleroux J, Cuspidi С, Samplen L, Bolla GB, Mancia G Cardiopulmonary 
reflex before and after regression of left ventricular hypertrophy in primary hypertension Hyperten­
sion 1988,12 227-237 
21 London GM, Weiss YA, Pannier BP, Laurent SL, Safar ME Tilt test in primary hypertension 
Differential responses in heart rate and vascular resistance Hypertension 1987,10 29-34 
22 Sleight P, Robinson JL, Brooks D, Rees PM Characteristics of single carotid sinus baroreceptor fibers 
and whole nerve activity m the normotensive and renal hypertensive dog Circ Res 1977,14 750-758 
23 Goldstein DS Plasma catecholamines and primary hypertension An analytical review Hypertension 
1983,5 86-99 
24 Esler M, Jennings G, Btviano B, Lambert G, Hasking G Mechanism of elevated plasma noradrenaline 
in the course of primary hypertension J Cardiovasc Pharmacol 1986,8(suppl 5) S39-S43 
25 Goldstein DS, Eisenhofer G, Garry M, Sax FL, Keiser HR, Kopin IJ Pharmacologic and tracer 
methods to study sympathetic function in primary hypertension Clin Exper Theory and Practice 
1989.A11 (supplì) 173-189 
26 Anderson EA, Sinkey CA, Lawton WJ, Mark AL Elevated sympathetic nerve activity in borderline 
hypertensive humans evidence from intraneural recordings Hypertension 1989,14 177 183 
27 Lenders JWM, de Boo Th, Lemmens WAJ, Reijenga J, Willemsen JJ, Thien Th Comparison of 
blood pressure response to exogenous epinephrine in hypertensive men and women Am J Cardiol 
1988,61 1288-1291 
28 Floras JS Epinephrine and the genesis of hypertension Hypertension 1992,19 1 18 
29 Michel MC, Brodde O-Ε, Insel PA Peripheral adrenergic receptors in hypertension Hypertension 
1990,16 107-120 
30 Manos J A long term study of doxazosin in the treatment of mild or moderate primary hypertension 
in general medical practice Am Heart J 1991,121 346-51 
31 Lund-Johansen P, Omvik P, Haugland H Acute and chronic haemodynamic effects of doxazosin in 
hypertension at rest and during exercise Br J Clin Pharmac 1986,21,45S-54S 
32 Eklund B, Hjemdahl P, Seideman P, Atterhog JH Effects of prazosin on hemodynamics and 
sympathoadrenal activity in hypertensive patients J Cardiovasc Pharmacol 1983,5 384-91 
33 ReidJL, Rubin PC Catecholamines and blood pressure In Catecholamines II ed U Trendelenburg, 
Werner Ν, 1989, Ch 17, ρ 319-356 
34 Man in t Veld AJ, Schalekamp MADH Effects of 10 different ß-adrenoceptor antagonists on 
hemodynamics, plasma renin activity, and plasma norepinephrine in hypertension The key role of 
vascular resistance changes in relation to partial agonist activity J Cardiovasc Pharmacol 1983,5(suppl 
1) S30-S45 
35 Best JD, Halter JR Blood pressure and norepinephrine spillover during propranolol infusion in man 
Am J Physiol 1988,248 R40-406 
36 Chang PC, Grossman E, Kopin IJ, Goldstein DS On the existence of functional beta-adrenoceptots 
on vascular sympathetic nerve endings in the human foreaim J Hypertension 1994,12 681-690 
37 Esler M, Jackman G, Leonard P, Skews H, Bobik A, Jennings G Effect of propranolol on 
noradrenaline kinetics in patients with primary hypertension Br J Clin Pharmac 1981,12 375-380 

Chapter 2 
Highly sensitive and specific H PLC with 
fluorometric detection for determination of 
plasma epinephrine and norepinephrine 
applied to kinetic studies in humans. 
Clinical Chemistry 1995;41:1455-1460 
J.J. Willemsen 
H.A. Ross 
М.С. Jacobs 
J.W.M. Lenders 
Th. Thien 
L.M.J.W. Swinkels 
T.J. Benraad 

Determination of plasma epinephrine and norepinephrine | 21 
Highly sensitive and specific HPLC with fluorometric detection 
for determination of plasma epinephrine and norepinephrine 
applied to kinetic studies in humans 
Abstract 
An HPLC separation method combined with fluorometric detection was extended to 
enable simultaneous assessment of plasma 3H-labeled and endogenous epinephrine and 
norepinephrine. Forearm fractional extraction of 3H-labeled epinephrine and norepine-
phrine and of endogenous epinephrine was measured in 40 healthy volunteers who were 
receiving a continuous infusion of 3H-labeled epinephrine and norepinephrine. Con-
centrations of arterial and venous epinephrine were 26.8 ± 1.95 (mean ± SE) and 6.8 ± 
0.75 ng/L, respectively. Arterial and venous norepinephrine and dopamine were also 
measured, with respective values of 140.7 ± 8.5 and 192.1 ± 15.1 for norepinephrine, 
and 13.1 ± 0.78 and 11.3 ± 0.70 ng/L for dopamine. The forearm fractional extraction 
of3H-labeled epinephrine was slightly but significantly higher (0.790 ± 0.016) than the 
forearm fractional extraction of either 3H-labeled norepinephrine or endogenous epi-
nephrine (0.748 ± 0.0146 and 0.745 ± 0.0185 respectively; P<0.001), the correlations 
being highly significant (r = 0.80, P<0.001) in both cases. The small difference between 
the forearm fractional extractions of epinephrine and of 3H-labeled epinephrine allows 
calculation of the apparent spillover of epinephrine. However, this spillover was negli-
gible compared with forearm norepinephrine spillover (0.0112 ± 0.0031 vs. 1.369 ± 
0.128 ng/L per minute. The high sensitivity of this measurement of venous epinephrine 
widens the possibilities for studying epinephrine kinetics under physiological condi-
tions. 
Introduction 
Several methods have been introduced for measurement of plasma catecholamines (CA). 
The early fluorometric method [1] was followed by the more sensitive and specific 
radioenzymatic assay [2,3]. The latter, in turn, has largely been replaced by less 
cumbersome and faster procedures such as HPLC with electrochemical detection [4-8]. 
However, for measurement of physiological concentrations of epinephrine (EPI), par-
ticularly in venous plasma, sensitivity is restrictive and, as a consequence, will make 
kinetic studies of EPI inappropiate. Measurements of the tritiated EPI (3H-EPI), 
however, using HPLC with electrochemical detection to perform kinetic studies, are 
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completely different from those of the concentrations of EPI and are relatively easy to 
obtain. For this reason, measurement of 3H-EPI is not the limiting factor in kinetic 
studies of EPI [5,9]. One method described for CA measurement uses HPLC separation 
of CA fluorescent derivatives with subsequent fluorometric detection [10,11]. This 
method reportedly has higher sensitivity for measurement of EPI. One of these studies 
[10] reported that a processed EPI calibrator of 2 ng/L could be detected. In the present 
study, we concentrated plasma extracts to assess the sensitivity and accuracy of the 
proposed assay. The rationale of the present study, however, was to investigate whether 
the high sensitivity and accuracy for assessment of endogenous EPI achieved with this 
new method, combined with simultaneous separation and measurement of 3H-EPI, 
supports the possibility of performing kinetic studies of EPI under physiological 
conditions. Therefore, we compared the forearm fractional extraction (FFE) of 3H-EPI 
vs endogenous EPI, on the assumption that FFE of endogenous EPI would be equal, or 
at least be close to, that of infused 3H-EPI. 
Materials and methods 
Subjects and sampling 
Forty volunteers (ages 37 ± 6 years, mean ± SD) participated in the study. All subjects 
gave their written informed consent. The study protocol was approved by the Hospital 
Ethics Committee. All participants underwent a physical examination before entry into 
the study. None of the subjects had cardiovascular or other major diseases, and none 
was under pharmacological treatment of any kind. The participants were in supine 
position during the procedure, which was carried out in a temperature-controlled room 
at 21CC. Forearm blood flow was measured according to Brakkee and Vendrik [12]. A 
brachial artery was cannulated for drawing arterial blood samples, and an intravenous 
catheter was inserted into a brachial vein in the same arm for collecting venous blood 
samples. A forearm venous catheter in the contralateral arm was used for intravenous 
infusion of 3H-EPI and 3H-labeled NE (3H-NE). Thirty minutes after installation of 
the catheters, a 15 ц С і / т 2 bolus of 3H-EPI and 3 H-NE was injected. Thereafter 3 H-EPI 
and 3 H-NE were infused simultaneously at a continuous rate of 0.35 ц С і / т 2 per 
minute. Then, 30 min after the start of the infusion, forearm arterial and venous blood 
samples were collected simultaneously. The blood samples were collected in precooled 
tubes on melting ice, containing 0.25 mol/L EGTA and 0.2 mol/L glutathione in 
distilled water (pH 7 A). The blood was centrifuged (10 min at 1500g, 4°C) immediately 
after collection, and plasma was stored at -20°C. At the end of the experiment, portions 
of the 3H-EPI and 3 H-NE infusâtes were stored at -80°C. Plasma samples and 3H-EPI 
and 3H-NE infusâtes were analysed together within 2 months after collection. 
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Materiah and instrumentation 
For the liquid-liquid extraction and derivatization, we used the same materials as 
described by van der Hoorn et al. [10]. L-[N-methyl-3H]-EPI (specific activity 55-85 
KCi/mol) and L-[ring 2,5,6-3H]-NE (specific activity 30-60 KCi/mol) were obtained 
from Du Pont, New England Nuclear ('s Hertogenbosch, The Netherlands). The purity 
of each batch of radiolabeled compound was established by HPLC with direct injection 
of the underivatized tritiated compounds onto a 250 X 4.6mm Ce column, after which 
fractions were collected and their radioactivity counted. The samples containing 3H-EPI 
and 3 H-NE were sterilized with the use of a micropore filter (0.22 μπι) and diluted in 
isotone saline (9 g/L NaCl), containing acetic acid (0.2 mol/L) and ascorbic acid (1 g/L), 
to prevent oxidation. The samples were stored until use at a concentration of approxi­
mately 70 mCi/L at -80°C for < 3 months. Sterilization, dilution and partition into 
aliquots took place under nitrogen. The aliquots were capped and, just before the study, 
the tracer was diluted in isotone saline. 
The system configuration for HPLC consisted of a Model 610 pump, a Model 600E 
system controller, a Model 470 scanning fluorescence detector (16 [ÍL flow cell), and 
an automated sample processor WISP 710B (all from Waters Associates, Millford, MA). 
Chromatography data were edited with Baseline 815 Chromatography Workstation 
Version 3.30 software. The separations were performed on a silica analytical Nova-
Pak™ (Waters Associates) Q e (150 X 3.9mm) column fitted with a Nova-Рак C I 8 
guard column. The 3H-EPI and 3 H-NE activities were collected for 1 minute with the 
use of a Gilson fraction collector, model 201-202 (Gilson Medical Electronics, Villiers 
le Bel, France), which was connected to the WISP 710B and programmed to start 
collecting the 3H-EPI and 3 H-NE fractions at the start of the EPI and NE peak positions, 
respectively, in the chromatogram. To these fractions was added 8 mL of scintillation 
fluid (Aqualuma; Lumac-LSC BV, Groningen, The Netherlands). The 3H-EPI and 
3 H-NE radioactivities were counted for 20 minutes in a Packard Tri-Carb 460 С liquid 
scintillation counter (background count rate, 11.7 ± 0.4 counts/min; efficiency, 40%). 
Sample preparation and chromatography 
The present laboratory procedure, an extension of the procedure described by van der 
Hoorn et al. [10], includes specific measurement of infused tracers in the same eluate. 
Each assay run included a standard mixture of NE (250 ng/L), EPI (250 ng/L) and 
dopamine (DA, 500 ng/L); a reagent blank; a control plasma; the venous and arterial 
plasma samples; and the 3H-EPI and the 3 H-NE infusâtes from an experiment in one 
subject. To different glass tubes were added 1 mL of the standard mixture in 0.01 mol/L 
HCl (A), 1 mL of 0.01 mol/L HCl (В), or 1 mL of control plasma or 1 mL venous or 
arterial plasma (C). We than added 50-μί aliquots of 3H-EPI or 3 H - N E infúsate to 
1 mL of venous baseline plasma sample that had been collected before 3H-EPI and 
3H-NE were infused (D), or to 1 mL of 0.01 mol/L HCl (D')· To each of these tubes 
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we added 250 μ ι (500 pg) of isoproterenol (IP) solution as internal standard. Another 
50 (J.L of 3H-EPI or 3 H-NE infúsate was pipetted into a counting vial for direct 
measurement of the 3H-EPI and 3H-NE (RT). Using these solutions, we determined 
the procedural recoveries of 3H-EPI and 3H-NE, and investigated the effect of the 
plasma matrix on the measurement of 3H-EPI and 3H-NE. 
Extraction of catecholamines was performed as described previously [10], but with the 
following modifications. We used only one-half of the previous volumes of reagents for 
the liquid-liquid extraction and made the final extraction of the CA with 37.5 μΐ of 0.08 
mol/L acetic acid. To convert the CA into their diphenyl-quinoxalin derivatives, we 
successively added 50 \lL of acetonitrile, 12.5 (iL of 1.75 mol/L Bicine (pH 7.05), and 
25 H-L of 1,2-diphenylethylenediamine solution (0.1 mol/L in 0.1 mol/L HCL), started 
the reaction by adding 5 [iL of potassium ferricyanide (20 mmol/L in distilled water), 
and incubated the mixture for 60 min in a closed oven at 37°C. After derivatization, we 
injected 120 μ ι of the solution into the chromatographic system. 
Assay performance 
To obtain "zero" plasma, we heated pooled plasma from healthy volunteers at 37°C 
until NE, EPI and DA detector responses had become equal to the response of reagent 
blank. For assessment of lower detection limits, we added to this zero plasma (a) 1 ng/L 
NE and EPI and 2 ng/L DA and (b) 2 ng/L NE and EPI and 4 ng/L DA. To these two 
samples as well as to the zero sample we then added 250 μΐ (500pg) of the IP solution 
and assayed each sample five times. 
Within-run variation was assessed by means of five determinations each of five samples, 
ranging from low to moderate CA concentrations. Sample 1 was obtained from a patient 
who had undergone bilateral adrenalectomy. Samples 2 and 3 originated from two 
different pooled plasmas, and samples 2a and 3a were prepared by CA supplementation 
of samples 2 and 3. 
Between-run variation was assessed by assaying a control (pooled) plasma over a period 
of 1,5 years in 52 different runs. 
Assay accuracy was assessed by measuring CA in supplemented samples and calculating 
the proportion of the added CA that was thus refound. To the zero plasma mentioned, 
as well as to sample 3 (which had normal CA concentrations), we added 250 ng/L NE 
and EPI and 250 or 500 ng/L DA. To sample 2 we added smaller quantities of CA: 25 
ng/L NE and 2.5 ng/L EPI and DA. 
The precision and accuracy of measurements of radiolabeled CA were determined as 
described in the Calculations section. 
Calculations 
Measurement of^H-Catecholamines. Identical amounts of IP internal standard were 
added to 1 mL of unknown plasma (C) and to the radioactivity calibration solution (D) 
Determination of plasma epinephrine and norepinephrine | 25 
(50 \ÏL of the 3H-EPI or 3H-NE infúsate mixed with 1 mL of venous baseline plasma). 
From the amounts of 3H activity (in counts/min or dpm) of the calibrator solution (D) 
and plasma samples (C) collected after derivatization and HPLC (RCA.D a n d RCA.C 
respectively) and the 3H-activity of 50-μί infúsate (R-r)> we can calculate the original 
activities of 3H-labeled CA (3H-CA) in 1 mL of plasma sample by means of the following 
formula: 
3 H - C A c = b ^ £ x ^ X R T (1) 
R Ρ 
^CA.D MP,C 
where РІР,С and PlP.D denote the μ ν readings corresponding to IP internal standard 
peak heights of sample С and radioactivity calibrator D respectively. 
After correction for the volume actually injected relative to the total volume after 
derivatization, the ratio RCA.D / R-T yields the true procedural recoveries of CA from 
sample D. 
The recovery for the unknown plasma samples (C) can be estimated by multiplying the 
ratio RCA.D / R T °y Pip.c / PlP,D· Division of RCA.C by this recovery gives the original 
activity in 1 mL unknown plasma sample C. 
Validation of3H-CA measurement. Although the true procedural recoveries of the 3H-CA 
can be measured as outlined in the previous paragraph, this value cannot be used to 
determine the 3H-CA concentration in an unknown plasma sample because the loss of 
CA during the procedures of extraction and derivatization may differ between samples. 
Instead, the internal standard method, which also is used to estimate the endogenous 
CA, is applied here. Therefore, we assume a direct proportionality between the recoveries 
of 3H-CA and IP in different matrices. The validity of this assumption was verified by 
the following experiment. To different plasma samples D(i), known amounts of tracer 
Rj(,) and known amounts of internal standard IP,D(i) were added. In parallel with these 
samples, a sample D' (without plasma), to which the same amount of tracer and IP was 
added, was analyzed. The ratios RCA,D(I) I PlP,D(i) 3n<^ RCA.D' / PlP.D' were then compared 
for 14 different plasma samples, each analyzed on different days; the quotient Q(i) was 
calculated according to: 
Q( i ) = b^lixili^_ ( 2 ) 
D p 
^CA.D' 1IP.D(i) 
where RCA.D' denotes the amount of 3 H activity in the fraction collected after derivati­
zation and HPLC of the 50 [iL· of infúsate added to 1 mL of 0.01 mol/L HCl, and ΡΙΡ,Ο' 
denotes the [iV readings of the corresponding internal standard peak height in the 
chromatogram. If this quotient Q(i) approximates unity, it means that the assumption 
is valid and is independent of different matrices. 
Fractional extraction. FFE was calculated as 1 - [V]/[A], where V and A represent venous 
and arterial concentrations of 3H-EPI or 3 H-NE. Assuming unidirectional clearance of 
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endogenous EPI and no local EPI release, its fractional extraction was calculated in the 
same way. 
Forearm spillover. Forearm spillover (ng/L per minute) was calculated from FFE of 
3H-EPI or 3H-NE and forearm plasma flow, where forearm plasma flow = forearm blood 
flow X (1 — hematocrit), in mL/L per minute, as follows: 
Forearm spillover = forearm plasma flow X [V - A X (1 - FFE)] 
where V and A denote venous and arterial endogenous CA concentrations, respectively. 
Statistics. Differences were tested by a paired t-test. Correlation coefficients were 
determined according to Pearson. 
Results 
Analytical evaluation 
The present HPLC method allows good separation of the CA. The sequence of elution 
was NE-EPI-DA-IP with retention times of 2.2, 3.75, 5-5, and 7.5 min, respectively 
(Fig 1). Even with these very short retention times, the separation of the tritiated 
compounds was complete. No radioactivity originating from 3H-NE could be detected 
in the 3H-EPI zone of the chromatogram, and vice versa. The procedural recoveries of 
the different 3H-NE and 3H-EPI infusâtes of the same batch, added to different 1-mL 
venous baseline plasma samples, were 37.1% ± 2.5% (mean ± SD, n=l4) for 3H-NE 
and 52.0% ± 2.2% for 3H-EPI. The quotient Q(i), calculated with Eq.2, was 0.968 ± 
0.025 (mean ± SD, n=l4) for 3H-NE and 0.983 ± 0.028 for 3H-EPI, respectively. The 
CVs of these latter ratios (2.6% and 2.8%, respectively) reflect the interassay CVs for 
the radiolabeled compounds with high count rates. The purity of each batch of 
(underivatized) radiotracers was >99%. 
In all instances where CA had been added, peaks corresponding to the fluorescence signal 
of derivatized NE, EPI and DA could be readily identified. Retention times varied, with 
CVs of 0.4%, 0.8% and 0.7% for NE, EPI and DA, respectively. CVs for EPI and DA 
could be further reduced to 0.2% and 0.3%, respectively, by normalization, with the 
retention times of IP in the corresponding chromatograms. The 99% confidence 
intervals of these retention times were calculated to allow us to classify the very small 
apparent peaks that were discernible in the chromatographs of the zero plasmas as 
representing either residual CA or baseline noise. In only one of five observations on 
zero plasmas was the "peak" retention time within those confidence limits. Thus we 
concluded that these apparent peaks must be classified as baseline noise. In all instances, 
responses for plasmas containing 1, 2 and 4 ng/L CA were much higher than the zero 
response and were close to expected values (Fig 2). In addition, the differences between 
1 and 2 ng/L and between 2 and 4 ng/L were highly significant (P < 0.001) (Table 1). 
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Figure 1. Chromatogram of a plasma sample containing 378 ng/L nor­
epinephrine (NE), 6.1 ng/L epinephrine (EPI), 11.7 ng/L dopamine (DA) 
and 500 ng/L of added isoproterenol (IP). 
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Figure 2. Example of chromatographic recording of detector response to 
0, 1 and 2 ng/L epinephrine (EPI), expressed in volts. 
0 ng/L (solid line), 1 ng/L (dotted line), 2 ng/L (dashed line) were added 
to zero plasma. 
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Table 1. Assay sensitivity: detector response in the lower concentration range (additions to zero plasma). 
Addition 
ng/L 
1 
2 
4 
NE 
1.03 ±0.145 
1.84 ±0.095 
Detector response a 
EPI 
1.15 ±0.200 
1.84 ±0.103 
DA 
1.99 ±0.188 
3.14 ±0.163 
1
 expressed in ng/L (mean ± SD, n=5) 
Defining the detection limit as three times the (pooled) SD in the lowest measurement 
range (1 and 2 ng/L) resulted in detection limits of 0.37, 0.58 and 0.47 ng/L for NE, 
EPI and DA, respectively. 
CA additions to two of three samples resulted in normal to moderately elevated values. 
Quintuplicate measurements of the five samples thus obtained yielded estimates of 
within-run precision (Table 2). 
Between-run precision, assessed over 1.5 years in 52 different assays of a control pooled 
plasma, was as follows (mean ± SD, CV %): NE, 173.3 ± 14.7 (8.5%); EPI, 28.0 ± 2.03 
(7.2%); and DA, 18.1 ± 2.15 (11.9%) ng/L. For assessment of accuracy, 250 ng/L NE 
and EPI and 500 ng/L DA were added to sample 3 (Table 2). Of these additions 99.9% 
± 2.6%, 104.6% ± 3.2% and 101.7% ± 1.7%, respectively, were found. Additions of 
250 ng/L NE, EPI and DA to the zero plasma were made in 10 replicates each. We 
found (mean ± SD) 94.9% ± 5.0%, 98.6% ± 3.6%, and 94.0% ± 4.4%, respectively, of 
the added materials. To sample 2 (Table 2), much lower quantities were added: 25 ng/L 
NE and 2.5 ng/L for EPI and DA; 24.1 ± 11.8, 2.84 ± 0.76 and 1.85 ± 0.49 ng/L were 
refound. The data from samples 2 and 2a also demonstrate that the precision of this 
assay allows for small changes in plasma concentrations to be detected; i.e., beginning 
with 20 or 10 ng/L, 2.5 ng/L increments in EPI and DA led to significantly (P < 0.001) 
higher signals. Thus changes of 10% already will be easily detectable. 
Plasma catecholamine values in subjects at rest 
A total of 40 arterial and 40 venous plasma paired samples were obtained 60 min after 
installing the cannulae. From the concentrations of 3H-EPI and 3H-NE and endogenous 
EPI, we could calculate fractional extraction (see above). Mean and SE of these 
concentrations are shown in Table 3. 
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Table 2. Within-run variation of assay for plasma samples. 
Sample 
1 
2 
2a a 
3 
За Ь 
Mean ± SD, ng/L (and CV, %; η = 5) 
NE EPI DA 
162.9 ± 3.63 (2.2) 1.59 ± 0.350(21.9) 8.35 ± 0.383(4.6) 
249.6 ± 11.58 (4.6) 20.7 ± 0.69 (3.4) 10.6 ± 0.34 (3.3) 
273.7 ± 12.0 (4.3) 23.5 ± 0.82 (3.5) 12.4 ± 0.61 (4.9) 
221.8 ± 5.03 (2.3) 35.9 ± 0.73 (2.0) 20.1 ± 0.40 (2.0) 
471.5 ±5.23 (2.6) 296.5 ± 11.48 (3.9) 528.6 ± 12.23 (2.3) 
1
 Sample 2 + 25 ng/L NE + 2.5 ng/L EPI + 2.5 ng/L DA; 
ь
 Sample 3 + 250 ng/L NE + 250 ng/L EPI + 500 ng/L DA. 
Table 3. Concentrations and activities of EPI and NE measured in 40 plasma samples taken at rest. 
Mean ± SE 
Venous Arterial 
[EPI], ng/L 6.8 ±0.75 26.9 ±1.9 
[NE], ng/L 192.1 ±15.1 140.7 ± 8.5 
3H-EPI, dpm/L χ 10"3 126.0 ± 8.5 622.0 ± 22.3 
3H-NE, dpm/L x 10'3 180.0 ± 9.8 729.0 ± 23.5 
Forearm fractional extraction and forearm spillover 
Average fractional extractions (mean ± SE) of 3 H-NE, 3H-EPI and EPI were rather close: 
0.748 ± 0.0146, 0.790 ± 0.0160 and 0.754 ± 0.0185. The difference between FFE of 
labeled and unlabeled EPI, albeit small, was statistically significant (P<0.001) and led 
to calculation of an apparant spillover of 0.0112 ± 0.0031 ng/L per minute. This, 
however, is two orders of magnitude lower than the forearm spillover of NE: 1.369 ± 
0.128 ng/L per minute. The FFE correlations of tritiated NE and EPI with endogenous 
EPI were highly significant, r = 0.80 (P<0.001) in both cases. As expected, FFE of 
unlabeled NE was negative (-0.615 ± 0.0624) because of NE release in the forearm. 
Discussion 
High sensitivity, especially for plasma EPI, has been attained in the present approach. 
This was accomplished by concentrating the plasma extracts and keeping the back­
ground noise very low compared with the peak heights. High sensitivity was obtained 
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not only with the use of pure standard but also for 1 and 2 pg of EPI and NE added to 
1 mL of zero plasma, which gave peaks that were clearly higher than the zero response. 
Moreover, the calculated concentrations were close to expected values. At an EPI 
concentration of 20 ng/L, within-run differences of only 10% already will be significant. 
This is of particular importance in detecting trends in or effects on venous plasma 
concentrations of EPI in dynamic studies. The high sensitivity for assessment of 
endogenous EPI, combined with simultaneous separation and measurement of 3H-EPI, 
yields the possibility of performing kinetic studies under physiological conditions. 
The true losses during extraction and derivatization cannot be assessed, because no 
quantitative relation between the amount of quinoxalin derivative and fluorescence 
signal can be established. This is a drawback compared with methods that use electro-
chemical detection of unmodified CA. However, the assumption of equal ratios between 
CA and IP recovery implicit in the calculation of plasma CA levels appears to be justified, 
as demonstrated by the quantitative recovery of pure standard added to different 
plasmas. Assessment of 3H-EPI and 3H-NE likewise depends on the validity of this 
assumption. Because in this case we could measure the procedural recovery of tritiated 
CA that had been added to plasma (37.1 ± 2.5% for 3H-NE and 52.0 ± 2.2% for 3H-EPI) 
(mean ± SD, n=l4), the existence of a direct proportionality between the true recovery 
and internal standard peak height could be demonstrated by experiments in which 
3H-EPI or 3H-NE and IP are added to plasma as well as to 0.01 mol/L HCL. This was 
done for 14 different plasmas on 14 days. The average quotient Q (mean ± SD; 0.968 
± 0.025 for 3H-NE and 0.983 ± 0.028 for 3H-EPI, calculated with the use of Eq. 2) 
demonstrates that the validity of this key assumption is matrix independent. 
The between-run CV of the quotient Q (2.6% for 3H-NE and 2.8% for 3H-EPI) is 
essentially the same as the CV that would have been obtained with still another sample 
to which high count rates of 3H-CA had been added and assessed with sample D as a 
calibrant (Eq. 1). This is because, as inspection of Eqs. 1 and 2 shows, the quotient is 
subject to the same sources of variation, the only exception being the much lower count 
rates in the plasma samples (C) obtained after infusion of 3H-CA. At these low count 
rates, counting error contributes to or even dominates the overall variation. It can be 
shown that, with a counting error of 6% or higher, the contribution of the other sources 
of variation, as reflected by the CV of quotient Q, becomes negligible (< 10%). Because 
this counting error of the activities in these plasma samples (C) with the lowest measured 
count rate is about 7% (achieved by counting the radioactivity of these samples for 20 
min), the CV of the radioactivity measurement in these plasma samples is expected to 
be approximately 7%. 
A high degree of purity of the tracers before processing is a necessary prerequisite for 
validity of the determination of 3H-CA. Damage occurring during derivatization and 
separation, however, leads only to lower procedural recovery, which then is completely 
compensated for in Eq. 1, which follows the same internal standard principle as for 
determinations of unlabeled CA. 
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Additionally, the conversion of the CA into diphenyl-quinoxalin derivatives involves 
only the dihydroxy groups on the catechol nucleus and therefore will not displace the 
tritium label from the catechol nucleus or anywhere else on the molecule. 
Optimal derivatization conditions differ significantly between the three CAs. Condi-
tions leading to an optimal recovery of one CA may lead to lower recovery of another. 
Because the differences between the plasma concentrations are obvious and require 
higher recoveries for the lower-concentration substances, the conditions chosen for the 
present study are a compromise that produces acceptable, though not optimal, recoveries 
for all three CAs. 
The bulk of plasma EPI is derived from adrenal medullary secretion. Synthesis of EPI 
in the central nervous system does not lead to release into plasma. It has been suggested 
that EPI is coreleased with neuronal NE from sympathetic nerves after uptake into 
sympathetic nerves from the circulation [13]. Such neuronal release of EPI, however, 
has been demonstrated only in the heart at very high rates of nerve stimulation, but not 
in unstimulated skeletal muscle [14]. Therefore, inasmuch as no difference in kinetics 
between exogenous 3H-substituted and unmodified EPI could be demonstrated [9], we 
anticipated that the FFE of endogenous EPI would equal or at least be close to that of 
infused 3H-EPI, and indeed, in this study only a small difference was observed. The 
origin of this small but significant difference between FFE of administered and endo-
genous EPI of about 5% is uncertain. First, the possibility of an assay artifact has to be 
considered. A systematic error averaging 1.7 ng/L in the estimations of venous EPI could 
account for this difference. However, even in the case of venous EPI estimation, such 
an error is unlikely because these amounts are well above the detection limit and in a 
concentration range with intraassay CV not expected to exceed 10%. Second, there 
might still be an isotope effect, too small to be detected by this approach, as reported 
by Eisenhofer et al. [9]. Third, if the rate of equilibration of the neuronal EPI pool lags 
somewhat behind that of the arterial pool of EPI, a smaller proportion of 3H-EPI 
entering the neuronal pool will be returned into the venous compartment than for 
endogenous EPI. This would account for the observed difference in 3H-EPI and 
endogenous EPI forearm fractional extraction. Finally, this difference could be explained 
by actual net release of endogenous EPI from the neuronal pool (spillover). The present 
technique is quite well suited for addressing this subject as well as for other studies on 
catecholamine kinetics. 
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Differential effects of low- and high-intensity lower body negative 
pressure on norepinephrine and epinephrine kinetics in humans 
Abstract 
Lower body negative pressure provides a means to examine neurocirculatory reflexive 
responses to decreases in venous return to the heart. We assessed whether the pattern of 
catecholaminergic responses to lower body negative pressure depends on the intensity 
of the stimulus (-15 vs -40 mmHg). In 14 healthy subjects, responses of forearm blood 
flow and norepinephrine spillover and of total body norepinephrine and epinephrine 
spillover were assessed during infusion of 3H-norepinephrine and 3H-epinephrine 
during -15 and -40 mmHg of lower body negative pressure. During lower body negative 
pressure at -15 mmHg, heart rate and pulse pressure did not change, but forearm vascular 
resistance increased by 25-50%. Forearm norepineph-rine spillover increased by about 
50%, from 0.63 ± 0.16 to 0.94 ± 0.23 pmol · min"1 · 100 ml"1 (P<0.05). Total body 
norepinephrine spillover did not change, and total body epinephrine spillover increased 
significantly by about 30%. Clearances of norepinephrine and epinephrine were un-
changed. During lower body negative pressure at -40 mmHg, heart rate increased and 
pulse pressure decreased. Forearm vascular resistance increased by about 100%, and 
forearm norepinephrine spillover increased by 80%, from 0.73 ± 0.19 to 1.32 ± 0.36 
pmol · min"1 • 100 ml"1 (P<0.05). Total body norepinephrine spillover increased by 
30%, and total body epinephrine spillover increased by about 50%. Clearances of both 
norepinephrine and epinephrine decreased. The results are consistent with the view that 
selective deactivation of cardiopulmonary baroreceptors during low-intensity lower 
body negative pressure increases sympathoneural traffic to forearm skeletal muscle and 
increases adrenomedullary secretion without a concomitant generalized increase in 
sympathoneural outflows. Concurrent deactivation of cardiopulmonary and arterial 
baroreceptors during high-intensity lower body negative pressure evokes a more gener-
alized increase in sympathoneural activity, accompanied by further increased ad-
renomedullary secretion and decreased plasma clearances of norepinephrine and 
epinephrine. The findings support differential increases in skeletal sympathoneural and 
adrenomedullary outflows during orthostasis, with more generalized sympathoneural 
responses to systemic hypotension. 
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Introduction 
The lower body negative pressure (LBNP) technique, introduced by Greenfield et al [1] 
in 1963, has been used frequently for examination of cardiopulmonary baroreflex 
function. By applying different levels of subatmospheric pressure to the lower half of 
the body, one can study reflexive neurocirculatory responses to decreases in venous 
return to the heart. Results of the studies of Zoller et al. [2] and Johnson et al. [3] have 
led to the view that LBNP at intensities less than -20 mmHg selectively deactivates 
cardiopulmonary baroreceptors and that, in humans, alterations in cardiopulmonary 
baroreceptor afferent traffic preferentially influence sympathetic outflows to skeletal 
muscle and skin. LBNP at intensities greater than -20 mmHg also deactivates arterial 
baroreceptors. Microneurographic studies have shown that both low- and high-intensity 
LBNPs increase efferent sympathoneural outflows to skeletal muscles in the arms and 
legs [4-6]. Because of differentiated autonomic response patterns during different forms 
of stress, microneurographic data about skeletal muscle and skin sympathetic nerve 
activity may not detect alterations in sympathetic nerve activity in other organs. 
Using a tracer approach, Baily et al [7] reported increases in forearm norepinephrine 
(NE) spillover but not in total body NE spillover (NE entry into arterial plasma) during 
low-intensity LBNP. Total body NE spillover responses to high-intensity LBNP have 
not been reported. Little is known about baroreflex regulation of adrenomedullary 
secretion in humans during LBNP or orthostasis. One study reported an increase in 
venous plasma epinephrine (EPI) levels during low-intensity LBNP in humans [8]. The 
meaning of this finding is unclear, since venous plasma EPI levels depend not only on 
adrenomedullary secretion but also on clearance of EPI from arterial plasma and on local 
catecholamine removal in the forearm. 
This study assessed effects of low- and high-intensity LBNP on total body and forearm 
kinetics of NE and EPI in healthy humans, using steady-state infusions of tracer amounts 
of 3 H-NEand 3 H-EPI[9] . 
Materials and methods 
Subjects 
Fourteen healthy male subjects (aged 25-38 years) participated in the study after giving 
their written informed consent. The study protocol was approved by the hospital ethics 
committee. Before entry into the study, all participants had a normal physical examina-
tion. None suffered from cardiovascular or other major diseases, and they took no 
medication. 
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Study protocol 
All subjects abstained from nicotine, alcohol, and caffeinated foods and beverages for at 
least 24 h before the study. The subjects were allowed to eat a light breakfast 2 h before 
the study. All experiments were carried out in the morning in a temperature-controlled 
observation room. 
During the study the subjects remained supine, with the lower body sealed at the iliac 
crests in an airtight Plexiglas™ box. The LBNP applied was recorded by a manometer 
connected to the inside of the box. 
After local anaesthesia using lidocaine, a cannula was inserted percutaneously into a 
brachial artery, for monitoring arterial blood pressure and heart rate (Hewlett Packard, 
Böblingen, Germany) and for drawing arterial blood samples. In the same arm, a cannula 
was inserted for collecting venous blood. Another venous cannula was inserted in the 
contralateral arm, for infusion of 3H-NE or 3H-EPI. 
Forearm blood flow (FBF) was measured using venous occlusion strain-gauge plethys-
mography [10] on the forearm contralateral to that used for 3H-NE infusion and it was 
positioned 10 cm above the mid-thoracic level. Measurements of FBF were obtained 
after exclusion of the hand circulation by inflating a wrist cuff to 100 mmHg above 
systolic blood pressure for at least 1 minute [11]. 
After instrumentation, the subjects rested for 30 min. During the last 3 min, baseline 
recordings of blood pressure, heart rate, and FBF (nine flow curves) were obtained. 
Blood pressure was recorded simultaneously with each FBF measurement. Thereafter, 
arterial and venous blood samples were drawn simultaneously for determinations of 
plasma catecholamines. Six subjects were infused with the radiotracer 3H-NE (L-
[ring-2,5,6-3H]-NE (specific activity 30-60 Ci/mmol)) and another six were infused 
with 3H-EPI (L-[N-methyl-3H]-EPI (specific activity 55-85 Ci/mmol)). An intravenous 
bolus of 15 (xCi · m~2 (0.55 MBq - m"2) was administered, followed by a constant infusion 
of 0.35 μ α · min"1 · m"2 (0.013 MBq · min"1 • m"2) for 120 min. In two subjects 3 H-NE 
and 3H-EPI were infused simultaneously. The first LBNP application began 30 min 
after the start of infusion of the radiotracers. 
LBNP at -15 mmHg was applied for 30 min. Blood pressure, heart rate, FBF and blood 
samples were taken in sequence, beginning after 7, 17 and 27 min of LBNP, so that the 
blood samples were drawn at 10,20, and 30 min of LBNP. A 30-min rest period ensued, 
followed by another 30 minutes of LBNP at -40 mmHg. Blood pressure, pulse rate, FBF 
and blood samples were obtained at the same time points as during LBNP at -15 mmHg. 
Materials 
Tritiated NE and EPI were obtained from Du Pont New England Nuclear ('s-Herto-
genbosch, The Netherlands). The radionuclides were sterilized using a 0.22 μπι filter 
and diluted in 0.9% NaCl containing acetic (0.2 mol · L"1) and ascorbic (1 mg · ml"1) 
acids. Aliquots of 70 цСі 3 H-NE and 3H-EPI were stored at -80°C until used. 
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Sterilization, dilution, and aliquoting were carried out under nitrogen. Just before use, 
an aliquot was diluted in 0.9% NaCl. The syringe containing the radiotracer was 
weighed just before and just after the infusion, in order to verify the infusion rate. 
Samples of the infusâtes were taken at the end of the infusion and stored at -80°C. 
Analytical methods 
Blood samples were collected in chilled tubes containing gluthatione (0.2 mol · L·1) and 
EGTA (0.25 mol · L"1). The tubes were centrifuged at 4°C and the plasma was separated 
and stored at -20°C. Assays of samples and infusâtes were carried out within 2 months 
of each study. 
Plasma samples were assayed for concentrations of EPI and NE using HPLC with 
fluorometric detection after precolumn derivatization with the fluorescent agent 1,2-
diphenylethylenediamine [12]. A Gilson fraction collector (Model 201-202), which was 
connected to an automatic sample injector (Wisp 710B), was used for collecting 3H-NE 
and 3H-EPI into scintillation vials, according to the retention times of NE and EPI 
standards. 
Data analysis 
Forearm vascular resistance (FVR) was calculated by dividing mean arterial blood 
pressure by FBF and was expressed in resistance units. 
The clearance of NE from arterial plasma was calculated from the infusion rate of 3H-NE 
and the steady-state arterial plasma concentration of the tracer, 3H-NEa: 
Total body NE clearance (1 · min'1) = 
infusion rate (dpm · min"1) / 3H-NEa (dpm · L"1) 
Total body NE spillover, the estimated rate of appearance of endogenous NE in arterial 
plasma, representing generalized sympathetic nerve activity, was calculated from the 
arterial plasma NE concentration (NEJ and the arterial steady-state clearance of NE, 
according to the equation: 
Total body NE spillover (nmol · min"1) = 
NEa (nmol · L"1) X total body NE clearance (L • min"1) 
Analogously, NE spillover in the forearm was estimated from: 
Forearm spillover (pmol · min"1· 100 ml"1) = 
(FPF x NEa x fNE) + FPF x (NE, - NEa ) 
where f^ = ( 3 H-NE a - 3H-NEv) / 3H-NEa, the fractional extraction of the tracer in the 
forearm; FPF is the forearm plasma flow, in units of ml · min"1 • 100 ml"1, calculated 
from the FBF and hematocrit; and 3H-NEv is the venous plasma concentration of 
3H-NE. 
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The removal of NE ¡η the forearm was calculated from: 
Forearm removal (pmol · m i n 1 · 100 ml·1) = FPF x NE
a
X f^E 
The clearance of EPI from arterial plasma and the estimated rate of appearance of 
endogenous EPI in arterial plasma were calculated according to the same formulas. 
Results are expressed as means ± SEM. For each variable, the mean of the three 
observations at the three time points during each LBNP was calculated. Within each 
group, the effects of LBNP on each variable were tested by the Wilcoxon signed-ranks 
test. This test was also used for testing differences between LBNP at -15 and at -40 
mmHg. A P-value below 0.05 defined statistical significance. 
Results 
Baseline measurements 
At baseline, total body spillover of NE (2.81 ± 0.34 nmol · m i n 1 ) was about seven to 
eight times higher than that of EPI (0.36 ± 0.05 nmol · m i n 1 ) . Clearances of NE and 
EPI from arterial plasma were similar (3.17 ± 0.34 and 2.84 ± 0.14 L · m i n 1 ) . 
LBNP at-15 mmHg 
Mean arterial blood pressure, pulse pressure, and heart rate did not change during LBNP 
at -15 mmHg (Table 1). FBF decreased significantly by about 30% and FVR increased 
by about 25-50%. 
The increase in venous plasma NE was larger than that of arterial plasma NE during 
LBNP at -15 mmHg, while the increase in venous plasma EPI was smaller than that of 
arterial plasma EPI (Table 2). The total body spillover of NE did not increase during 
LBNP at -15 mmHg (Fig 1), whereas the forearm spillover of NE increased in seven out 
of eight subjects, from 0.63 ± 0.16 to 0.94 ± 0.23 pmol · min"1 · 100 ml·1 (P<0.05) (Fig 
1). The clearance of NE from arterial plasma tended to decrease (P< 0.10). The removal 
of NE from the forearm did not change during LBNP at -15 mmHg (Table 2). The 
fractional extraction of NE increased slightly, from 0.64 ± 0.04 to 0.73 ± 0.03 (P<0.05). 
The total body spillover of EPI increased by about 30% during LBNP at -15 mmHg, 
from 0.36 ± 0.05 to 0.48 ± 0.07 nmol · m i n 1 (Table 2). The individual responses of 
total body spillover of EPI are shown in Fig 2. The clearance of EPI from arterial plasma 
and the removal of EPI from the forearm did not change during LBNP at -15 mmHg 
(Table 2). 
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Table 1. Hemodynamic variables before (basal) and during LBNP at -15 and at -40 mmHg. 
3 H - N E infusion (n=8) 
Mean arterial pressure (mmHg) 
Pulse pressure (mmHg) 
Heart rate (beats/min) 
FBF (ml · min' 1 · 100 ml'1) 
FVR (arbitrary units) 
3 H-EPI infusion (n=8) 
Mean arterial pressure (mmHg) 
Pulse pressure (mmHg) 
Heart rate (beats/min) 
FBF (ml · min' 1 · 100 m l 1 ) 
FVR (arbitrary units) 
basal 
90 ± 3 
66 ± 3 
58 ± 4 
1.81 ±0.27 
64 ± 3 
81 ± 2 
58 ± 3 
54 ± 3 
1.59 ± 0.23* 
59 ± 8 
LBNP-15 
89 ± 3 
63 ± 4 
57 ± 4 
1.38 ±0.22* 
80 ± 12* 
83 ± 2 
57 ± 3 
53 ± 2 
1.11 ±0.20* 
90 ± 14* 
basal 
92 ± 2 
62 ± 3 
56 ± 4 
1.85 ±0.24 
57 ± 8 
88 ± 2 
53 ± 5 
53 ± 2 
1.49 ± 0.25 
74 ± 12 
LBNP -40 
93 ± 3 
55 ± 3 * 
63 ± 4 * 
1.00 ±0.22* 
122 ± 19* 
90 ± 2 
47 ± 6 * 
61 ± 3 * 
0.90 ± 0.23* 
147 ± 32* 
Values are expressed as means ± SEM. Statistical significance (Wilcoxon signed-rank test): * P<0.05. 
Table 2. Plasma concentrations of NE and EPI, total body and forearm spillover and removal of NE 
before (basal) and during LBNP at -15 and at -40 mmHg. 
3 H - N E infusion (n=8) 
Venous NE (nmol · L"1) 
Arrenai NE (nmol · L'1) 
Total body NE spillover 
(nmol · min ) 
NE clearance (L · min ) 
Forearm NE spillover 
(pmol · min' 1 · 100 m l 1 ) 
Forearm NE removal 
(pmol · min"1 · 100 ml' 1) 
3 H-EPI infusion (n=8) 
Venous EPI (nmol · L'1) 
Arterial EPI (nmol · L'1) 
Total body EPI spillover 
(nmol • min"1) 
EPI clearance (L · min' ) 
Forearm EPI removal 
(pmol · min' 1 · 100 ml'1) 
basal 
0.90 ±0.10 
0.90 ± 0.06 
2.81 ± 0.34 
3.17 ±0.34 
0.63 ±0.16 
0.62 ±0.11 
0.06 ±0.01 
0.13 ±0.02 
0.36 ± 0.05 
2.84 ±0.14 
0.07 ±0.01 
LBNP-15 
1.44 ± 0.20* 
1.10 ±0.10* 
2.78 ± 0.30 
2.57 ±0.19 
0.94 ± 0.23* 
0.67 ±0.13 
0.08 ± 0 . 0 1 * 
0.18 ±0.02* 
0.48 ± 0.07* 
2.63 ±0.17 
0.07 ± 0.01 
basal 
1.13 ±0.19 
1.01 ±0.12 
3.00 ± 0.42 
3.12 ±0.39 
0.73 ±0.19 
0.70 ±0.15 
0.07 ± 0.01 
0.19 ±0.02 
0.50 ± 0.07 
2.51 ±0.18 
0.10 ±0.02 
LBNP -40 
2.60 ± 0.30* 
1.88 ±0.07* 
3.89 ± 0.30* 
2.08 ±0.15* 
1.32 ±0.36* 
0.91 ±0.24 
0.14 ± 0.02* 
0.34 ± 0.03* 
0.72 ± 0.08* 
2.07 ±0.16* 
0.11 ±0.03 
Values are expressed as mean ± SEM. Statistical significance (Wilcoxon signed-rank test): * Ρ < 0.05. 
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Figure 1. Total body NE spillover and forearm NE spillover before 
and in response to LBNP at -15 and at -40 mmHg. NS, not significant. 
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(E-CL) in eight subjects, to LBNPs at -15 ( light bar) and -40 mmHg 
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LBNP at-40 mmHg 
Mean anerial blood pressure did not change significantly during LBNP at -40 mmHg 
but pulse pressure decreased and heart rate increased significantly in both groups (Table 
1 ). FBF decreased significantly by about 40-50% and the FVR increased by about 100%. 
The increase of venous plasma NE was larger than that of arterial plasma NE during 
LBNP at -40 mmHg (Table 2). In contrast to LBNP at -15 mmHg, the total body 
spillover of NE increased by about 30% during LBNP -40 mmHg while the forearm 
spillover of NE increased by about 80% from 0.73 ± 0.19 to 1.32 ± 0.36 pmol · min"1 
• 100 ml"1 (Fig 1). Fig 1 shows that the forearm spillover of NE increased in seven out 
of eight subjects. The clearance of NE from arterial plasma decreased significantly while 
the removal of NE from the forearm did not change significantly during LBNP at -40 
mmHg (Table 2). The fractional extraction of NE increased slightly from 0.62 ± 0.05 
to 0.76 ± 0.03 (P<0.05) during LBNP at -40 mmHg. 
The total body spillover of EPI increased by about 50% in all subjects during LBNP at 
-40 mmHg (Table 2 and Fig 2). The clearance of EPI from arterial plasma decreased 
while removal of EPI from the forearm remained unchanged (Table 2). 
Comparison of LBNP at -15 and at -40 mmHg 
Comparison of the responses during LBNP at -15 and -40 mmHg was made for the 
variables whose values changed during both LBNP periods. The increase in FVR was 
larger during LBNP at -40 than at -15 mmHg (P<0.05) (Table 1). The increments in 
venous and arterial plasma NE and EPI were also significantly larger during LBNP at 
-40 than at -15 mmHg (Table 2). The increase in forearm spillover of NE tended to be 
larger at -40 mmHg (0.59 ± 0.24 pmol · min"1 -100 ml"1) than at -15 mmHg (0.31 ± 
0.13 pmol · min"1 · 100 ml"1, P=0.09, Fig 3). The increment in total body spillover of 
EPI was larger during LBNP at -40 mmHg (0.22 ± 0.04 nmol · min"1) than at -15 
mmHg (0.12 ± 0.03 nmol · min"1, P< 0.05, Fig 3). 
Discussion 
The main new findings of this study were: (1) low-intensity LBNP increased forearm 
NE spillover and EPI spillover without affecting total body NE spillover; (2) high-in-
tensity LBNP increased total body NE spillover; (3) LBNP elicited intensity-related 
increments in total body spillover of EPI and decreases in plasma clearances of NE and 
EPI. 
Zoller et al. [2] and Johnson et al. [3] demonstrated that a LBNP of less than -20 mmHg 
selectively deactivates cardiopulmonary baroreceptors. At negative pressures exceeding 
-20 mmHg, there is additional deactivation of arterial baroreceptors. Our data are in 
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agreement with selective deactivation of cardiopulmonary baroreceptors during low-in-
tensity LBNP (-15 mmHg), since we found no increase in heart rate or a decrease in 
pulse pressure in response to this stimulus. During LBNP at -40 mmHg, heart rate 
increased and pulse pressure decreased. At this stage, it is impossible to examine arterial 
baroreceptors separately from cardiopulmonary baroreceptors with LBNP since arterial 
baroreceptor deactivation cannot be attained without simultaneous pertubation of the 
cardiopulmonary baroreceptors. Two other factors impede an examination of the arterial 
baroreceptors separately. First, the stronger intensity of LBNP at -40 mmHg does not 
only cause a concurrent deactivation of arterial baroreceptors but probably also elicits a 
gradually stronger deactivation of cardiopulmonary baroreceptors. Second, there is a 
functional interaction between arterial and cardiopulmonary baroreceptors that does 
not allow assessment of effects of arterial baroreceptor deactivation by subtracting the 
effects of unloading of cardiopulmonary baroreceptors from that of simultaneous 
deactivation of arterial and cardiopulmonary baroreceptors. 
During low-intensity LBNP, there was an increase in forearm NE spillover but not in 
total body NE spillover. This not only confirms that cardiopulmonary baroreceptors 
play an important role in reflexive regulation of FBF but also indicates the regionaliza-
tion of sympathoneuronal responses to this stressor. In contrast, total body spillover of 
NE increased during concomitant deactivation of cardiopulmonary and arterial barore-
ceptors, suggesting more diffuse increases in sympathetic nerve outflows. Measurements 
of total body spillover of NE during orthostasis may therefore fail to detect regional 
sympathoneuronal responses. Differentiated sympathoneuronal response patterns have 
also been demonstrated for several other stressors. 
The plasma clearance of NE tended to decrease during cardiopulmonary baroreceptor 
deactivation and decreased further during simultaneous deactivation of arterial and 
cardiopulmonary baroreceptors. These decreases in plasma NE clearance probably 
resulted from decreases in cardiac output and splanchnic blood flow, as has been 
demonstrated during cardiopulmonary and arterial baroreceptor deactivation [13, 14]. 
Apart from sympathoneural activation during LBNP, we also found small but significant 
elevations in venous and arterial EPI levels. The increments were larger during high-in-
tensiry LBNP than during low-intensity LBNP. Increments in plasma EPI levels during 
low-intensity LBNP are in agreement with a previous study [8]. Since we found no 
decrease in the clearance of EPI and an increase in total body spillover of EPI, the 
increments in plasma EPI levels during low-intensity LBNP probably result from 
increased adrenomedullary secretion. During combined deactivation of cardiopulmon-
ary and arterial baroreceptors, there was a further increase in adrenomedullary secretion 
of EPI, but now the decreased clearance of EPI contributed to the larger increment in 
plasma EPI levels during high-intensity LBNP. 
LBNP at —45 to —50 mmHg is equivalent to head-up tilt to 90°, with respect to the 
amount of blood translocated. As shown previously, plasma NE and EPI levels nearly 
double during orthostasis, and this is in agreement with the plasma catecholamine 
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responses during LBNP at -40 mmHg in the present study. These increments in plasma 
catecholamine levels result from both increased arterial NE spillover and decreased 
plasma NE clearance [15]. In the present study, using LBNP at -40 mmHg, responses 
of spillover and clearance were qualitatively similar to those reported previously for 
head-up tilt. 
LBNP induced a vasoconstrictor response in the forearm that was largest when both 
types of baroreceptors were deactivated simultaneously during high-intensity LBNP. 
This is in agreement with the further increase in forearm NE spillover during high-in-
tensity LBNP. The larger responses of FVR and forearm NE spillover during high-in-
tensity LBNP can be explained by either a stronger deactivation of cardiopulmonary 
baroreceptors, or by the concurrent deactivation of arterial baroreceptors or both. Since 
there must be arterial baroreceptor deactivation during high-intensity LBNP [2,3], our 
data indicate that arterial baroreceptors are probably as important for baroreflex control 
of the forearm skeletal muscle circulation as cardiopulmonary baroreceptors. This 
conclusion is supported by the findings of microneurographic studies, showing that 
sympathetic nerve traffic responses were larger during deactivation of arterial barorecep-
tors than during deactivation of cardiopulmonary baroreceptors [6,16]. Previous studies 
have suggested that cardiopulmonary baroreceptors play a major role in the reflex control 
of the skeletal muscle circulation [17]. 
The contribution of the skin to the FBF and thus to the forearm NE spillover should 
be considered. Some but not all previous studies showed that LBNP produced graded 
vasoconstriction of the skin vessels, thus contributing to the forearm vasoconstrictor 
response [7, 18]. Assuming that sympathetic nerve traffic to the skin is also increased 
during LBNP, the increase in forearm NE spillover may overestimate the increase in 
muscle sympathoneural activity; however, if the increments in NE spillover from the 
skin and the muscles were proportionally the same at -15 and at -40 mmHg, then the 
conclusion that arterial baroreceptors are important for reflex regulation of skeletal 
muscle circulation would be still valid. 
In conclusion, the data of this study indicate that selective deactivation of cardiopul-
monary baroreceptors during low-intensity LBNP increases NE release in the forearm 
and EPI release by the adrenals. Concurrent deactivation of arterial baroreceptors during 
high-intensity LBNP produces further increases in forearm vasoconstriction and NE 
spillover, with increases also in total body NE and EPI spillover and decreases in 
clearances of NE and EPI. 
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Neurohumoral antecedents of vasodepressor reactions 
Abstract 
Vasodepressor (vasovagal) syncope, the most common cause of acute loss of conscious­
ness, can occur in otherwise vigorously healthy people during exposure to stimuli 
decreasing cardiac filling. Antecedent physiological or neuroendocrine conditions for 
this dramatic syndrome are poorly understood. This study compared neurocirculatory 
responses to non-hypotensive lower body negative pressure in subjects who subsequently 
developed vasodepressor reactions during hypotensive lower body negative pressure with 
responses in subjects who did not. 
In 26 healthy subjects, lower body negative pressure -15 and -40 mmHg was applied to 
inhibit cardiopulmonary and arterial baroreceptors. All the subjects tolerated 30 min of 
lower body negative pressure at -15 mmHg, but during subsequent lower body negative 
pressure at -40 mmHg 11 subjects had vasodepressor reactions, with sudden hypoten­
sion, nausea, and dizziness. In these subjects, arterial plasma epinephrine responses to 
lower body negative pressure both at -15 and at -40 mmHg exceeded those in subjects 
who did not experience these reactions. In 16 of the 26 subjects, forearm norepinephrine 
spillover was measured; in the eight subjects with a vasodepressor reaction, mean forearm 
norepinephrine spillover failed to increase during lower body negative pressure at -15 
mmHg (Δ = -0.06 + (SEM) 0.04 pmol • min"1 • 100 ml"1), whereas in the eight subjects 
without a vasodepressor reaction, mean forearm norepinephrine spillover increased 
significantly (Δ = 0.31 ± 0.13 pmol · min"1 · 100ml"1). Plasma levels of ß-endorphin 
during lower body negative pressure at -15 mmHg increased in some subjects who 
subsequently had a vasodepressor reaction during lower body negative pressure at -40 
mmHg. 
The findings suggest that a neuroendocrine pattern including adrenomedullary stimu-
lation, skeletal sympathoinhibition, and release of endogenous opioids can precede 
vasodepressor syncope. 
Introduction 
Vasodepressor syncope, or fainting, is the most frequent cause of sudden loss of 
consciousness [1] and can occur in otherwise healthy people during exposure to 
emotional stress, heat, prolonged upright posture, or pain. The hemodynamic hallmark 
of vasodepressor reactions is systemic vasodilation [2], especially in skeletal muscle [3, 
4], with or without vagally mediated bradycardia. Microneurographic studies have 
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shown that precipitously decreased skeletal sympathetic nervous outflow accompanies 
the vasodilation [5]. Plasma norepinephrine (NE) levels, measured immediately after or 
at the time of fainting, are decreased or inappropriately normal [6, 7] and release of NE 
into the venous drainage in the heart [8] and kidneys [9] decreases virtually to zero. In 
contrast, plasma epinephrine (EPI) levels often are increased [6]. Vagal bradycardia does 
not cause vasodepressor reactions, because parasympatholytic drugs may not reverse or 
prevent the hypotension [10]. 
Mechanisms responsible for the abrupt decreases in sympathetic outflows have been 
unclear. One possibility is sudden central resetting of baroreflexes, so that hypotension 
fails to release sympathoneural outflows from baroreceptor restraint. Since endogenous 
opioids augment the extent of sympathoinhibition during a hypotensive stimulus (e.g. 
haemorrhage) [11], sudden release of endogenous opioids in the brain could contribute 
to baroreflex resetting and thereby produce sympathoinhibition despite hypotension. 
Vasopressin also augments baroreflex restraint of sympathoneural outflows [12], and 
extremely high circulating vasopressin levels often accompany vasodepressor syncope 
[13]. Alternatively, stimulation of ventricular stretch receptors that increase activity of 
non-myelinated, inhibitory afferent C-fibers [14,15], or collapse-firing of low pressure 
baroreceptors in the right atrium and great veins [16], evoke vasodepressor reactions. 
The common feature of the central and peripheral hypothesized mechanisms is sym-
pathoinhibition despite hypotension. 
The suddenness and unexpectedness of vasodepressor reactions have hampered efforts 
to identify antecedent hemodynamic and neurohumoral events. Prolonged head-up tilt, 
with or without intravenous isoproterenol infusion [17], or relatively large amounts of 
lower body negative pressure (LBNP) [18] can provoke these episodes. In the current 
study, we examined circulatory, catecholaminergic, and ß-endorphin responses to a 
small decrease in cardiac filling during mild LBNP (-15 mmHg) and to systemic 
hypotension during subsequent more intense LBNP (-40 mmHg) in healthy people. 
LBNP at less than -20 mmHg reduces central venous pressure without altering arterial 
blood pressure or pulse pressure, suggesting relatively selective inhibition of cardiac 
baroreceptors [19], whereas higher intensity LBNP decreases blood pressure and pulse 
pressure, inhibiting cardiac and arterial baroreceptors. We compared responses in groups 
of subjects who did, vs. those who did not, develop a vasodepressor reaction during 
high-intensity LBNP, in order to identify possible neurochemical antecedents of vasode-
pressor syncope. 
To assess neurohumoral responses during inhibition of cardiopulmonary and arterial 
baroreceptors, plasma catecholamine concentrations were measured. Plasma NE levels, 
however, have some limitations as a measure of sympathetic activity since they are the 
net result of the rate by which NE spills over into the circulation (after neuronal release 
and neuronal uptake) and the rate by which NE is removed from the plasma. Therefore 
we used the radiotracer dilution technique [20] that enables calculation of the total body 
spillover of NE into the circulation. This is a better, although not ideal, measure of total 
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body neuronal NE release and thus over-all sympathetic activity. Since in many 
conditions sympathetic outflow is not uniformly distributed to different organs, calcu-
lation of the regional spillover of NE in an organ is preferred as a measure of regional 
sympathetic activity. Forearm spillover and removal of NE can be calculated by 
measuring forearm blood flow, venous and arterial plasma NE levels and the extraction 
of the tracer tritiated NE. Measurement of NE spillover and removal in the forearm 
enables to identify whether increments in venous forearm plasma NE levels are due to 
an increased neuronal release to or to a decreased removal of NE from the forearm 
circulation. 
Patients and methods 
Subjects 
Twenty-six healthy male subjects participated in the study after giving their written 
informed consent. The study protocol was approved by the Hospital Ethics Committee. 
Before entry into the study, all participants had a normal physical examination. None 
suffered from cardiovascular or other major diseases, and they took no medication. None 
of the participants had a history of syncopal attacks. 
Study protocol 
All subjects abstained from nicotine, alcohol, and caffeinated foods and beverages for at 
least 24 h before the study. The subjects were allowed to eat a light breakfast 2 h before 
the study. All experiments were carried out in the morning in a temperature-controlled 
observation room. 
During the study, the subjects remained supine, with the lower body sealed at the iliac 
crests in an airtight Plexiglas™ box. The applied LBNP pressure was recorded by a 
manometer connected to the inside of the box. 
After local anesthesia using lidocaine, a cannula was inserted percutaneously into a 
brachial artery, for monitoring arterial blood pressure and heart rate (Hewlett Packard 
GmbH, Böblingen, Germany) and for drawing arterial blood samples. In the same arm, 
a cannula was inserted for collecting venous blood. In 16 of the 26 subjects, another 
venous cannula was inserted in the contralateral arm, for infusion of 3H-norepinephrine 
(3H-NE). 
Forearm blood flow (FBF) was measured using venous occlusion strain-gauge plethys-
mography [21]. The forearm contralateral to that used for 3H-NE infusion was posi-
tioned 10 cm above the mid-thoracic level. Measurements of FBF and blood samples 
were obtained after exclusion of the hand circulation by inflating a wrist cuff to 100 
mmHg above systolic blood pressure for at least 1 min [22]. 
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After instrumentation, the subjects rested for at least 30 min. During the last 3 min, 
baseline recordings of blood pressure, heart rate, and FBF (nine flow curves) were 
obtained. Blood pressure was recorded simultaneously with each FBF measurement. 
Thereafter, arterial and venous blood samples were drawn simultaneously for determi­
nations of plasma catecholamines. 
LBNP at -15 mmHg was then applied for 30 min. Blood pressure, heart rate, FBF 
recordings and blood samples were taken in sequence beginning after 7, 17 and 27 min 
of LBNP, so that the blood samples were drawn at 10, 20, and 30 min of LBNP. A 30 
min rest period ensued, followed by another 30 min of LBNP -40 mmHg. Blood 
pressure, pulse rate, FBF, and blood samples were obtained at the same time points as 
for LBNP-15 mmHg. 
H-NE infusion 
3 H-NE (levo-[ring-2,5,6-3H]-NE) was infused to assess plasma NE kinetics. Tritiated 
NE was obtained from Du Pont New England Nuclear ('s-Hertogenbosch, the Neth­
erlands). The radionuclide was sterilized using a 0.22 |lm filter and diluted in 0.9% 
NaCl containing acetic (0.2 mol-L"1) and ascorbic (1 mg · mL"1) acid. Aliquots of 50 
\ld 3 H-NE were stored at -80°C until used. Sterilization, dilution, and aliquoting were 
carried out under nitrogen. Just before use, an aliquot was diluted in 0.9% NaCl. The 
radiotracer was administered intravenously as a bolus of 15 цСі · m"2 followed by a 
constant infusion of 0.35 цСі · m i n ' · m 2 for 120 min. The first LBNP application 
began at 30 min of infusion of 3 H-NE. The weight of the syringe containing the 
radiotracer was measured just before and just after the infusion, in order to check the 
infusion rate. Samples of the infúsate were taken at the end of the infusion. 
Analytical methods 
Blood samples were collected in chilled tubes containing gluthatione (0.2 mol-L"1) and 
EGTA (0.25 mol · L"1)· The tubes were centrifuged at 4°C and the plasma separated 
and stored at -20°C. Assays of all samples and infusâtes occurred within 2 months of 
each study. 
Plasma samples were assayed for concentrations of epinephrine (EPI), total NE, and 
3H-NE, using high performance liquid chromatography (HPLC) with fluorometric 
detection after precolumn derealization with the fluorescent agent 1,2-diphenylethyle-
nediamine [23]. A fraction collector connected to an automatic sample injector (WISP 
710B, Waters-Millipore, Milford, MA, USA), was used for collecting 3H-NE into 
scintillation vials, according to the retention time of NE standard. 
Arterial plasma immunoreactive ß-endorphin levels were measured by a radioimmu-
noassay [24] in the 16 subjects in whom plasma NE kinetics were studied. 
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Data analysis 
Forearm vascular resistance (FVR) was calculated by dividing mean arterial blood 
pressure by FBF and was expressed in resistance units (RU). 
The clearance of NE from arterial plasma was calculated from the infusion rate of 3 H-NE 
and the steady-state arterial plasma concentration of 3 H-NE, 3 H-NE
a
: 
Total body NE clearance (L • min_1)= 
Infusion rate (dpm · min"1) / 3 H-NE
a
 [dpm · L"1) (1) 
Total body NE spillover, the estimated rate of appearance of endogenous NE in arterial 
plasma, was calculated from the arterial plasma NE concentration (NEJ and the arterial 
steady-state clearance of NE, according to the equation: 
Total body NE spillover (nmol · min"1) = 
NE
a
 (nmol · L"1) X total body NE clearance (L · min"1) (2) 
Analogously, NE spillover in the forearm was estimated from: 
Foream NE spillover (pmol · m i n 1 · 100 ml"1) = 
( Р Р Р х Н Е
а
х ^
Е
)
 + ( Р Р Р х № - № а ) ) (3) 
where fNE= ( 3 H - N E
a
-
 3H-NEy) / 3 H-NE
a
, the fractional extraction of the tracer in the 
forearm; FPF is the forearm plasma flow, in units of mL · m i n 1 · 100 mL"1, calculated 
from the forearm blood flow and haematocrit; and 3H-NEv is the venous plasma 
concentration of 3 H-NE. 
The removal of NE in the forearm was calculated from: 
Forearm NE removal (pmol • min"1 · 100 ml"1) = FPF x N E
a
x fNE (4) 
Subjects were classified post hoc into two groups. Subjects in group A underwent both 
30 min periods of LBNP without experiencing dizziness, nausea, weakness, or hypoten­
sion. Subjects in group В underwent LBNP at -15 mmHg without symptoms but 
developed a vasodepressor reaction during LBNP at -40 mmHg. The criteria for a 
vasodepressor reaction were hypotension (systolic blood pressure < 100 mmHg or a rapid 
decrease of >20 mmHg) and symptoms (nausea, dizziness, or weakness). 
Results are expressed as means ± SEM. For each LBNP period, values for all dependent 
variables were averaged across the three time points during LBNP. To assess the effects 
of LBNP, the Wilcoxon signed rank test was used to compare the baseline with the 
average value of a variable during LBNP. Responses at each time point were expressed 
as the absolute change at a time point from the baseline value, and two-way analyses of 
variance (ANOVA's) for repeated measures were used to compare the changes as a 
function of time in the two groups. A P-value less then 0.05 defined statistical 
significance. 
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Results 
Of the 26 subjects, 15 (group A) underwent 30 min of LBNP at -15 mmHg as well as 
at -40 mmHg without any signs of a vasodepressor reaction. The remaining 11 subjects 
(group B) developed a vasodepressor reaction during LBNP at -40 mmHg. There were no 
differences in age, resting blood pressure, or heart rate between the two groups (Table 1). 
All but one subject in group В had both hypotension and bradycardia during LBNP at 
-40 mmHg, bradycardia being defined as a pulse rate less than 50 bpm or a rapid decrease 
of more than 10 bpm. In group В subjects, LBNP at -40 mmHg was terminated 
immediately when the first signs of a vasodepressor reaction emerged. All group В 
Table 1. Clinical characteristics of group A (without syncope) and group В (with syncope) 
Parameter Group A Group В 
Number (n) 
Age (years) 
Height (cm) 
Weight (kg) 
Quetelet index (kg · m"2) 
SBP (mmHg) 
DBP (mmHg) 
HR (bpm) 
15 
30 ±5 
184 ±8 
82.0 ± 10.6 
24.4 ± 3.2 
120 ±9 
72 ± 8 
70 ±10 
11 
29 ±6 
184 ±9 
81.7 ± 10.3 
24.2 ± 3.6 
125 ± 10 
73 ±9 
67 ±7 
Mean ± SD are given. The data in this table show blood pressure and heart rate values obtained at the 
screening visit prior to entry in the study. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, 
heart rate. 
subjects complained of nausea, and some became pale; one lost consciousness. The 
vasodepressor response occurred in the first 10 min of LBNP at -40 mmHg in two 
subjects, between 10 and 20 min in seven subjects, and in the last 10 min in two subjects. 
Consequently, the data summarized below for LBNP at -40 mmHg are incomplete for 
group B. 
LBNP at-15 mmHg 
During LBNP at -15 mmHg, FBF decreased and FVR increased significantly in both 
groups (Table 2), and the groups did not differ in values for these variables. Blood 
pressure, pulse pressure, and heart rate did not change during LBNP at -15 mmHg in 
either group. 
Baseline levels of venous plasma NE were similar in the two groups (0.92 ±0.10 nmol 
• L"1 in group A and 1.00 ± 0.09 nmol · L"1 in group B). During LBNP, venous plasma 
NE levels increased significantly in both groups to 1.38 ± 0.13 nmol • L"1 in group A 
and 1.26 ± 0.11 nmol · L"1 in group В at 30 min of LBNP. There was a tendency for 
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Table 2. Haemodynamic data during LBNP at -15 mmHg in group A (without syncope, n= 15) and group 
В (with syncope, n=l 1). 
FBF (mL · min"1 · 100 mL' 
FVR (resistance units) 
SBP (mmHg) 
DBP (mmHg) 
Pulse pressure (mmHg) 
Heart rate (bpm) 
') Baseline 
LBNP -15 
Baseline 
LBNP -15 
Baseline 
LBNP-15 
Baseline 
LBNP -15 
Baseline 
LBNP -15 
Baseline 
LBNP-15 
Group A 
1.61 ±0.19 
1.16 ±0.15** 
64 ±8 
90 ± 10** 
126 ± 4 
127 ± 3 
73 ± 3 
75 ± 3 
61 ± 2 
59 ± 2 
55 ± 3 
54 ± 3 
Group В 
1.46 ±0.19 
1.06 ±0.15** 
71 ± 10 
99 ± 13** 
128 ± 4 
130 ± 4 
67 ± 2 
69 ± 3 
6 4 ± 2 
61 ± 2 
59 ± 2 
60 ± 2 
Mean ± SEM are given. SBP, systolic blood pressure; DBP, diastolic blood pressure; FBF, forearm blood 
flow; FVR, forearm vasular resistance. ** Ρ < 0.01 with respect to baseline. 
smaller venous plasma NE responses in the group with subsequent syncope but the 
increments in venous NE levels were not significantly different between the two groups 
(Fig 1). 
Baseline arterial plasma NE levels also did not differ between the groups. Arterial NE 
levels increased from 0.94 ± 0.08 to a maximal value of 1.10 ± 0.08 nmol • L"1 in group 
A and from 0.92 ±0.11 nmol · L 1 to 1.03 ± 0.09 nmol · L·1 in group B. 
Baseline arterial EPI levels were similar in the two groups (0.16 ± 0.03 nmol · I/ 1 in 
group A and 0.17 ± 0.03 nmol · L'1 in group B). In both groups, arterial EPI levels 
increased significantly during LBNP at -15 mmHg; however, in group A, arterial EPI 
levels plateaued at about 0.22 nmol · L"1 after 10 min, whereas in group B, arterial EPI 
levels progressively rose to a peak value of 0.34 ± 0.05 nmol · L"1. Thus, the absolute 
increments in arterial EPI levels were larger in the group with than in the group without 
subsequent syncope (Fig 2). Venous plasma EPI responses did not differ between the 
two groups. 
In the 16 subjects who received a 3 H-NE infusion, mean forearm NE spillover at baseline 
was not significantly different between group A (n=8) and group Β (n=8) subjects (0.63 
± 0.16 vs 0.76 ± 0.16 pmol · m i n 1 · 100 m L 1 , Table 3). During LBNP at -15 mmHg, 
the average response of forearm NE spillover across all time points was larger in the 
56 I Chapter 4 
0 6 0 r 
Π no syncope 
0 syncope 
OOO 
0 2 4 r 
10 mm 20 mm 30 min 
D no syncope 
0 syncope 
0 0 0 10 min 20 min 30 min 
P<005 No syncope vs. syncope (two-way ANOVA) 
Figure 1. Increments in venous 
plasma norepinephrine (NA, 
means ± SEM) after 10, 20, and 
30 min of lower body negative 
pressure for group A (n=15, no 
syncope) and group В ( n = l l , 
syncope). 
Figure 2. Increments in arterial 
plasma epinephrine (A, means ± 
SEM) after 10, 20, and 30 min 
of lower body negative pressure 
for group A (n= 15, no syncope) 
and group В (n=l 1, syncope). 
group A subjects (0.31 ±0.13 pmol · min"1 • 100 ml/ 1) than in the group В subjects 
(-0.06 ± 0.04 pmol · min'1 · 100 ml/ 1 , P< 0.05, Figure 3). 
Values for total body NE spillover did not change significantly in either group during 
LBNP at -15 mmHg (Table 3). Values for total body NE clearance decreased by about 
30% in group A and did not change in group B. In neither group did values for forearm 
NE removal change during LBNP at -15 mmHg. 
Baseline plasma ß-endorphin levels did not differ between the groups and did not change 
significantly during LBNP at -15 mmHg in group A (27 ± 3 pg · mL"1 at baseline to 30 
± 4 pg · mL"1 during LBNP). In group B, plasma ß-endorphin increased in three of the 
eight subjects; the average increase, from 38 ± 11 pg • mL"1 at baseline to 62 ± 28 pg · 
mL"1 during LBNP at -15 mmHg, was not significant. 
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Table 3. Norepinephrine kinetics values during LBNP at -15 mmHg in group A (without syncope, n=8) 
and group В (with syncope, n=8). 
Arterial plasma NE 
(nmol · L"1) 
Forearm NE spillover 
(pmol-min'MOOmL"1) 
Total body NE spillover 
(nmol · min"1 m ) 
Total body NE clearance 
(L • min''τη'2) 
Baseline 
LBNP-15 
Baseline 
LBNP-15 
Baseline 
LBNP-15 
Baseline 
LBNP-15 
Group A 
0.90 ± 0.06 
1.10 ±0.12* 
0.63 ±0.16 
0.94 ± 0.23* 
1.39 ±0.19 
1.37 ±0.15 
1.56 ±0.18 
1.26 ± 0.08* 
Group В 
0.88 ±0.15 
0.95 ±0.10 
0.76 ±0.16 
0.70 ±0.13 
0.99 ±0.16 
1.26 ±0.16 
1.30 ±0.14 
1.32 ± 0.07 
Means ± SEM arc given. NE, norepinephrine. * Ρ < 0.05 with respect to baseline. 
ài 
il 
га i 
i l 
u.
 w 
1.0 
0.8 
0.6H 
0.4 
0.2 H 
0.0 
-0.2 
-0.4 J 
p<0.05 
I 
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Figure 3. Individual responses of fore­
arm norepinephrine (NE) spillover in 
eight subjects without and eight sub­
jects with syncope. FAV= forearm vol­
ume. 
LBNP at-40 mmHg 
In both group A and group B, FBF decreased and FVR increased during LBNP at -40 
mmHg, analogous to the changes during LBNP at -15 mmHg (Table 4); however, the 
changes in values for both variables were larger during LBNP at -40 mmHg than during 
LBNP at -15 mmHg. Systolic blood pressure and pulse pressure decreased and heart 
rate increased, both in the group A subjects and in the nine group В subjects. 
Baseline levels of venous plasma NE were similar in the two groups (1.08 ± 0.13 nmol 
• L"1 in group A and 1.10 ± 0.12 nmol · L"1 in group B). During LBNP, venous plasma 
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Table 4. Haemodynamic data during LBNP at -40 mmHg in group A (without syncope, n=15) and 
group В (with syncope, n=9 *). 
FBF 
(mL · min"1 · 
FVR 
100 mL"1) 
(resistance units) 
SBP 
(mmHg) 
DBP 
(mmHg) 
Pulse pressure 
(mmHg) 
Heart rate 
(bpm) 
Baseline 
LBNP -40 
Baseline 
LBNP -40 
Baseline 
LBNP -40 
Baseline 
LBNP -40 
Baseline 
LBNP -40 
Baseline 
LBNP -40 
Group A 
1.49 ±0.17 
0.88 ±0.14*** 
71 ± 8 
135 ± 1 8 * " 
129 ± 2 
125 ± 3*** 
73 ± 3 
75 ± 3 
57 ± 3 
50 ± 4*** 
54 ± 2 
62 ± 3*** 
Group В 
1.16 ±0.16 
0.65 ±0.10** 
94 ± 11 
165 ±21*** 
140 ± 5 
131 ± 5*** 
75 ± 3 
75 ± 3 
65 ± 3 
56 ± 3*** 
57 ± 2 
68 ± 4** 
Means ± SEM are given. SBP, systolic blood pressure; DBP, diastolic blood pressure; FBF, forearm blood 
flow; FVR, forearm vasular resistance. * Represents the data of nine subjects of group В (n= 11) who tolerated 
the first 10 min of LBNP at -40 mmHg but who later developed a vasodepressor reaction. Two subjects 
had a vasodepressor reaction in the first 10 min of LBNP at -40 mmHg. ** Ρ < 0.01, * " Ρ < 0.001 with 
respect to baseline. 
Table 5. Norepinephrine kinetics values during LBNP at -40 mmHg in group A (without syncope, n=8) 
and group В (with syncope, n=6 *). 
Group A Group В 
Arterial plasma NE 
(nmol · L"1) 
Baseline 
LBNP -40 
1.01 ±0.12 
1.88 ± 0.08* 
0.82 ±0.11 
1.50 ±0.21* 
Forearm NE spillover 
(pmol - min"1 · 100 ml"1) 
Total body NE spillover 
(nmol · min"1 · m"2) 
Baseline 
LBNP -40 
Baseline 
LBNP -40 
0.73 ±0.19 
1.32 ±0.36* 
1.47 ± 0.20 
1.91 ±0.15** 
0.60 ±0.17 
0.73 ±0.15 
1.05 ±0.18 
1.87 ± 0.24 
Total body NE clearance Baseline 
( L - m i n 1 - m " 2 ) LBNP-40 
1.51 ±0.17 
1.02 ± 0.07* 
1.25 ±0.10 
1.31 ±0.20 
Means ± SEM are given. NE, norepinephrine. * Represents the data for six subjects of group Β (n=8) who 
tolerated the first 10 min of LBNP at -40 mmHg but who developed a vasodepressor reaction later. Two 
subjects had a vasodepressor reaction in the first 10 min of LBNP at -40 mmHg. * P<0.05 and ** P<0.01 
with respect to baseline. 
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NE levels increased significantly in both groups to 2.12 ± 0.22 nmol · L"1 in group A 
and 2.11 ± 0.22 nmol · L'1 in group B. 
In the group A subjects, arterial plasma NE increased from 1.01 ± 0.10 to 1.76 ± 0.09 
nmol · L"1 (P<0.01). In the nine group В subjects, the arterial plasma NE response (from 
0.93 ± 0.10 to 1.50 ± 0.14 nmol · L·1, P<0.01) after 10 min of LBNP at -40 mmHg did 
not differ significantly from that in the group A subjects. 
Arterial plasma EPI levels increased in the group A subjects from 0.21 ± 0.02 nmol · L·1 
to 0.39 ± 0.04 nmol · L·1 (P<0.01) during LBNP at -40 mmHg and increased markedly 
in the nine group В subjects from 0.30 ± 0.04 nmol · L"1 to 1.24 ± 0.44 nmol · L"1 
(P<0.01) after 10 min of LBNP. 
In group A total body NE spillover increased significantly by about 30% during LBNP 
at -40 mmHg, and NE clearance decreased significantly by about 40% (Table 5); in 
group B, total body NE spillover increased in five subjects, but this response was not 
significant (Table 5). Forearm NE spillover increased in the group A subjects, from 0.73 
± 0.19 to 1.32 ± 0.36 pmol · min"1 · 100 mL"1, P<0.05, whereas in group В there was 
no significant change (Table 5). 
Plasma ß-endorphin levels did not change during LBNP at -40 mmHg in group A (34 
± 6 pg • mL"1 at baseline, 38 ± 5 pg · mL"1 during LBNP), whereas in group В plasma 
ß-endorphin increased in six of the eight subjects; the average increase, from 59 ± 12 pg 
• mL"1 at baseline to 82 ± 22 pg · mL"1 during LBNP at -40 mmHg, was not significant. 
Discussion 
Few occurrences in clinical medicine match vasodepressor reactions for abruptness, 
unexpectedness, and drama. The neurocirculatory basis for vasodepressor reactions was 
long presumed to be diffusely increased vagal "tone", since people experiencing them 
often have nausea, sweating, and bradycardia; however, cholinergic blockade may not 
prevent or reverse the hypotension. More recently, microneurographic [5] and neuro-
chemical [6, 7] evidence has convincingly demonstrated virtually complete shutdown 
of sympathoneural cardiovascular outflows, with generally preserved or augmented 
adrenomedullary secretion [25]. This combination could contribute to the skeletal 
vasodilation that virtually always accompanies vasodepressor reactions. 
Lower body negative pressure at -15 mmHg inhibits cardiac "low pressure" baro recep-
tors. During LBNP at -15 mmHg, skeletal muscle sympathoneural outflow normally 
increases reflexively [7, 26, 27]. Exposure to LBNP at -40 mmHg inhibits cardiac and 
arterial baroreceptors, increasing sympathoneural outflow in several vascular beds and 
concurrently increasing adrenomedullary secretion. Diffuse reflexive sympathoadrenal 
stimulation in this setting probably supports systemic blood pressure and cerebral 
perfusion. 
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In the present study, sudden vasodepressor reactions occurred in 11 of 26 healthy 
subjects during prolonged exposure to LBNP at -40 mmHg. The study design enabled 
review of catecholaminergic function before the actual vasodepressor reactions, that is 
during LBNP at -15 mmHg. The findings indicate that a combination of attenuated 
noradrenergic and exaggerated adrenomedullary and possibly endogenous opioid re­
sponses to mildly decreased cardiac filling (LBNP at -15 mmHg) characterized subjects 
who subsequently developed vasodepressor reactions during exposure to more severely 
decreased cardiac filling (group B). These subjects failed to increase forearm NE spillover 
during exposure to LBNP at -15 mmHg and had enhanced increases in arterial EPI 
levels. 
Forearm vasoconstriction occurred in the group В subjects during LBNP at -15 mmHg, 
despite the absence of increased forearm NE spillover. The basis for the forearm 
vasoconstriction without concurrently increased regional NE spillover cannot be deter­
mined from the present data. Several explanations are possible, including augmented 
extraneuronal removal of NE escaping the neuroeffector junctions, release of vasocon­
strictor peptides such as NPY or ATP, blockade of formation of endothelium-derived 
relaxing factors, or concurrent inhibition of sympathetic cholinergic vasodilation. 
It is a possibility that this pattern of sympathoinhibition and adrenomedullary stimula­
tion reflects a central neural process and arises from sudden resetting of baroreflexes. 
Analogous resetting occurs during haemorrhage [28] and hypoglycaemia [29] in labo­
ratory animals and produces a neurocirculatory positive feedback loop that leads rapidly 
to hypotension and circulatory shock. Moreover, electrical stimulation of specific 
hypothalamic regions can concurrently increase vagal and decrease sympathoneural 
outflows, evoking hypotension [30]. Disruption of vagal afférents or blockade of 
receptors for vasopressin or endogenous opioids can reverse the sympathoinhibition 
attending haemorrhage or hypoglycaemia, and it is therefore possible that central 
processes involving these compounds may also operate in some vasodepressor reactions. 
Vasovagal syncope frequently occurs in emotionally distressing circumstances. Individu-
als who developed a vasodepressor reaction had enhanced plasma EPI responses. 
Exaggerated endogenous EPI responses may also be part of a centrally generated pattern 
that triggers or reinforces a neurocirculatory positive feedback loop. Consistent with this 
view, a recent study in a small group of subjects also reported increases in plasma EPI 
levels before the onset of fainting and suggested that increased plasma EPI contributed 
to the vasodilation [31]. This helps to explain why ß-adrenoceptor blockade can be 
useful in treating patients with recurrent vasodepressor syncope [32,33]. Exogenous 
administration of EPI alone does not cause syncope in healthy people. 
Several investigators have proposed that in volume-depleted subjects, cardiac contrac-
tion around a near-empty ventricle at end-systole can paradoxically stimulate inhibitory 
ventricular myocardial receptors, evoking a depressor reflex [14]. This mechanism, 
although widely accepted, has never actually been demonstrated as a cause of vasovagal 
syncope. On the contrary, infusion of a vasodilator has been reported to evoke vasode-
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pressor syncope in a heart transplant recipient who lacked cardiac innervation [34], and 
heart transplant recipients do not differ from healthy control subjects in their suscep-
tibility to LBNP-induced vasodepression [35]- In cats and rats, but not in dogs, 
interference with cardiac vagal C-fibre afférents prevents haemorrhage-induced vasode-
pression [15]. These findings suggest that the occurrence of vasodepressor syncope in 
humans may not require altered neuronal afferent input from ventricular baroreceptors 
and that the relative contributions of peripheral and central mechanisms vary among 
species. 
The central aetiology hypothesis has direct therapeutic implications, since ß-adrenocep-
tor blockade, administration of an α-adrenoceptor agonist or sympathomimetic amine, 
blockade of endogenous opiate effects, or blockade of vasopressin receptors would be 
expected to abort or prevent vasodepressor syncope. The beneficial effects of ß-blockade 
were noted above [32, 33]. Treatment with dextroamphetamine [36], pseudoephedrine 
or phenylephrine [37] appears to prevent syncope in patients with positive tilt testing. 
Pre-treatment with naloxone, however, does not prevent vasodepressor responses during 
repeat exposure to LBNP in healthy subjects with previous LBNP-induced syncope [38]. 
We did not find reports about effects of vasopressin antagonists. 
In summary, healthy subjects who developed vasodepressor reactions during high-in-
tensity LBNP had antecedent exaggerated adrenomedullary and attenuated sym-
pathoneural responses during mild LBNP; some subjects who developed a vasodepressor 
reaction during high-intensity LBNP had ß-endorphin responses during mild LBNP. 
The findings are consistent with the view that sudden, central resetting of baroreflex 
function can evoke a pattern of sympathoneural inhibition combined with ad-
renomedullary and vagal activation, producing neurocirculatory positive feedback loops 
that lead precipitously to hypotension and syncope. 
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Adrenomedullary secretion of epinephrine is increased in mild 
primary hypertension 
Abstract 
To assess whether patients with mild primary hypertension have excessive activities of 
the sympathoneural and adrenomedullary systems, we examined total body and forearm 
spillovers and clearances of norepinephrine and epinephrine in 47 subjects with mild 
primary hypertension (25 males, 22 females, age 36.5 ± 5-9 years) and in 43 normoten-
sive subjects (19 males, 24 females, age 38.1 ± 6.7 years). The isotope dilution method 
with infusions of tritiated norepinephrine and epinephrine was used at rest and during 
sympathetic stimulation by lower body negative pressure at -15 and at -40 mmHg. 
Hypertensive subjects had a higher arterial plasma epinephrine concentration (0.20 ± 
0.01 nmol · L·1; mean ± SEM) than the normotensives (0.15 ±0.01 nmol· L'1) (p<0.01). 
The increased arterial plasma epinephrine levels appeared to be due to a higher total 
body epinephrine spillover rate in the hypertensives (0.23 ± 0.02 nmol · min"1 · m"2) 
then in the normotensives (0.18 ± 0.01 nmol · min"1 · m"2) (p<0.05) and not to a 
decreased plasma clearance of epinephrine. The arterial plasma norepinephrine level, the 
total body and forearm norepinephrine spillover rates and the plasma norepinephrine 
clearance were not altered in the hypertensives. The responses of the catecholamine 
kinetic variables to lower body negative pressure were not consistently different between 
normotensives and hypertensives. These data indicate that patients with mild primary 
hypertension have: 1) elevated arterial plasma epinephrine concentrations that are due 
to an increased total body epinephrine spillover rate, indicating an increased ad-
renomedullary secretion of epinephrine, 2) have no increased generalized sympathoneu-
ral activity and no increased forearm norepinephrine spillover, and 3) have similar 
responses of both the sympathoneural and adrenomedullary systems to sympathetic 
stimulation by lower body negative pressure. 
Introduction 
The sympathetic nervous system plays not only an important role in the regulation of 
blood pressure but is probably also involved in the pathogenesis of human primary 
hypertension. Several lines of evidence indicate that hypertensive subjects have an 
elevated sympathetic neural outflow. Biochemical measurements like plasma catecho-
lamine concentrations have been used extensively to document this. Several studies 
reported on increased plasma norepinephrine (NE) levels or increased plasma epineph-
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riñe (EPI) levels in hypertensive patients, in particular under the age of forty years [1]. 
Plasma catecholamine concentrations are however not a reliable index of sympatho-
neuronal and adrenomedullary activities for several reasons. First, plasma NE and EPI 
levels are determined not only by the rate at which these catecholamines enter plasma 
but also by their rates of removal [2]. Secondly, sympathetic outflow to different organs 
is not uniform and in particular during sympathetic stimulation, sympathoneuronal 
responses show a differentiated pattern across different organs, depending on the kind 
of stimulus [3]. Thus, venous and even arterial plasma NE and EPI concentrations have 
a limited value as measures of sympathetic and adrenomedullary activities. 
The isotope dilution method can provide more detailed information since there is a 
proportional relationship between the sympathetic nerve firing rate to an organ and the 
rate of spillover of NE into the circulation [4]. This method enables calculating spillover 
and clearance rates of NE and EPI, both for the whole body and for specific vascular 
beds. Several groups investigated NE kinetics in hypertensive patients, showing normal 
total body NE spillover with decreased neuronal uptake of NE or increased total body 
NE spillover in young hypertensives [5,6,7]. Other investigators however found no 
significant difference in total body spillover of NE between normo-and hypertensives 
[8]. 
In contrast to NE kinetics, much less attention has been paid to EPI kinetics. Several 
studies reported on increased plasma EPI levels in hypertensives [1], but it is unclear 
whether these increased plasma EPI concentrations are due to an increased ad-
renomedullary secretion of EPI or to a diminished clearance of EPI from plasma. Up to 
now, no direct comparison between normo- and hypertensives has been carried out with 
regard to EPI kinetics. 
The purpose of the present study was to assess simultaneously sympathoneural and 
adrenomedullary activities as measured by the isotope dilution technique, using simul-
taneous infusions of tritiated NE and tritiated EPI in untreated patients with mild 
primary hypertension. Since excessive activity of the sympathoneuronal and ad-
renomedullary systems may only be disclosed during sympathetic stimulation, the 
kinetics of NE and EPI were also assessed during low and high intensities of lower body 
negative pressure (LBNP) [9,10]. 
Methods 
Subjects 
Forty-seven patients with mild primary hypertension and 43 normotensive control 
subjects participated in the study. Before entry in the study all participants (ages 20-45 
years) had a negative medical history and a normal physical examination. Thirty-one of 
the 47 hypertensive patients had discontinued their antihypertensive medication for at 
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least four weeks before the study while the remaining 16 subjects had not yet received 
any antihypertensive treatment. Blood pressure was measured at two occasions (in 
triplicate at each occasion after 10 minutes of supine rest) at two-weeks intervals using 
a mercury sphygmomanometer. Mild hypertension was defined as having a diastolic 
blood pressure between 90-105 mmHg four weeks after stopping the antihypertensive 
therapy. Secondary hypertension was excluded according to standard clinical criteria. 
Normotension was defined as having a blood pressure of less than 140/90 mmHg. 
Subjects with a body weight higher than the ideal body weight +10% were excluded 
from the study [11]. The normotensive control subjects were recruited by means of a 
newspaper announcement. The study protocol was approved by the Hospital Ethics 
Committee and all subjects gave their written informed consent. 
Study protocol and procedures 
All subjects were required to abstain from alcohol, nicotine, and caffeinated foods and 
beverages for at least 24 hours before each study. The subjects were allowed to take a 
light breakfast two hours before the study. All experiments were carried out in the 
morning in a temperature-controlled room (21-22 °C). During the study the subjects 
remained supine. The lower body of the subjects was sealed at the iliac crests in an airtight 
Plexiglass™ lower body negative pressure box. The applied subatmospheric pressure 
was recorded by a manometer connected to the inside of the box. 
After local anesthesia, a brachial artery was cannulated (Angiocath, 20G, Deseret 
Medical, Becton Dickinson, Sandy, UT, USA) for monitoring blood pressure and heart 
rate (Hewlett Packard GmbH, Böblingen, Germany) and for drawing arterial blood 
samples. An intravenous cannula was inserted into a deep brachial vein in the ipsilateral 
arm for drawing venous blood samples. A venous cannula in the contralateral arm was 
used for simultaneous infusion of the radiotracers. Forearm blood flow (FBF) was 
recorded in the same arm that was also used for collecting arterial and venous blood 
samples, using venous occlusion strain-gauge plethysmography (Hokanson EC4, D.E. 
Hokanson, Washington, USA) with air-filled cuffs [12]. During measurement of FBF 
and blood sampling, the hand circulation was excluded by inflation of a wrist cuff to 
100 mmHg above systolic blood pressure [13]. After instrumentation, the subjects rested 
for 30 minutes. Thereafter both radiotracers were infused each as a bolus of 15 ЦСі · 
m"
2
, followed by a constant infusion at a continuous rate of 0.35 |lCi · min"1 · m"2 for 
a total duration of 90 minutes. During the last 3 minutes of the rest period of 30 minutes, 
baseline recordings of intra-arterial blood pressure, heart rate, and FBF were obtained 
and arterial and venous blood samples were drawn for measurement of labeled and 
unlabeled plasma catecholamines. Blood pressure was recorded simultaneously with the 
FBF measurement. FBF was measured three times per minute. Thereafter LBNP was 
applied at an intensity -15 mmHg for 15 minutes. Blood pressure, heart rate, and FBF 
recordings and blood samples were collected in this sequence in the last 3 minutes of 
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the LBNP period. After 30 minutes of rest, another LBNP period at -40 mmHg for 15 
minutes followed with similar obtainment of blood pressure, heart rate, FBF recordings 
and arterial and venous blood samples. The weights of the syringes containing the 
radiotracers were measured before and after the infusion to verify the infusion rate. 
Samples of the infusâtes were taken at the end of each infusion. 
3H-NE (levo-[ring-2,5,6-3H]-norepinephrine) (specific activity 30-60 Ci/mmol) and 
3H-EPI (levo-[N-methyl-3H]-epinephrine) (specific activity 50-85 Ci/mmol) (Du Pont 
New England Nuclear, 's Hertogenbosch, the Netherlands) were sterilized using a 
micropore filter (0.22 \lm) and diluted in NaCl 0.9%, containing acetic (0.2 mol/L) 
and ascorbic (5.7 mmol/L) acid. Sterilization, dilution and storage took place under 
nitrogen. The vials were stored until usage at -80 °C for maximal 3 months. Just prior 
to a study, an aliquot of each radiotracer was diluted in normal saline for intravenous 
infusion. 
Analytical methods 
Blood samples were collected in prechilled tubes containing 0.25 mol/L EGTA and 0.2 
mol/L glutathione and immediately placed on melting ice. Plasma was separated by 
refrigerated centrifugati on and frozen until assayed within two months from collection. 
The samples were analyzed for concentrations of unlabeled NE and EPI and 3H-NE 
and 3H-EPI, using high performance liquid chromatography (HPLC) with fluorometric 
detection after selective precolumn derivatization of the catecholamines with the fluo-
rescent agent 1,2-diphenylethylenediamine [14]. 
The detection limits of unlabeled NE and EPI are 2.2 and 3.2 pmol/L respectively. The 
intra-assay coefficients of variation of unlabeled NE and EPI at plasma levels of 1.31 
and 0.11 nmol/L are 2.3% and 3.4% respectively. At plasma levels of 1.02 and 0.15 
nmol/L, inter-assay coefficients of variation are 8.5% and 7.2% respectively. The 
detection limit of 3H-NE and 3H-EPI is 6 dpm. The interassay coefficient of variation 
of 3H-NE and 3H-EPI is 7.0% in venous plasma samples. 
Data analysis 
Forearm vascular resistance (FVR) was calculated as the quotient of mean arterial blood 
pressure (MAP) and FBF and was expressed in Arbitrary Units (AU). The average of the 
hemodynamic data during the three minutes recording was taken. 
The total body clearance rate of each catecholamine was calculated from the infusion 
rate of each tritiated catecholamine (3H-CA) and the steady state arterial plasma 
concentration of each tritiated catecholamine (3H-CAart) according to the formula: 
Total body CA. clearance (L • min"1 · m"2) = 3H-CA infusion rate (dpm · min"1 · m"2) / 
3H-CAan(dpm · L"1). Total body spillover rate of each catecholamine was calculated 
from the arterial plasma catecholamine concentration (CAart) and the total body 
clearance of a catecholamine according to the formula: Total body CA spillover (nmol 
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• min"1 • m"2) = CA
arI (nmol · L"1) X total body CA clearance (L · min' 1 · m' 2). The 
regional kinetic variables of each catecholamine in the forearm have been expressed per 
100 ml forearm volume (FAV). Regional catecholamine spillover in the forearm was 
estimated from the following equation: Forearm spillover (pmol · 100ml'1 FAV · min'1)= 
((CA
ven
 — CAart) + (CA
a r t X fractional extraction)) X FPF, where fractional extraction = 
(ЗН-САап - 3H-CA
v e n
) / 3 Н-СА
Ш
 and FPF is the forearm plasma flow in ml · 100 ml'1 
FAV · min"1, calculated from the FBF and hematocrit. The forearm clearance of each 
catecholamine was calculated according to the formula: Forearm clearance (ml • 100ml 1 
FAV · min*1) = FPF X fractional extraction of each catecholamine. 
Data are expressed as mean ± SEM unless indicated otherwise. Differences between 
normo- and hypertensive subjects were tested by the Mann-Whitney U test. For each 
variable, the responses to LBNP were tested by the Wilcoxon Matched-Pairs Signed 
Ranks Tests. For calculating correlations between hemodynamic and catecholamine 
kinetic variables the Spearman correlation was used. A p-value of less than 0.05 was 
considered to be significant. 
Results 
Baseline values 
The descriptive characteristics of all participants are summarized in Table 1. There was 
no significant difference between the ages of the normotensive and hypertensive groups 
but the hypertensives had a slightly but significantly higher Quetelet index than the 
normotensives. As expected, blood pressure was higher in the hypertensives than in the 
normotensives and this applied also for the heart rate. Forearm blood flow was similar 
Table 1. Clinical characteristics of the hypertensive patients and the normotensive subjects. 
Characteristic 
Number 
Males/females 
Age, years 
Quetelet Index, kg · m 
Systolic BP, mmHg 
Diastolic BP, mmHg 
HR, beats per minute 
Urinary sodium, mmol/mmol creatinine 
NT 
43 
19/24 
36.5 ± 5.9 
23.1 ± 3.0 
119 ± 14 
73 ± 9 
67 ± 10 
11.1 ±4.0 
(n=37) 
HT 
47 
25/22 
38.1 ± 6.7 
24.8 ± 2 . 2 " 
150 ± 15 
98 ± 8 
72 ± 11* 
10.4 ±3.8 
(n-43) 
NT indicates normotensives; HT, hypertensives; BP, blood pressure; HR, heart rate; 
Values are mean ± SD. * p<0.05 and **p<0.01 versus normotensives. 
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Table 2. The baseline values and the responses (Δ) of the catecholamine kinetic variables to lower body 
negative pressure (LBNP) at -15 mmHg in the hypertensives and normotensives 
Baseline level Δ at LBNP at-15 mmHg 
Catecholamine kinetic variable NT HT NT HT 
Venous plasma NE, nmol · L"1 1.13 ± 0.09 1.29 ± 0.09 0.34 ± 0.05 § 0.35 ± 0.05 * 
Arterial plasma NE, nmol · L"1 0.83 ± 0.05 0.95 ± 0.05 0.23 ± 0.03 * 0.18 ± 0.03 s 
ТВ NE Spill, nmol · min"1 · m"2 0.85 ± 0.06 0.87 ± 0.05 0.07 ± 0.03 0.06 ± 0.03 * 
ТВ NE CL, L · min"1 -m"2 1.03 ± 0.03 0.9 5 ± 0.03 -0.15 ± 0.02 * -0.10 ± 0.03 m 
FA NE Spill, pmol • 100ml'1 · min 1 0.77 ± 0.07 0.90 ± 0.06 0.08 ± 0.05 0.10 ± 0.04 x 
FA NE CL, ml • 100ml"1 · min"1 0.64 ± 0.04 0.69 ± 0.04 -0.08 ± 0.03 5 -0.10 ± 0 . 0 3 " 
Venous plasma EPI, nmol · L"1 0.04 ± 0.01 0.06 ± 0.0 Г* 0.00 ± 0.00 0.00 ±0.01 
Arterial plasma EPI, nmol · L"1 0.15*0.01 0.20 ± 0 . 0 1 " 0.06 ± 0.01 s 0.06 ± 0.01* 
ТВ EPI Spill, nmol · min"1 · m"2 0.18 ±0.01 0.23 ± 0.02* 0.02 ± 0.01 * 0.03 ± 0.01 x 
ТВ EPI CL, L • min"1 -m"2 1.22 ± 0.04 1.14 ± 0.04 -0.22 ± 0.03 s -0.16 ± 0.03 s 
FA EPI Spill, pmol · 100ml'1 · min"1 0.008 ± 0.002 0.009 ± 0.004 -0.001 ± 0.002 0.000 ± 0.006 
FA EPI CL, ml · 100ml'1 • min'1 0.69 ± 0.04 0.74 ± 0.05 -0.07 ± 0.04 x -0.12 ± 0.03 s 
NE indicates norepinephrine; EPI indicates epinephrine; NT, normotensives; HT, hypertensives; ТВ, total 
body; FA, forearm; Spill, spillover; CL, clearance. Values are mean ± SEM; * p<0.05 ** p<0.01 versus 
normotensives; * p<.05 x x p<.001 § p<.0001 versus baseline values 
in both groups with 1.65 ± 0.12 and 1.51 ± 0.10 ml/lOOml/minute respectively while 
forearm vascular resistance was slightly higher in the hypertensive (81 ± 4 AU) than in 
the normotensive subjects (70 ± 4 AU) (p<0.05). 
Both arterial and venous plasma NE concentrations were not significantly different 
between hypertensives and normotensives (Table 2). No differences were found in total 
body NE spillover and clearance between hypertensives and normotensives. Regional 
forearm NE spillover and clearance were also similar in the two groups (Table 2, Figure 
1). There was no correlation between systolic, diastolic, or mean arterial blood pressure 
and arterial plasma NE level or total body NE spillover. 
The baseline arterial and venous plasma EPI concentrations were significantly higher in 
the hypertensive (p<0.01) than in the normotensive group (Table 2, Figure 2). Among 
all subjects, there were weak but significant correlations between arterial plasma EPI 
level and systolic blood pressure (r = 0.29; p<0.01), diastolic blood pressure (r = 0.31; 
p<0.01), and heart rate (r = 0.25; p<0.05). The total body spillover of EPI was 
significantly increased in the hypertensives (Figure 3), while total body and forearm 
clearances of EPI were similar in both the hypertensive and normotensive groups. In 
both groups there were extremely low forearm spillovers of EPI that were both signifi­
cantly different from zero (p<0.01) but there was no difference between normo- and 
hypertensives (Table 2). 
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Figure 1. Individual values of norepinephrine (NE) spillover from the 
forearm in mild primary hypertensive patients (HT) and normotensive 
control subjects (NT). Triangles indicate male subjects and circles indicate 
female subjects. 
Lower body negative pressure 
During LBNP at -15 mmHg, both systolic and diastolic blood pressure did not change 
but the heart rate increased slightly but significantly in both groups by +1 ± 1 and +1 ± 
1 beats/minute. Pulse pressure decreased in the normotensives by 2 ± 1 mmHg (p<0.01) 
and by 3 ± 1 mmHg in the hypertensives (p<0.01) but these decrements were not 
significantly different. Forearm vascular resistance increased similarly in both groups by 
+ 17 ± 3 and+22 ± 3 AU. 
The venous and arterial plasma NE concentrations increased significantly by 31 ± 3% 
and 31 ± 4% in the normotensives, and by 34 ± 5% and 24 ± 4% in the hypertensives 
(Table 2). The increments of forearm and total body NE spillover reached only 
significance in the hypertensive group and not in the normotensive group but these 
increments were not significantly different between the groups (Table 2). Total body 
NE clearance decreased significantly in both groups. 
The venous plasma EPI concentration did not change during LBNP at -15 mmHg but 
the arterial plasma EPI level increased by 36 ± 5% in the normotensives and 38 ± 7% 
in the hypertensives (NS) (Table 2). The increments in arterial plasma EPI levels during 
LBNP appeared to be due to both an increase in total body EPI spillover (+13 ± 5%, 
normotensives and +19 ± 6%, hypertensives) and to a reduction in total body EPI 
clearance (-17 ± 2% and -12 ± 3%). The forearm spillovers of EPI did not increase 
significantly during LBNP in both groups (Table 2). 
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Figure 2. Individual values of arterial plasma epinephrine (EPI) concen­
tration in mild primary hypertensive patients (HT) and normotensive 
control subjects (NT). Triangles indicate male subjects and circles indicate 
female subjects. * p<0.01 hypertension versus normotension. 
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Figure 3. Individual values of total body epinephrine (EPI) spillover in 
mild primary hypertensive patients (HT) and normotensive control sub­
jects (NT). Triangles indicate male subjects and circles indicate female 
subjects. * p<0.05 hypertension versus normotension. 
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Table 3. The baseline values and the responses (Δ) of the catecholamine kinetic variables to lower body 
negative pressure (LBNP) at -40 mmHg in the hypertensives and normotensives 
Baseline levels Δ at LBNP at -40 mmHg 
Catecholamine kinetic variable N T H T N T H T 
Venous plasma NE, nmol · L 1 1.17 ±0.10 1.26 ±0.09 1.02 ± 0.10 * 1.18 ± 0.09 5 
Arterial plasma NE, nmol · L"1 0.86 ± 0.05 0.94 ± 0.05 0.64 ± 0.06 s 0.83 ± 0.06 " 5 
ТВ NE Spill, nmol · min"1 · m"2 0.83 ± 0.06 0.86 ± 0.05 0.30 ± 0.04 * 0.46 ± 0.06 § 
ТВ NE CL, L · min"1 · m"2 0.96 ± 0.03 0.92 ± 0.03 -0.15 ± 0.02 s -0.17 ± 0.02 § 
FA NE Spill, pmol · 100ml"1 · min"1 0.82 ± 0.08 0.82 ± 0.08 0.36 ±0.1 I s 0.36 ± 0.07 % 
FA N E CL, m l · 100ml 1 -min"1 0.64 ± 0.04 0.62 ± 0.04 -0.17 ± 0.04 5 -0.14 ± 0.05 § 
Venous plasma EPI, nmol · L"1 0.04 ± 0.01 0.06 ± 0.01 " 0.02 ± 0.01 § 0.06 ± 0.01 " 5 
Arterial plasma EPI, nmol · L'1 0.19 ± 0.01 0.25 ± 0.02" 0.19 ± 0.02 § 0.34 ± 0.07 § 
ТВ EPI Spill, nmol · min"1 · m"2 0.21 ± 0.02 0.27 ± 0.02* 0.12 ± 0.02 s 0.23 ± 0.06 * 
ТВ EPI CL, L • min' 1 · m"2 1.09 ± 0.04 1.06 ± 0.04 -0.21 ± 0.03 s -0.24 ± 0.03 s 
FA EPI Spill, pmol • 100ml"1 · min"1 0.005 ± 0.001 -0.006 ± 0.005 -0.005 ± 0.002 "-0.025 ± 0.019 x 
FA EPI CL, m l · 100ml"1 -min"1 0.71 ± 0.04 0.69 ± 0.05 -0.22 ± 0.04 5 -0.19 ± 0.04 s 
NE indicates norepinephrine; EPI indicates epinephrine; NT, normotensives; HT, hypertensives; ТВ, total 
body; FA, forearm; Spill, spillover; CL, clearance. Values are mean ± SEM; * p<0.05 ** p<0.01 versus 
normotensives; x p<0.05 ' p<0.0001 versus baseline values 
During LBNP at -40 mmHg, pulse pressure decreased significantly more in the 
hypertensives (-13 ± 1 mmHg) than in the normotensives (-9 ± 1 mmHg) (P<0.05) 
while the heart rate increased similarly ¡n both groups by 10 ± 1 and 9 ± 1 beats per 
minute respectively (NS). 
The venous plasma NE concentrations increased similarly by 94 ± 6% and 111 ± 11% 
in the normotensives and hypertensives respectively. Arterial NE increased more in the 
hypertensive (96 ± 8%) than in the normotensive group (83 ± 8%) (Table 3) while there 
was no difference between the normotensive and hypertensive groups with regard to the 
responses of forearm and total NE spillovers, and total body and forearm NE clearances 
(Table 3). 
The responses of the arterial plasma EPI concentrations increased by 108 ± 10% in the 
normotensives and 136 ± 18% in the hypertensives, which are not significantly different 
responses (Table 3). The total body spillover of EPI increased by 69 ± 12% and 81 ± 
13%, whereas the total body clearance of EPI decreased by 16 ± 6% and 21 ± 3%. These 
differences between normo- and hypertensives were not significant. The forearm spill-
overs of EPI showed a slight but significant decrease in both groups. 
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Discussion 
The present study not only confirms the previously reported elevated plasma EPI levels 
in patients with primary hypertension but also demonstrates that this is due to an 
increased adrenomedullary release of EPI into the bloodstream and not to a decreased 
clearance of EPI. This is indicated by the increased total body spillover of EPI in 
combination with an unaltered EPI clearance. Several previous studies have demon-
strated elevated plasma EPI levels in patients with primary hypertension [1,15-18], 
suggesting increased adrenomedullary secretion of EPI in hypertensives. Although EPI 
is released from the adrenal medulla directly into the bloodstream, arterial plasma EPI 
levels can not be used as an index of adrenomedullary EPI secretion because most of the 
circulating EPI is removed rapidly from the circulation [19]. To take into account the 
removal of EPI from the circulation, adrenomedullary EPI secretion can be assessed by 
the isotope dilution technique [20]. This technique requires a high analytical sensitivity 
for measuring low venous EPI concentrations and venous 3H-EPI activity [14]. Using 
this technique, the present study demonstrates for the first time that the elevated plasma 
EPI levels in primary hypertensives are due to an increased adrenomedullary secretion 
of EPI. Since the adrenal medulla serves as a sympathetic ganglion, the increased adrenal 
EPI release in the mild hypertensives reflects an increased sympathetic outflow selectively 
to the adrenal medulla in these patients. 
An increased sympathetic nervous system activity has been implicated as an important 
pathophysiological mechanism in primary hypertension for a long time [21]. An 
increased activity of the sympathetic system may not only be manifest at different levels 
of the sympathoneuronal axis but has also been demonstrated as an increased local NE 
spillover in certain organs like the heart, kidneys, brain and skeletal muscles [6,7]. The 
present observation demonstrates that this increased sympathetic outflow extends also 
to the adrenal medulla. In contrast, global sympathoneuronal activity, estimated as total 
body NE spillover, was not elevated in the hypertensive subjects. This is at variance with 
some but not all previous studies, demonstrating an increased total body NE spillover 
in hypertensive subjects [5,6]. It should be noted that reports on NE kinetics or 
microneurographic data in hypertensive subjects have mainly been based on male 
subjects [22]. The present study comprises an approximately equal number of male and 
female subjects in both groups. 
A particular additional finding in the present study is the forearm spillover of EPI in 
both normo- and hypertensives. These spillover rates, although extremely low, are 
significantly different from zero. Under normal conditions, EPI is mainly synthesized 
in the adrenal medulla and in certain brain nuclei. However, in patients with heart failure 
but also in healthy subjects during intensive aerobic exercise, EPI can be released from 
the heart. This released EPI is EPI that is predominantly derived from the circulation, 
from which it is taken up by sympathetic nerves [23]. Apparently, forearm EPI can 
recycle since it can be co-released along with NE from sympathetic nerves. Synthesis of 
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EPI in the human forearm is unlikely, since the key enzyme (phenylethanolamine 
N-methyltransferase), necessary for the synthesis of EPI from NE, has not been 
demonstrated in the forearm. Alternative possible explanations for the measured forearm 
EPI spillover include an assay artefact, an isotope effect of 3H-EPI, or a delayed recycling 
of the 3H-EPI as compared to unlabeled endogenous EPI because of a too short infusion 
time of the tracer [14]. Thus it is unclear whether the measured spillover of EPI in the 
forearm indicates a basal release of EPI. During sympathetic stimulation, as is the case 
during high-intensity LBNP, forearm EPI spillover did not increase but even decreased 
slightly. This could be related to an increased forearm extraction of EPI because of the 
sympathetic-induced decrease in forearm blood flow. 
Sympathetic stimulation by low-intensity LBNP did not disclose any further differences 
in sympathoneuronal and adrenomedullary activities between normo- and hypertensive 
subjects. Low-intensity LBNP deactivates cardiopulmonary baroreceptors [9,10], and 
by using the microneurographic technique it has previously been shown that cardiopul-
monary baroreceptor control of sympathetic nerve activity is enhanced in patients with 
mild primary hypertension [24]. In our study however, the response of foream NE 
spillover to cardiopulmonary baroreceptor deactivation in the hypertensive subjects was 
not enhanced. Although we did not measure muscle sympathetic nerve traffic by 
microneurography, it is unlikely that sympathetic nerve traffic response to LBNP was 
enhanced in the hypertensives because the forearm vascular resistance response in the 
hypertensives was also not increased. The apparent discrepancy between the results 
obtained by microneurography and by NE kinetics might be explained by a different 
study population (borderline hypertensives versus mild hypertensives) or by an interfer-
ing effect of peripheral sympathoneural mechanisms like neuronal re-uptake of NE. In 
addition, it should be noted that we did not measure central venous pressure in this 
study. If the hypertensives would have had a smaller decrease in central venous pressure 
in response to low-intensity LBNP than the normotensives, this might also be an 
explanation for the similar increments in forearm NE spillover in the hypertensives. 
High-intensity LBNP deactivates both cardiopulmonary and arterial baroreceptors 
[9,10]. The arterial plasma levels of NE and EPI and total body spillovers of NE and 
EPI tended to increase more during high-intensity LBNP in the hypertensive than in 
the normotensive group. This is probably caused by the larger fall in pulse pressure in 
the hypertensive group during LBNP and does therefore not necessarily mean that the 
hypertensives have an enhanced arterial baroreceptor control of sympathoneural and 
adrenomedullary activities. Previous studies have also shown a normal arterial barore-
ceptor control of sympathetic activity in patients with borderline hypertension [24]. In 
view of the larger decrease in pulse pressure in the hypertensives, the apparent normal 
heart rate response to arterial baroreceptor deactivation in the hypertensives fits with the 
well-documented impaired arterial baroreceptor control of heart rate in mildly hyper-
tensives [25]. 
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It is still an unresolved issue whether an increased release of adrenal EPI is of patho-
physiological significance in primary hypertension. Based on evidence obtained in 
isolated tissue preparations and animal experiments [26-28], Brown and Macquin 
hypothesized that intermittent increments in circulating EPI facilitate the neuronal 
release of NE by a stimulating effect of EPI on the presynaptic p2-adrenergic receptors, 
thus contributing to the development of hypertension [29]. Support for this hypothesis 
came also from studies in humans, showing that EPI has a facilitatory effect on peripheral 
noradrenergic transmission and that this effect was enhanced in patients with primary 
hypertension [30,31]. Patients who develop hypertension would be more susceptible to 
stressful stimuli and exhibit elevated stress-related increments in circulating EPI. There 
is indeed an abundance of evidence that, in particular at a young age, patients with 
primary hypertension have increased sympathetic responses to psychological kinds of 
stress [15,32]. The slightly increased plasma EPI concentrations in the hypertensive 
subjects fit with the hypothesis of Brown and Macquin [29]. 
A question of particular concern is whether the increased plasma EPI levels may 
contribute to the deleterious cardiovascular sequelae of hypertension on the long term. 
The development of these complications may be mediated by the well-known adverse 
effects of catecholamines like induction of cardiac arrythmias, stimulation of vascular 
and ventricular hypertrophy, and platelet activation [33-35]. Although the arterial 
plasma EPI levels in the subjects with mild hypertension were only slightly higher than 
in the normotensives, it can not be excluded that chronic exposure of the heart and 
blood vessels to this circulating EPI may be harmful on the longterm. 
In conclusion, this study demonstrates that patients with mild primary hypertension 
have increased plasma EPI levels and that this is due to an increased basal adrenomedul-
lary secretion of EPI. This indicates that mildly hypertensive subjects have an increased 
sympathetic outflow to the adrenals. In contrast to some previous studies, we did not 
find an increased general sympathoneural activity, measured as total body NE spillover. 
No gross abnormalities were noted during sympathetic stimulation by different levels 
of LBNP. It is tempting to speculate that the increased plasma EPI levels in the 
hypertensives may be of pathophysiological significance for the development of the 
cardiovascular complications of hypertension on the longterm. 
Acknowledgements 
We thank Eugenie Olde Riekerink for her assistance during the study. 
References 
1. Goldstein DS. Plasma catecholamines in essential hypertension: An analytical review. Hypertension 
1983;5:86-99. 
Sympathoadrenal activity in essential hypertension | 79 
2 Esler M, Jennings G, Lambert G, Meredith I, Home M, Eisenhofer G Overflow of catecholamine 
neurotransmitters to the circulation Source, fate, and functions Physiol Rev 1990,70 963-985 
3 Folkow В Physiological aspects of primary hypertension Physiol Rev 1982,62 347-504 
4 Esler M, Jennings G, Körner Ρ, Willett I, Dudley F, Hasking G, Anderson W, Lambert G Assessment 
of human sympathetic nervous system activity from measurements of norepinephrine turnover 
Hypertension 1988,11 3-20 
5 Esler M, Jackman G, Bobik A, Leonard P, Kelleher D, Skews H, Jennings G, Körner Ρ Nor­
epinephrine kinetics in essential hypertension Defective neuronal uptake of norepinephrine in some 
patients Hypertension 1981,3 149-156 
6 Esler M, Jennings G, Biviano B, Lambert G, Hasking G Mechanism of elevated plasma noradrenaline 
in the course of essential hypertension J Cardiovasc Pharmacol 1986,8(Suppl 5) S39-S43 
7 Ferner С, Esler M D , Eisenhofer G, Wallin G, Home M, Сох HS, Lambert G, Jennmgs GL Increased 
norepinephrine spillover into the jugular veins in essential hypertension Hypertension 1992,19 62-
69 
8 Goldstein DS, Horwitz D, Keiser HR, Polmsky RJ, Kopin IJ Plasma l-[ H]-norepinephrine, 
d-[ C]-norepinephrine, and d,l-[ H]-isoproterenol kinetics in essential hypertension J Clin Invest 
1983,72 1748-1758 
9 Zoller RP, Mark AL, Abboud FM, Schmid PG, Heistad D D The role of low pressure baroreceptors 
in reflex vasoconstrictor responses in man J Clin Invest 1972,51 2967-2972 
10 Johnson JM, Rowell LB, Niederberger M, Eisman MM Human splanchnic and forearm vasocon­
strictor responses to reductions of right atrial and aortic pressures O r e Res 1974,34 515-523 
11 Statistical Bulletin of the Metropolitan Life Insurance Company 1959,40 
12 Brakkee AJM, Vendnk AJH Strain gauge plerhysmography, theoretical and practical notes on a new 
design J Appi Physiol 1966,21 710-714 
13 Lenders JWM, Janssen GJ, Smits P, Thien Th Role of the wrist cuff in forearm plethysmography 
Clin Sci 1991,80 413-417 
14 Willemsen JJ, Ross HA, Jacobs MC, Lenders JWM, Thien Th, Benraad TJ Highly sensitive and 
specific HPLC method with fluorometric detection for determination of plasma epinephrine and 
norepinephrine applied to kinetic studies in humans Clin Chem 1995,41 1455-1460 
15 Ehasson K, Hjemdahl P, Kahan Τ Circulatory and sympathoadrenal responses to stress in borderline 
and established hypertension J Hypertens 1983,1 131 139 
16 Bertel O, Buhler FR, Kiowski W, Lutold BE Decreased beta-adrenoceptor responsiveness as related 
to age, blood pressure, and plasma catecholamines in patients with essential hypertension Hyperten­
sion 1982,2 130-138 
17 Franco-Morselli R, Elghozi JL, Joly E, di Giuilli S, Meyer Ρ Increased plasma adrenaline concentra­
tions in benign essential hypertension Br Med J 1977,2 1251 1254 
18 Kjeldsen SE, Eide I, Aakesson I, Leren Ρ Increased arterial catecholamine concentrations m 
50 year-old men with essential hypertension Scand J Clin Lab Invest 1983,43 343-349 
19 Ginn R, Vane JR Disappearance of catecholamines from the circulation Nature 1968,219 740 742 
20 Rosen SG, Linares OA, Sanfield JA, Zech LA, Lizzio VP, Halter JB Epinephrine kinetics in humans 
radiotracer methodology J Clin Endocrinol Metab 1989,69 753-761 
21 Julius S, Esler M D , Randall OS Role of the autonomic nervous system in mild essential hypertension 
Clin Sei Mol Med 1975,48 243s-252s 
22 Anderson EA, Sinkey CA, Lawton WJ, Mark AL Elevated sympathetic nerve activity in borderline 
hypertensive humans Evidence from direct intraneural recordings Hypertension 1989,14 177-183 
23 Esler M, Eisenhofer G, Jennings G, Meredith I, Lambert G, Thompson J, Dan A Is adrenaline 
released by sympathetic nerves in man' Clin Auton Res 1991,1 103-108 
24 Rea RF, Hamdan M Baroreflex control of muscle sympathetic nerve activity in borderline hyperten­
sion Circulation 1990,82 856 862 
25 Takeshita A, Tanaka S, Kuroiwa A, Nakamur M Reduced baroreceptor sensitivity in borderline 
hypertension Circulation 1975,51 738-742 
80 I Chapter 5 
26. Adler-Graschinsky E, Langer SZ. Possible role of a beta-adrenoceptor in the regulation of norad-
renaline release by nervous stimulation through a positive feed-back mechanism. Br J Pharmacol 
1975;53:43-50. 
27. Majewski H, Tung LH, Rand MJ. Adrenaline activation of prejunctional beta-adrenoceptors and 
hypertension. J Cardiovasc Pharmacol 1982;4:99-106. 
28. Quinn P, Borkowski KR, Collins MG. Epinephrine enhances neurogenic vasoconstriction in the rat 
perfused kidney. Hypertension 1984;7:47-52. 
29. Brown MJ, Macquin I. Is adrenaline the cause of essential hypertension? Lancet 1981;2:1079-1082. 
30. Floras JS, Aylward PE, Victor RG, Mark AL, Abboud FM. Epinephrine facilitates neurogenic 
vasoconstriction in humans. J Clin Invest 1988;81:1265-1274. 
31. Floras JS, Aylward PE, Victor RG, Mark AL, Abboud FM. Epinephrine facilitates neurogenic 
vasoconstriction in borderline hypertensive subjects. J Hypertens 1990;8:443-448. 
32. Lenders JWM, Willemsen JJ, de Boo T, Lemmens WAJ, Thien T. Disparate effects of mental stress 
on plasma noradrenaline in young normotensive and hypertensive subjects. J Hypertens 1989:7:317-
323. 
33. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac 
sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325:618-
624. 
34. Ardlie NG, Glew G, Schwartz CJ. Influence of catecholamines on nucleotide-induced platelet 
aggregation. Nature 1966;212:415-417. 
35. Egan B, Julius S. Vascular hypertrophy in borderline hypertension: relationship to blood pressure 
and sympathetic drive. Clin Exp Hypertens 1985;A7:243-255. 
Chapter 6 
Chronic α!-adrenergic blockade increases 
sympathoneural but not adrenomedullary 
activity in patients with primary hypertension 
Journal of Hypertension 1995;13:1837-1841 
M.C. Jacobs 
J.W.M. Lenders 
J.J. Willemsen 
Th. Thien 

aj-Adrenocepcor antagonism and sympathoadrenal activity | 83 
Chronic α ι-adrenergic blockade increases sympathoneural but not 
adrenomedullary activity in patients with primary hypertension 
Abstract 
Doxazosin, a selective α ι -adrenoceptor antagonist, lowers blood pressure by reducing 
peripheral vascular resistance without causing reflex tachycardia. To discover whether 
antihypertensive treatment of hypertension with an (X\ -adrenoceptor blocker is accom­
panied by an increase in sympathoadrenomedullary activity, we studied plasma catecho­
lamine kinetics before and during treatment with doxazosin. 
Eleven patients with primary hypertension were studied before and after 3 months' 
treatment with doxazosin (4-8 mg daily). 3H-norepinephrine and 3H-epinephrine were 
infused simultaneously and blood samples were collected to calculate plasma catecho­
lamine kinetics before and during sympathoadrenomedullary stimulation (lower body 
negative pressure). 
Doxazosin decreased systolic and diastolic blood pressure and forearm vascular resis­
tance, whereas heart rate did not change significantly. During doxazosin, baseline arterial 
plasma norepinephrine increased from 0.97 ± 0.07 to 1.21 ± 0.07 nmol/1, and this 
appeared to be due to an increase in total body norepinephrine spillover from 1.54 ± 
0.15 to 1.84 ± 0.16 nmol/min; norepinephrine clearance did not change significantly. 
Forearm norepinephrine spillover also increased, from 0.89 ± 0.18 to 1.48 ± 0.23 
pmol/ 100ml per min. In contrast, arterial plasma epinephrine, total body epinephrine 
spillover and epinephrine clearance were not significantly affected by doxazosin treat­
ment. The response of plasma norepinephrine and total and forearm spillover of 
norepinephrine to lower body negative pressure (-40 mmHg) was significantly increased 
during doxazosin administration, whereas the responses of the epinephrine kinetic 
parameters were not altered. 
The blood pressure reduction induced by a chronic administration of the (Xi-adreno-
ceptor blocker doxazosin elicits a baroreceptor-mediated reflexive increase in sym­
pathoneural but not in adrenomedullary activity. The latter finding might partly explain 
why the heart rate is not increased during chronic treatment with this ОЦ -adrenoceptor 
blocking drug. 
Introduction 
Doxazosin is a selective OL\-adrenoceptor blocking drug with a slow onset of action; it 
lowers blood pressure by decreasing systemic vascular resistance [1,2]. In contrast to the 
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acute administration of QL\ -adrenoceptor blockers, chronic administration in hyperten-
sive patients does not elicit a reflexive increase in the heart rate. This suggests that 
baroreflex-mediated sympathetic activity is not increased during chronic treatment with 
doxazosin. The lack of reflex tachycardia has also been attributed to the absence of an 
interruption of the presynaptic inhibitory effect by norepinephrine (NE) upon neuronal 
NE release [3]. Central CCj -adrenoceptor antagonism has been suggested as an alterna-
tive mechanism for the absence of reflex tachycardia [4]. However, treatment with 
prazosin, a similar 0,\ -adrenoceptor blocker to doxazosin but with a rapid onset of action, 
induces an increase in plasma levels of NE [5-7]. Although it has been assumed that the 
increased plasma NE levels are caused by an increase in baroreflex-mediated sympathetic 
activity, no definitive explanation is available for the increase in plasma NE levels. 
Elevated plasma NE levels might be due to a reflexive increase in sympathoneuronal 
release of NE or to a reduced clearance of NE. 
The main objective of the present study was to assess the effects of a chronic blood 
pressure reduction by the 0.\ -adrenoceptor blocker doxazosin on the baroreflex-medi-
ated activity of the sympathoadrenomedullary system. For this purpose, we used the 
isotope dilution method with steady-state infusion of tritiated catecholamines [8]. 
Before and after chronic doxazosin treatment (3 months), spillover and clearance of NE 
and epinephrine EPI were assessed in primary hypertensives and this was examined 
before and during stimulation of the sympathoadrenomedullary system by two different 
intensities of lower body negative pressure (LBNP). 
Subjects and methods 
Subjects 
Eleven subjects with primary hypertension (mean ± SD age: 35.8 ± 2.3 years) partici-
pated in the study. Before entry all participants had a normal physical examination and 
none were found to suffer from cardiovascular or other diseases. Secondary hypertension 
was excluded according to standard clinical criteria and all subjects had a normal renal 
function. The mean ± SD Quetelet index was 23.6 ± 0.7 kg/m2. Antihypertensive 
treatment was withdrawn at least 4 weeks before the study; after it was withdrawn, blood 
pressure was measured three times at 2-week intervals. The mean ± SD basal systolic/dia-
stolic blood pressure before treatment with doxazosin was 147 ± 3/95 ± 2 mmHg and 
the heart rate was 77 ±3 beats/minute. All subjects gave written informed consent and 
the study protocol was approved by the Hospital Ethics Committee. 
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Study protocol 
All patients were studied twice: before and after treatment with doxazosin for 3 months. 
Each patient started with doxazosin 2 mg once a day and blood pressure was monitored 
every 3 weeks. The dose was increased every 3 weeks by 2 mg to a maximum of 8 mg a 
day unless diastolic blood pressure had fallen by at least 25% on the current dose. Patients 
with a sufficient blood pressure fall remained on the titrated dose until the end of the 
3-month period. After 3 months, two patients were taking 4 mg a day, one was taking 
6 mg a day, and nine were taking 8 mg doxazosin a day. 
On each study day, the subjects were allowed a light breakfast. All were required to 
abstain from alcohol, nicotine, and caffeinated foods and beverages for at least 24 h 
before each study day. All studies were carried out in the morning in a room with 
constant temperature. During the study the subjects remained supine in a lower body 
negative pressure box that was used to stimulate sympathoadrenomedullary activity. 
After instrumentation, radiotracer infusions (see below) were started and the subjects 
rested for 30 minutes. During the last 3 min, baseline recordings of blood pressure, heart 
rate, and nine forearm blood flow curves were obtained. Then arterial and venous blood 
samples were drawn simultaneously to determine plasma concentrations of endogenous 
and tritiated catecholamines. 
Thereafter, LBNP was applied at -15 mmHg for 15 min. Blood pressure, heart rate, and 
forearm blood flow recordings and blood samples were collected in sequence beginning 
after 12 min of LBNP. A rest period of 30 min ensued and then another 15 minutes of 
LBNP at -40 mmHg was applied, and blood pressure, heart rate and forearm blood flow 
recordings and blood samples were obtained as before. 
Procedures 
A brachial artery was cannulated to monitor blood pressure and the heart rate (Hewlett 
Packard GmbH, Böblingen, Germany) and to draw arterial blood samples. An intrave-
nous catheter was inserted into a deep brachial vein in the ipsilateral arm for collecting 
venous blood samples. A forearm venous catheter in the contralateral arm was used for 
simultaneous infusion of 3H-norepinephrine (3H-NE) and 3H-epinephrine (3H-EPI). 
Forearm blood flow was recorded by venous occlusion strain-gauge plethysmography 
with air-filled cuffs [9]; during this measurement and while blood samples were drawn, 
the hand circulation was excluded by inflating a wrist cuff to 100 mmHg above systolic 
blood pressure [10]. 
To assess catecholamine kinetics, 3H-NE (L-[0-2,5,6-3H]-norepinephrine) and 3H-
EPI (L-[N-methyl-3H]-epinephrine), with high specific activity, were infused intrave-
nously. Tritiated catecholamines were obtained from Du Pont New England Nuclear 
('s Hertogenbosch, the Netherlands), sterilized using a micropore filter (0.22 \lm) and 
diluted in 0.9% NaCl, containing acetic (0.2 mol/1) and ascorbic (1 mg/ml) acid. The 
aliquots were stored until used at -80°C for a maximum of 3 months. Sterilization, 
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dilution and aliquoting were carried out under nitrogen. Just before use, an aliquot of 
each radiotracer was diluted in 0.9% NaCl. 
After a bolus injection of each tracer at 15 ц С і / т 2 of each tracer, both tracers were 
infused continuously for 90 min at a rate of 0.35 ц С і / т 2 per min. The weights of the 
two syringes containing the radiotracers were measured before and after the infusion, to 
verify the infusion rate. Samples of the infúsate were taken at the end of the infusion 
and stored at -80 °C until assayed. 
Analytical methods 
Blood samples were collected in prechilled tubes containing ethyleneglycol-bis-(ß-ami-
noethylether)-N,N,N',N'-tetraacetic acid (0.25 mol/1) and glutathione (0.2 mol/1). The 
blood samples were placed on melting ice. Plasma was separated by refrigerated centrifu-
gation and frozen until assayed within 2 months from collection. Plasma samples were 
analysed for concentrations of both NE, EPI, 3H-NE and 3H-EPI, using high-perform-
ance liquid chromatography with fluorometric detection after selective precolumn 
derivatization of the catecholamines with the fluorescent agent 1,2-diphenylethyle-
nediamine [11]. Using a Gilson fraction collector, model 201-202, (Gilson Medical 
Electronics, Villiers le Bel, France) connected to an automatic sample injector, Wisp 
710B, (Waters Associates, Milford, Massachusetts, USA), we collected 3H-NE and 
3H-EPI into scintillation vials for 1 min, starting at the beginning of the peaks of NE 
and EPI in the standard mixture. 
Data analysis 
Forearm vascular resistance was calculated by dividing mean arterial blood pressure by 
forearm blood flow and was expressed in arbitrary units (AU). The average of the 
haemodynamic data during 3 min of recording was calculated. 
The clearance of NE from arterial plasma was calculated by dividing the rate of 3H-NE 
infusion by the steady-state arterial plasma concentration of 3H-NE. Total body NE 
spillover, the estimated rate of appearance of endogenous NE in arterial plasma, was 
calculated by multiplying the steady-state arterial plasma NE concentration by the 
clearance. Analogously, NE spillover in the forearm (pmol/min per 100 ml), was 
estimated as: 
Forearm NE spillover = FPF x NEa X fNE + (FPF X (NEv- NEJ) 
where FPF is forearm plasma flow, NEa is arterial plasma norepinephrine, NEy is venous 
plasma norepinephrine and 
f = ( 3 H-NE a - 3H-NEv) / 3H-NEa. 
The function f represents the fractional extraction of the tracer in the forearm. The 
forearm plasma flow, in units of ml/min/100 ml, was calculated from the forearm blood 
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flow and haematocrit. The clearance of NE in the forearm (ml/min per 100 ml) was 
calculated by multiplying the forearm plasma flow by the function f. 
The clearance of EPI from arterial plasma and the estimated rate of appearance of 
endogenous EPI into arterial plasma were calculated according to similar formulas. 
Results are expressed as means ± SEM unless indicated otherwise. To test the effects of 
doxazosin on baseline plasma kinetic variables, the Wilcoxon signed rank test was used. 
This test was also used to test for the effects of LBNP on each variable. Ρ < 0.05 
(two-sided) was considered significant. 
Results 
Hemodynamic data 
Doxazosin decreased systolic blood pressure from 147 ± 3 to 135 ± 4 mmHg and 
diastolic pressure from 95 ± 2 to 85 ± 3 mmHg (P<0.05). The heart rate decreased 
slightly, from 77 ± 3 to 70 ± 2 beats/min, but this was not significant. Forearm vascular 
resistance decreased significantly (P <0.05), from 89 ± 7 to 64 ± 6 AU. 
Doxazosin had no effect on the blood pressure and heart rate response to a LBNP of-15 
mmHg but the increase in forearm vascular resistance during LBNP at -15 mmHg was 
smaller after doxazosin treatment (+7 ± 2 AU) than before (+31 ± 8 AU; P<0.05). The 
blood pressure and heart rate responses to LBNP at -40 mmHg were also unaffected by 
doxazosin, but the increase in forearm vascular resistance was again significantly smaller 
after doxazosin treatment (+5 ± 2 AU) than before (+32 ± 9 AU; P<0.05). 
Plasma norepinephrine kinetics 
After treatment with doxazosin, all subjects had an approximately 20% higher plasma 
NE level than before (Table 1). This increase in arterial plasma NE appeared to be due 
to an increase in total body NE spillover of about 20% (Fig. 1 ), since total body clearance 
of NE was not significantly altered (Table 1). Forearm NE spillover was also signifi­
cantly increased after doxazosin treatment (Fig. 1) while the local clearance of NE by 
the forearm was not significantly affected (Table 1). 
The changes in plasma NE, total body and forearm NE spillover and total body and 
forearm NE clearance in response to LBNP (-15 mmHg) were not affected by doxazosin. 
However, with -40 mmHg LBNP, the increase in plasma NE was significantly larger 
after doxazosin (+1.33 ± 0.11 nmol/1) than before (+0.88 ± 0.10 nmol/1; P<0.05). Total 
body and forearm NE spillover increases were also significantly higher during -40 mmHg 
LBNP after doxazosin treatment than before (Fig. 2). The decreases in total body NE 
clearance during LBNP at -40 mmHg were not significantly affected by doxazosin and 
the same applied to the reductions in forearm NE clearance (Fig. 2). 
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Figure 1. Individual responses by total body and forearm norepinephrine 
spillover before and after treatment with doxazosin. 
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Figure 2. Mean ± SEM arterial plasma norepinephrine (NE), total body 
(TSO) and forearm (FSO) spillover and total body (TCL) and forearm 
(FCL) clearance of norepinephrine in response to lower body negative 
pressure at -40 mmHg before (light bar) and after (dark bar) doxazosin 
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Table 1. Plasma levels and kinetics of norepinephrine and epinephrine before and after treatment with 
doxazosin. 
Before doxazosin After doxazosin 
Norepinephrine 
Arterial plasma level (nmol/1) 0.97 ± 0.07 1.21 ± 0.07* 
Total body spillover (nmol/1) 1.54 ±0.15 1.84 ±0.16* 
Total clearance (1/min) 1.57 ±0.10 1.52 ±0.09 
Forearm spillover (pmol/100ml per min) 0.89 ±0.18 1.48 ± 0.23* 
Forearm clearance (ml/100ml per min) 0.58 ± 0.06 0.82 ±0.10 
Epinephrine 
Arterial plasma level (nmol/1) 0.21 ± 0.03 0.15 ± 0.02 
Total body spillover (nmol/1) 0.42 ± 0.07 0.27 ± 0.04 
Total clearance (1/min) 1.94 ± 0.10 1.81 ± 0.11 
Forearm clearance (ml/100ml per min) 0.70 ± 0.07 0.89 ± 0.12 
* Ρ < 0.05 versus before doxazosin. 
Plasma epinephrine kinetics 
After the administration of doxazosin, basal arterial plasma EPI was lower than before 
doxazosin treatment but the difference did not reach significance (Table 1). Total body 
EPI spillover was also lower after doxazosin but, again, the decrease was not significant. 
Total body clearance of EPI was not affected by doxazosin (Table 1). 
The changes in EPI kinetics in response to LBNP of-15 and -40 mmHg were not 
significantly altered by doxazosin. 
Discussion 
The main new finding of the present study is that longterm antihypertensive treatment 
with the Ot]-adrenoceptor blocker doxazosin elicits a selective increase in sympathetic 
but not adrenomedullary activity. This was demonstrated by the increase in plasma NE 
and total body and forearm NE spillover with no concurrent increase in plasma levels 
and total body spillover of EPI. 
Chronic antihypertensive treatment with the αϊ-adrenoceptor blocker doxazosin re­
sulted in a significant decrease in blood pressure and forearm vascular resistance. The 
heart rate did not increase, as shown previously for prazosin. The following three 
explanations for the unchanged heart rate have been put forward: vasodilation through 
αϊ-adrenoceptor blockade does not induce a reflexive increase in sympathetic activity 
because of resetting of the arterial baroreceptor reflex; blockade of central a¡-adreno-
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ceptors [4]; selective α ¡-adrenoceptor blocking drugs preserve the normal presynaptic 
CC2-adrenoceptor-mediated auto-inhibition of neuronal NE release by NE [3]. 
However, in the present study plasma NE levels were increased, as were total body and 
forearm NE spillover. This is in accord with previous studies [5-7] on prazosin. An 
increase in the spillover of NE into the blood compartment can be caused by an increase 
in sympathetic nerve traffic, by a decrease in neuronal uptake of NE or by decreased 
inhibition of NE release through presynaptic (^-adrenoceptors. The last mechanism is 
unlikely to have occurred in the present study, since the affinity of doxazosin for 
0C2-adrenoceptors is about 400 times lower than that for 0.\ -adrenoceptors [12]. Alter-
natively, presynaptic 0.\ -adrenoceptors might be considered a possibility; however, 
although present in some species [13,14], no presynaptic CI] -adrenoceptors are func-
tionally present in human blood vessels. Thus, an effect of doxazosin on presynaptic 
0C2-adrenoceptors or on eventual presynaptic (Xi-adrenoceptors has to be rejected as a 
possible explanation for the increase in NE spillover. The most likely explanation for 
the increase in NE spillover, both systemically and in the forearm vascular bed, is that 
there was reflexive increase in sympathetic nerve traffic due to the blood pressure 
reduction. This argues strongly against a resetting of the arterial baroreceptor reflex 
during chronic treatment with doxazosin. 
If there is, indeed, an increase in baroreflex-mediated sympathoneural activity during 
chronic (Χι -adrenoceptor blockade, then why is there no increase in the heart rate? Since 
cardiac β ι-adrenoceptors are equally sensitive to NE as to EPI in vitro, the increased NE 
spillover may be expected to elicit an increase in the heart rate. However, in vivo, NE 
usually induces a decrease in the heart rate because of the baroreflex-mediated increase 
in vagal nerve activity. An alternative explanation for the absence of an increase in the 
heart rate could be provided by the absence of an increase in plasma EPI and in total 
body EPI spillover. Total body EPI spillover reflects adrenomedullary secretion of EPI. 
Apparently, the blood pressure reduction induced by doxazosin does not stimulate 
adrenomedullary secretion of EPI but only the sympathoneuronal release of NE. This 
differentiated response to a reduction in blood pressure has also been described for other 
vasodilating antihypertensive drugs and is therefore not a specific effect of OCj-adreno-
ceptor blockers [15]. 
During LBNP at -40 mmHg, both arterial and cardiopulmonary baroreceptors were 
deactivated and a marked increase in sympathoadrenomedullary activity ensued, as 
illustrated by the increase in forearm vascular resistance, in plasma NE and forearm NE 
spillover and in total body NE and EPI spillover. During doxazosin treatment, the blood 
pressure and heart rate responses to LBNP were not significantly altered but forearm 
vascular resistance response was lower than before doxazosin. This is at variance with a 
previous study with prazosin, demonstrating unaltered responses by peripheral vascular 
resistance to isometric exercise and exposure to cold [16]. 
Taken together, these data indicate that doxazosin is a very powerful <X\-adrenoceptor 
antagonist that blocks postsynaptic α ι-adrenoceptors adequately, even during strong 
αϊ-Adrenoceptor antagonism and sympathoadrenal activity | 91 
sympathetic stimulation. During chronic treatment with doxazosin there is a dear 
increase in baroreflex-mediated sympathoneural activity whereas adrenomedullary ac­
tivity is not increased. This latter finding might provide a partial explanation for the 
absence of an increase in the heart rate during chronic treatment with doxazosin. 
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Chronic β\-adrenergic blockade restores adrenomedullary activity 
in primary hypertension 
Abstract 
In this study we examined the effects of chronic treatment of nineteen patients with 
primary hypertension with the ßj-adrenoceptor antagonist atenolol on norepinephrine 
and epinephrine kinetics, at rest and during sympathoadrenal stimulation by lower body 
negative pressure. Norepinephrine and epinephrine kinetics were measured using the 
radio-isotope dilution technique by steady state infusion of tritiated norepinephrine and 
epinephrine. The patients were studied before and at the end of 3 months treatment 
with atenolol (50 or 100 mg daily). A control group of four normotensive subjects was 
studied before and after 3 months without any drug treatment. In this group, only 
arterial blood samples were collected without infusion of the tritiated catecholamines. 
Atenolol decreased blood pressure and heart rate while forearm vascular resistance was 
not affected by atenolol. During atenolol, baseline arterial plasma epinephrine decreased 
from 0.23 ± 0.02 to 0.17 ± 0.01 nmol/L (P<0.05) and this was accompanied by a decrease 
in total body epinephrine spillover from 0.50 ± 0.05 to 0.35 ± 0.04 nmol/min (P<0.05). 
In the control group, arterial plasma epinephrine had not decreased after 3 months. In 
addition, the increment of arterial plasma epinephrine during lower body negative 
pressure at -40 mmHg was attenuated during atenolol. Atenolol had no effect on total 
body and forearm norepinephrine spillover rates, neither at rest, nor during lower body 
negative pressure. Clearance rates of epinephrine and norepinephrine were not signifi-
cantly affected by atenolol. 
These results suggest that treatment of patients with primary hypertension with the 
β l-adrenoceptor blocker atenolol inhibits the adrenomedullary secretion of epinephrine, 
while it does not affect the biochemical indices of sympathoneural activity. It remains 
speculative whether this selective effect of atenolol on epinephrine secretion contributes 
to its hypotensive action and to its cardioprotective effects on the long term. 
Introduction 
Since a long time, β ι-adrenoceptor blocking agents have been widely used as effective 
antihypertensive drugs. The mechanism how they reduce blood pressure is still incom­
pletely understood. The antihypertensive action is presumed to be dependent on a 
competitive antagonism with endogenous catecholamines at the ß-adrenoceptor sites. 
These ß-adrenoceptors are found pre- and postsynaptically in many tissues, like the 
96 I Chapter 7 
heart, the brain, the adrenal medulla and the arterial resistance arteries. Several mecha-
nisms have been suggested to be implicated in the blood pressure reduction during 
ßi-blockade: resetting of the baroreflex, central nervous system mechanisms, decreased 
peripheral sympathetic discharge due to presynaptic ß-receptor inhibition, and reduc-
tion of cardiac output [1,2]. Chronic treatment of patients with hypertension with 
ßi-blockers might have an effect on sympathetic nervous system activity but plasma 
norepinephrine (NE) levels are unsuited for a reliable assessment of sympathetic nervous 
system activity. Plasma NE levels during chronic treatment have been reported to be 
increased, unchanged or decreased [ 1 ]. Plasma catecholamine levels are determined both 
by their spillover into the circulation as by their clearance from the circulation. The 
clearance, depending on cardiac output, might be affected by β ι-adrenoceptor blocking 
agents. To assess the effects of β ι -blockade on catecholamine spillover and clearance 
rates, the isotope dilution method can be used [3]. Previous studies, reporting on NE 
kinetics during chronic ß-blockade, showed decreased or unchanged NE spillover rates, 
or decreased NE clearance rates [4,5]. Epinephrine (EPI) kinetics during ßj-blockade 
have never been examined in humans. In this study we investigated the effects of three 
months treatment of patients with primary hypertension with atenolol on clearance and 
sympathoneural and adrenomedullary spillover of NE and EPI. This was carried out 
both at rest and during sympathoadrenal stimulation by lower body negative pressure 
(LBNP). 
Subjects and methods 
Subjects 
Nineteen patients with primary hypertension (12 males and 7 females; mean ± SD age 
40.9 ± 5-2 years) participated in the study. All participants had a normal physical 
examination before entry in the study. Secondary hypertension was excluded according 
to standard clinical criteria, and all subjects had a normal renal function. The mean ± 
SD Quetelet index was 25.2 ± 2.2 kg · m"2. Thirteen of these nineteen participants used 
antihypertensive medication which was withdrawn at least four weeks before the study. 
After stopping the antihypertensive medication blood pressure was measured three times 
at 2-week intervals. The mean ± SD basal systolic/diastolic blood pressure before 
treatment with atenolol was 156 ± 16/100 ± 8 mmHg and the heart rate was 70 ±11 
bpm. Four normotensive subjects (mean ± SD basal systolic/diastolic blood pressure: 125 
± 6/82 ± 5 years) served as a control group (mean ± SD age 45.9 ±2.1 years). All subjects 
gave their written informed consent. The study protocol was approved by the Hospital 
Ethics Committee. 
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Study protocol 
All patients with hypertension were studied twice: before and after treatment with 
atenolol for three months. Each patient started with atenolol at 50 mg a day and blood 
pressure was recorded every three weeks. The dose was increased to 100 mg a day after 
six weeks unless heart rate had decreased by more than 25% or below 45 beats per 
minute. After three months 8 subjects were taking 50 mg atenolol a day and eleven 
subjects were taking 100 mg atenolol a day. The control group of four normotensive 
subjects were also studied twice with an interval of 3 months. This group was enclosed 
to control for a time effect, so they did not receive atenolol. However in this group we 
only studied the reproducibility of the arterial plasma catecholamine levels and we did 
not apply the tracer infusions in this group. 
On each study day the subjects were allowed a light breakfast. All participants were 
required to abstain from alcohol, nicotine, and caffeinated foods and beverages for at 
least 24 h before each study day. All studies were carried out in the morning in a 
temperature-controlled room. During the study the subjects remained supine in a LBNP 
box that was used to stimulate sympathoadrenomedullary activity. After instrumenta­
tion, radiotracer infusions (see below) were started and the subjects rested for 30 minutes. 
During the last three minutes, baseline recordings of blood pressure, heart rate and 
forearm blood flow were obtained. Then arterial and venous blood samples were drawn 
simultaneously to determine plasma concentrations of endogenous and tritiated 
catecholamines. Thereafter, LBNP was applied at -15 mmHg for 15 minutes. Blood 
pressure, heart rate and forearm blood flow recordings and blood samples were collected 
in sequence beginning after 12 minutes of LBNP. A rest period of 30 minutes ensued 
and then another 15 minutes of LBNP at -40 mmHg was applied, and blood pressure, 
heart rate and forearm blood flow recordings and blood samples were obtained as before. 
Procedures 
A brachial artery was cannulated with a cannula to monitor blood pressure and heart 
rate (Hewlett Packard GmbH, Böblingen, Germany) and to draw arterial blood samples. 
An intravenous catheter was inserted into a deep brachial vein in the ipsilateral arm to 
collect venous blood samples. A forearm venous catheter in the contralateral arm was 
used for simultaneous infusion of 3H-NE and 3H-EPI. Forearm blood flow was recorded 
in the arm with the sampling catheters, by venous occlusion strain-gauge plethysmogra-
phy with air-filled cuffs [6]. During the measurement of forearm blood flow and the 
sampling of the blood samples, the hand circulation was excluded by inflation of a wrist 
cuff to 100 mmHg above systolic blood pressure [7]. 
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Radiotracer infusion 
3H-NE (levo-[ring-2,5,6-3H]-NE and 3H-EPI (levo-[N-methyl-3H]-EPI, with high 
specific activity, were infused intravenously to assess catecholamine kinetics. Tritiated 
catecholamines were obtained from Du Pont New England Nuclear ('s Hertogenbosch, 
the Netherlands), sterilized using a micropore filter (0.22 [lm) and diluted in NaCl 
0.9%, containing acetic (0.2 mol/1) and ascorbic (1 mg/ml) acid. The vials were stored 
until usage at -80 °C for maximal 3 months. Sterilization, dilution and storage took 
place under nitrogen. Just prior to the study an aliquot of each radiotracer was diluted 
in normal saline. 
After a bolus injection of each radiotracer at 15 дСі/т 2 , both tracers were infused for 
90 minutes at a continuous rate of 0.35 |lCi/m2/min. The weight of the two syringes 
containing the radiotracers was measured before and after the infusion, to verify the 
infusion rate. Samples of the infúsate were taken at the end of the infusion and stored 
at -80 °C until assayed. 
Analytical methods 
The blood samples were collected in prechilled tubes containing 0.25 mol/1 EGTA and 
0.2 mol/1 glutathione in distilled water (pH=7.4). The blood samples were placed on 
melting ice. Plasma was separated by refrigerated centrifugation and frozen until assayed, 
which occurred within two months after collection. The samples were analyzed for 
concentrations of both unlabelled and tritium-labelled NE and EPI, using high perform-
ance liquid chromatography (HPLC) with fluorometric detection after selective preco-
lumn derivatization of the catecholamines with the fluorescent agent 1,2- diphenyl-
ethylenediamine [8]. Using a Gilson fraction collector (model 201-202), connected to 
an automatic sample injector (Wisp 710B), we collected 3H-NE and 3H-EPI into 
scintillation vials, starting at the beginning of the peaks of NE and EPI in the standard 
mixture. 
Data analysis 
Forearm vascular resistance (FVR) was calculated by dividing mean arterial blood 
pressure (MAP) by forearm blood flow (FBF) and was expressed in Arbitrary Units (AU). 
The average of the hemodynamic data during three minutes was calculated. 
The clearance rate of NE (L/min) from arterial plasma was calculated by dividing the 
infusion rate of 3H-NE (dpm/min) by the steady state arterial plasma concentrations of 
3H-NE (dpm/L). Total body NE spillover rate (nmol/min), the estimated rate of 
appearance of endogenous NE in arterial plasma, was calculated by multiplying the 
steady state arterial plasma NE concentration (nmol/L) by the clearance (L/min). 
Analogously, NE spillover in the forearm was estimated as: 
Forearm NE spillover (pmol/min per 100 ml) = FPF X NEa X f + [FPF X (NEa - NEJ] 
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where FPF is forearm plasma flow (ml/min per 100 ml), NE
a
 is arterial plasma 
norepinephrine (nmol/L), NEy is venous plasma norepinephrine (nmol/L) and f is the 
fractional extraction = ( 3 H-NE
a
 -
 3H-NEV) / 3 H-NE a . The forearm plasma flow was 
calculated from the forearm blood flow and hematocrit. The clearance of NE from the 
forearm (ml/min per 100 ml) was calculated by multiplying the forearm plasma flow by 
the fractional extraction. The clearance of EPI from arterial plasma and the estimated 
rate of appearance of endogenous EPI into arterial plasma were calculated according to 
similar formulas. 
Results are expressed as mean ± SEM unless indicated otherwise. To test the effects of 
atenolol on baseline plasma kinetic variables, the Wilcoxon signed rank test was 
performed. This test was also used to test for the effects of LBNP and to compare the 
responses to LBNP before and during atenolol. A P-value of less than 0.05 (two-sided) 
was considered to be significant. 
Results 
Haemodynamic data 
After treatment with atenolol, systolic (SBP) and diastolic (DBP) blood pressure 
decreased significantly from 166 ± 4/89 ± 2 to 146 ± 4/75 ± 3 (P<0.05). Heart rate 
decreased from 60 ± 3 to 49 ± 2 (P<0.05). Forearm blood flow (FBF) and forearm 
vascular resistance (FVR) were not significantly affected by atenolol (1.91 ± 0.25 and 
1.72 ± 0.22 ml/min/100 ml and 81.4 ± 8.7 and 80.9 ± 9.4 AU respectively). 
LBNP at -15 mmHg had no effects on SBP, DBP and HR and this was the case both 
before and after atenolol. The increase in FVR at LBNP of-15 mmHg was not affected 
by atenolol. The blood pressure responses to LBNP at -40 mmHg were not altered, 
while the increase in HR was impaired (+8 ± 1 before and +5 ± 1 beats/minute after 
atenolol (P<0.05). The increase in FVR to LBNP at -40 mmHg was similar before and 
after atenolol. 
Plasma epinephrine kinetics 
After treatment with atenolol, the subjects had an approximately 35% lower basal arterial 
plasma EPI than before treatment (Table 1). This decrease in arterial plasma EPI was 
accompanied by a significant decrease in total body EPI spillover (Fig 1), while total 
body clearance and forearm clearance of EPI were not altered by atenolol (Table 1). In 
the control group we could not demonstrate a decrease in basal arterial plasma EPI when 
the subjects were restudied after 3 months. 
The responses of total body EPI spillover and clearance and of forearm EPI clearance to 
LBNP at -15 mmHg were not affected by atenolol. However, atenolol did attenuate the 
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increase in total body EPI spillover to LBNP at -40 mmHg (+0.77 ± 0.26 nmol/min 
before and 0.21 ± 0.04 nmol/min after atenolol (P<0.05) (Fig 2), whereas the responses 
of total body and forearm clearance rates were not affected by atenolol. The attenuated 
response in total body EPI spillover to LBNP at -40 mmHg after atenolol was reflected 
by an attenuated increase in arterial plasma EPI concentration to LBNP at -40 mmHg 
after atenolol although the difference was not significant (+0.52 ± 0.14 nmol/L before 
and +0.23 ± 0.03 nmol/L after atenolol, P=0.11). 
Plasma norepinephrine kinetics 
Baseline arterial plasma NE, total body NE spillover and total body NE clearance were 
not affected by treatment with atenolol. Also forearm NE spillover (Fig 1) and forearm 
NE clearance were not changed by atenolol (Table 1). The responses of forearm NE 
spillover and total body NE spillover as well as forearm clearance and total body clearance 
of NE to LBNP at -15 mmHg and at -40 mmHg were not altered by atenolol. 
Table 1. Plasma levels and kinetics of epinephrine and norepinephrine before and after treatment with 
atenolol. 
Before atenolol After atenolol 
Epinephrine 
Arterial plasma level (nmol/L) 0.23 ± 0.02 * 0.17 ± 0.01 
Total body spillover (nmol/min) 0.50 ± 0.05 * 0.35 ± 0.04 
Total body clearance (L/min) 2.20 ± 0.11 2.10 ± 0.12 
Forearm clearance (ml/lOOml/min) 0.83 ± 0.09 0.69 ± 0.07 
Norepinephrine 
Arterial plasma level (nmol/L) 0.98 ±0.10 0.92 ± 0.09 
Total body spillover (nmol/min) 1.82 ±0.16 1.75 ± 0.26 
Total body clearance (L/min) 1.95*0.13 1.85 ±0.11 
Forearm spillover (pmol/100ml/min) 0.87 ± 0.09 0.82 ±0.10 
Forearm clearance (ml/100ml/min) 0.78 ± 0.08 0.63 ± 0.06 
* P<0.05; Mean ± SEM are given 
β l-adrenoceptor antagonism and sympathoadrenal activity | 101 
Ξ 1 .501 
о 
E 
Ol 
> 
О 
α 
и 
Ξ 
ш 
>. 
•о 
о 
1.00-
0.50 
Ъ 0.00 
>2.00 
• 1.50 
1.00 
0.50 
0.00 
'с 
1 
ε 
о 
о 
Τ ­
Ο 
E 
Ol 
> 
О 
α. 
(А 
α 
Figure 1. Individual values of total body epinephrine (EPI) spillover (nmol/min) 
and forearm norepinephrine (NE) spillover before (B) and after (A) three months 
treatment with atenolol. * P<0.05 
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Figure 2. The responses of total body spillover of epinephrine (TBSE, nmol/min) 
and norepinephrine (TBSNE, nmol/min), forearm spillover of norepinephrine 
(FASNE, pmol/100ml/min), total body clearance of epinephrine (TBCLE, l/min) 
and norepinephrine (TBCNE, l/min) and forearm clearance of norepinephrine 
(FACNE, ml/100 ml forearm volume/min) to lower body negative pressure at -40 
mmHg before (black bars) and after (open bars) chronic treatment with atenolol. 
Mean ± SEM are given. 
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Discussion 
The principal finding of the present study is that chronic treatment with the β]-adreno­
ceptor blocking agent atenolol decreases total body EPI spillover, while it does not affect 
total body NE spillover. The plasma clearance rates of both NE and EPI are not decreased 
by atenolol. Since the total body EPI spillover reflects the release of EPI from the adrenal 
medulla, these data imply that chronic β ι-adrenergic blockade attenuates adrenomedul-
lary EPI release, but does not affect sympathoneural activity. In addition, EPI and NE 
spillover and clearance during sympathoadrenal stimulation by LBNP at -15 mmHg is 
not affected by atenolol, whereas the adrenomedullary secretion of EPI during LBNP 
at -40 mmHg is attenuated. So, chronic administration of atenolol does reduce baseline 
as well as stimulated release of EPI from the adrenal medulla in patients with primary 
hypertension. 
Several mechanisms should be discussed to explain the differentiated response of the 
sympathetic nervous system during longterm treatment with atenolol, leading to dimin­
ished EPI release from the adrenal medulla with a concomitant unchanged NE spillover. 
First, diminished adrenomedullary EPI release might be a direct effect of blockade of 
facilitatory β]-adrenoceptors on the adrenomedullary chromaffin cell membranes, as 
was shown in rat adrenal medulla cells in vitro [9]. In contrast, the presynaptic 
ß-adrenoceptors at the sympathetic nerve endings appear to be of the ß2-subtype and 
therefore the NE spillover is not expected to decrease during atenolol administration 
[2]. Second, a decreased circulating EPI concentration might result from a decreased 
sympathetic impulse nerve traffic to the adrenal medulla. This however, would not be 
consistent with the unchanged NE spillover, unless atenolol would affect exclusively the 
sympathetic outflow to the adrenal medulla. Finally, it could be possible that the 
decreased arterial plasma EPI levels and the decreased EPI release from the adrenal 
medulla could be a time effect, or be just the expression of an attenuated defense reaction 
to the stress of the experimental procedure. However, the plasma EPI levels in the control 
group were not reduced at the second study after three months, although this also 
involved an arterial cannulation. Although we have no kinetic data in this control group, 
it is highly unlikely that the reduced arterial plasma EPI level after three months is 
aspecific and not related to the atenolol treatment. 
Data on catecholamine spillover and clearance rates during chronic ß^adrenergic 
blockade in human hypertension are not available from previous studies. EPI kinetics 
during ß-blockade in humans has never been studied at all. NE kinetics were studied 
after acute administration of β ι-selective [5] and non-selective ß-blockers [4] or chronic 
administration of non-selective ß-blockers [10]. These data are hard to compare with 
our data on chronic ßj-blockade, since acute administration of ß-blocking agents or use 
of non-selective ß-blockade show important differences with regard to sympathetic 
nervous activity, organ blood flow or ß-receptor occupation, thus influencing catecho-
lamine kinetics. 
β l-adrenoceptor antagonism and sympathoadrenal activity | 103 
Acute administration of a selective or non-selective ß-Ыоскег causes a reduction of 
cardiac output and a baroreflex-mediated increase in total peripheral resistance, whereas 
peripheral resistance generally returns to the pretreatment level during chronic ß-block-
ade [1]. The increased intraneuronally measured muscle sympathetic activity after a 
bolus injection with a ßj-blocker is restored during chronic ß]-blockade [11,12] 
Moreover, baroreflex sensitivity is increased in chronic ß-blocker treatment but not in 
acute administration [13,14]. In addition to baroreceptor-mediated effects on sympa-
thetic outflow, catecholamine kinetics are influenced at the synaptic level by local blood 
flow, since catecholamine clearance is blood-flow-dependent [5]. A non-selective ß-
blocker has different sites of actions than a ßj-selective blocker, which may affect 
catecholamine kinetics as well. NE release from the sympathetic nerve terminals is 
modulated by presynaptic ß2-adrenoceptors, which can be blocked by a non-selective 
blocker, but probably not by β [-selective blockers. Also, NE clearance is more ß2-ad-
renoceptor dependent than ßj-adrenoceptor dependent, since in rats NE clearance is 
decreased by propranolol but not by atenolol [15]. In a study with intra-arterial 
ß-blocker infusions, thus preventing systemic hemodynamic effects, both metoprolol 
and propranolol decreased NE spillover [5]. There are however no inhibitory β!-adreno­
ceptors on sympathetic nerve terminals. Alternatively it remains possible that the high 
local dose of metoprolol that was used was not β ι-selective anymore. 
The EPI spillover response to LBNP at -40 mmHg was attenuated, though the NE 
spillover response was not changed. The neurohumoral responses to sympathoadrenal 
stimulation during β ι -adrenoceptor blockade have never been assessed in previous 
studies. Our data on NE kinetics confirm and extend earlier observations using mi-
croneurography that demonstrated that responses of sympathetic nerve traffic to graded 
LBNP were not attenuated by propranolol [16]. 
In conclusion, the results of this study suggest that treatment of patients with primary 
hypertension with the ßi-adrenoceptor blocker atenolol inhibits the basal and stimulated 
adrenomedullary secretion of EPI, while it does not affect the biochemical indices of 
sympathoneural activity. It remains speculative whether this selective effect of atenolol 
on EPI secretion contributes to its hypotensive action and to its cardioprotective effects 
on the long term. 
References 
1. Man in t Veld A| , Schalekamp MADH. Effects of 10 different ß-adrenoceptor antagonists on 
hemodynamics, plasma renin activity, and plasma norepinephrine in hypertension: the key role of 
vascular resistance changes in relation to partial agonist activity. J Cardio vase Pharmacol 1983;5(suppl 
1):S30-S45. 
2. Langer SZ, Caverò I, Massingham R. Recent developments in noradrenergic neurotransmission and 
its relevance to the mechanism of action of certain antihypertensive drugs. Hypertension 1980;2:372-
382. 
104 I Chapter 7 
3. Esler M, Leonard P, O'Dea K, Jackman G, Jennings G, Korner P. Biochemical quantification of 
sympathetic nervous activity in humans using radiotracer methodology, fallibility of plasma norad-
renaline measurements. J Cardiovasc Phatmacol 1982;4.S152-S157. 
4. Rosen SG, Supiano MA, Perry TJ, Linares OA, Hogikyan RV, Smith MJ, Halter JB ß-adrcnergic 
blockade decreases norepinephrine release in humans. Am J Physiol 1990;258:E999-D1005-
5. Chang PC, Grossman E, Kopin IJ, Goldstein DS On the existence of functional beta-adrenoceptors 
on vascular sympathetic nerve endings in the human forearm. J Hypertension 1994,12 681-690. 
6. Brakkee AJM, Vendrik AJH. Strain gauge plethysmogaphy, theoretical and practical notes on a new 
design J Appi Physiol 1966;21:701-704 
7. Lenders JMW, Janssen GJ, Smits P, Thien Th. Role of the wrist cuff in forearm plethysmography. 
Clin Sci 1991,80:413-417. 
8. Willemsen JJ, Ross HA, Jacobs MC, Lenders JWM, Thien Th, Swinkels LMJW, Benraad TJ. Highly 
sensitive and specific HPLC with fluorometnc detection for determination of plasma epinephrine 
and norepinephrine applied to kinetic studies in humans Clin Chem 1995,41· 1455-1460 
9. Gutman Y, Boonyavroj Ρ Activation of adrenal medulla adenylate cyclase and catecholamine 
secretion. Naunyn-Schmiedeberg's Arch Pharmacol 1979,307-39-44. 
10. Esler M, Jackman G, Leonard P, Skews H, A Bobik, G Jennings. Effect of propranolol on 
noradrenaline kinetics in patients with essential hypertension Br J Clin Pharmac 1981; 12-375-380. 
11. Sundlof G, Wallin BG, Stromgren E, Nerhed С Acute effects of metoprolol on muscle sympathetic 
activity in hypertensive humans. Hypertension 1983;5 749-756 
12 Wallin BG, Sundlof G, Stromgren E, Abeg H Sympathetic outflow to muscles during treatment of 
hypertension with metoprolol. Hypertension 1984;6:557-562. 
13. Parati G, Mutti E, Frattola A, Castighoni P, di Rienzo M, Mancia G ß-Adrenergic blocking treatment 
and 24-hour baroreflex sensitivity in essential hypertensive patients. Hypertension 1994;23 .992-996. 
14. Watson RDS, Stallard TS, Littler WA Effects of beta-adrenoceptor antagonists on sinoaortic 
baroreflex sensitivity and blood pressure in hypertensive man Clin Sci 1979,57.241-247. 
15. Kent Keeton T, Biediger AM. Propranolol and atenolol inhibit norepinephrine spillover rate into 
plasma in conscious spontaneously hypertensive rats. Naunyn-Schmiedeberg's Arch Pharmacol 
1991:344-47-55. 
16. Jacobsen TN, Converse RL, Victor RG Contrasting effects of propranolol on sympathetic nerve 
activity and vascular resistance during orthostatic stress. Circulation 1992;85 1072-1076. 
General discussion | 105 
Chapter 8 
General discussion and conclusions 
Over the past decades a large amount of research has been carried out to clarify the role 
of the sympathetic nervous system in the pathogenesis of primary hypertension. An 
increased sympathetic reactivity or responsiveness to a variety of stimuli was presumed 
to contribute to the pathophysiology of hypertension. However, it appeared extremely 
difficult to measure sympathetic nervous system activity accurately because the system 
has a widespread distribution with a non-uniform and a highly variable outflow. In 
addition, it is affected by numerous circulating and local interfering compounds at the 
site of neurotransmission in the target organ or at a central level. 
In the studies described in this thesis we assessed sympathetic nervous system activity 
by using the isotope dilution technique. This means that steady state infusions with 
tracer-labeled catecholamines are required. Plasma concentrations of epinephrine (EPI), 
norepinephrine (NE) and the radiolabeled NE and EPI concentrations have to be 
measured by an assay technique that is sensitive and specific enough to measure 
simultaneously the very low plasma concentrations of these compounds. This enables 
the calculation of spillover and clearance rates of the endogenous catecholamines. The 
catecholamine kinetics can be calculated for the whole body without taking into account 
the contribution of specific organs. From arterial and venous plasma samples and the 
blood flow through a specific organ like for instance the human forearm, one can 
calculate the local kinetics of the forearm i.e. the skeletal muscles. The EPI secretion by 
the adrenal medulla can be assessed by calculation of the total body EPI spillover. 
In chapter 2 we describe a modification of a specific and sensitive HPLC-method with 
fluorometric detection for the analysis of plasma concentrations of endogenous EPI and 
NE and of tritiated EPI and NE. The detection limits for EPI and NE are 3.2 and 2.2 
pmol/L respectively. The detection limit of 3H-NE and 3H-EPI is 6 dpm. Particularly 
the sensitivity for EPI is considerably higher than that can be attained with other 
analytical methods like HPLC with electrochemical detection. 
Sympathetic and adrenomedullary activity have to be assessed not only in the basal state 
but also during sympathetic stimulation. In the present studies we used the lower body 
negative pressure (LBNP) technique to induce sympathetic stimulation. The applied 
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negative pressure to the lower body evokes a shift of blood from the upper to the lower 
part of the body. The decreased venous return and the subsequent decreased cardiac 
filling pressures will unload the cardiopulmonary and/or arterial baroreceptors, depend-
ing on the intensity of the applied negative pressure. The ensuing increase in sympathetic 
activity will lead to vasoconstriction, thereby preserving the arterial blood pressure level. 
At a LBNP intensity of less than -20 mmHg, cardiopulmonary baroreceptors will be 
unloaded selectively whereas at a LBNP intensity of more than -20 mmHg, both 
cardiopulmonary and arterial baroreceptors will be unloaded. Application of different 
levels of LBNP makes it possible to examine selectively the effects of unloading of 
cardiopulmonary baroreceptors. 
In chapter 3 we describe the effects of LBNP on catecholamine kinetics in normotensive 
subjects. Cardiopulmonary baroreceptor unloading was achieved by non-hypotensive 
LBNP at -15 mmHg, and combined arterial and cardiopulmonary baroreceptor deacti-
vation was attained by hypotensive LBNP at -40 mmHg. Forearm NE spillover and 
total body EPI spillover increased during LBNP at -15 mmHg but total body NE 
spillover did not change. During LBNP at -40 mmHg forearm NE spillover, total body 
EPI spillover, and total body NE spillover increased. Clearances of NE and EPI were 
unchanged during LBNP at -15 mmHg but decreased during LBNP at -40 mmHg. 
Apparently, selective deactivation of the cardiopulmonary baroreceptors during non-
hypotensive LBNP increases sympathoneural activity to forearm skeletal muscles and 
increases adrenomedullary activity without a generalized increase in sympathoneural 
activity. Simultaneous deactivation of cardiopulmonary and arterial baroreceptors dur-
ing hypotensive LBNP elicited a generalized increase in sympathoneural activity, 
concomitant with a further increase in adrenomedullary activity. Our data indicate that 
forearm sympathoneural and adrenomedullary outflow are increased during decreases 
in cardiac filling pressures, with augmented and more generalized responses to systemic 
hypotension. 
During the pilot studies it appeared that several subjects were prone to vasodepressor 
syncope during prolonged hypotensive LBNP at -40 mmHg. The neurohumoral 
regulation of such an unexpected event is poorly understood because of its suddenness. 
Chapter 4 deals with the sympathoneural and adrenomedullary regulation in the time 
period that precedes a vasodepressor syncope. Healthy normotensive subjects underwent 
30 minutes of low reduction of cardiac filling during non-hypotensive LBNP at -15 
mmHg, followed by 30 minutes of more pronounced reduction of cardiac filling during 
hypotensive LBNP at -40 mmHg. Non-hypotensive LBNP at -15 mmHg was well 
tolerated by all participants without any symptom, whereas hypotensive LBNP at -40 
mmHg provoked a presyncope in 11 of the 26 subjects, with sudden hypotension, nausea 
and dizziness. In the latter group, forearm NE spillover failed to increase during LBNP 
at -15 mmHg, whereas the arterial plasma EPI response to LBNP at -15 mmHg was 
exaggerated. These findings suggest that a neuroendocrine pattern of decreased sym-
pathoneural activity and increased adrenomedullary activity precedes a vasodepressor 
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syncope. The cause of the exaggerated plasma EPI responses has to be elucidated but is 
probably of central origin. A causal relationship between the enhanced adrenomedullary 
activity and the subsequent syncope has to be examined by further research. 
In chapter 5 we describe the NE and EPI kinetics in 47 patients with primary 
hypertension and 43 normotensive control subjects, at rest and during LBNP at -15 and 
-40 mmHg. Hypertensives showed a slightly higher basal arterial EPI concentration than 
the normotensive controls. We could demonstrate that the increased circulating arterial 
EPI concentration is due to an increased adrenomedullary release of EPI and not to 
diminished clearance. Venous and arterial NE concentrations at rest, as well as NE 
spillover in the forearm and in the whole body were similar in hypertensives and 
normotensives. The noradrenergic and adrenergic responses to cardiopulmonary and 
arterial baroreceptor unloading were similar in the two groups. These results confirm 
and extend earlier reports on increased plasma EPI concentrations in hypertension. 
Increased circulating EPI concentrations in hypertensives provide support for the "EPI 
hypothesis". In the EPI hypothesis it has been suggested that circulating EPI may induce 
hypertension by stimulating prejunctional ß2-adrenoceptors and thus facilitating NE 
release from the sympathetic nerve terminals. On the longterm, this could lead to 
hypertension by increasing peripheral vascular resistance. Our data could provide some 
support for the EPI hypothesis despite the absence of increased NE spillovers in the 
hypertensives. It should be kept in mind that the absence of an increased NE spillover 
into the circulation does not prove that there is no increase in neuronal NE release. 
Two subgroups of hypertensive patients were studied before and after treatment with 
an aj-adrenoceptor antagonist or a β [-adrenoceptor antagonist for three months. These 
results are described in chapter 6 and 7 respectively. Eleven patients were treated with 
the selective OC]-blocker doxazosin. Doxazosin lowers blood pressure by reducing pe­
ripheral vascular resistance without concomitant tachycardia. The absence of reflex 
tachycardia seems paradoxical to the vasodilation-induced sympathetic activation. Our 
catecholamine kinetic studies demonstrated that arterial plasma NE increased as a 
consequence of increased NE spillover in the forearm and in the whole body. In contrast, 
arterial plasma EPI concentrations and EPI spillovers were not affected by doxazosin. 
Apparently, the vasodilation induced a reflex-mediated increase in sympathoneural 
outflow but not in adrenomedullary activity. The absence of tachycardia might be 
explained by the absence of an adrenomedullary response. It remains to be seen whether 
the increased plasma levels of NE that are found during chronic OCi-adrenoceptor 
blockade are innocent on the longterm. 
Nineteen patients were treated with the ßi-adrenoceptor antagonist atenolol. Atenolol 
did not affect total body and forearm spillover rates of NE, whereas arterial plasma EPI 
levels and total body EPI spillover rate were reduced. The decreased circulating EPI 
concentrations might result in attenuation of presynaptic ß2-adrenergic facilitation of 
neuronal NE release. It remains speculative whether this selective effect of atenolol on 
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EPI secretion contributes to its hypotensive action and to its cardioprotective effects on 
the longterm. 
Conclusions 
1. The excellent sensitivity and specificity of high performance liquid chromatography 
with fluorometric detection for the measurement of low physiological concentrations 
of norepinephrine and epinephrine, combined with simultaneous measurement of 
tritiated norepinephrine and epinephrine, permits reliable assessment of norepi­
nephrine and epinephrine kinetics in clinical studies. 
2. Cardiopulmonary baroreceptor deactivation elicits a selective increase in sympathetic 
outflow to skeletal muscles and adrenal medulla. 
3. Arterial baroreceptor deactivation in combination with cardiopulmonary barorecep­
tor deactivation evokes a diffuse increase in sympathetic outflow to the whole body. 
4. Normotensive subjects, prone to vasodepressor syncope during lower body negative 
pressure at -40 mmHg, show adrenomedullary activation and sympathoneural 
inhibition in response to decreased cardiac filling. This abnormal neurohumoral 
regulation can already be demonstrated in the absence of any symptoms indicative 
of an imminent syncope. 
5. Patients with mild primary hypertension have increased arterial plasma epinephrine 
levels and this can be ascribed to an increased adrenomedullary release and not to 
diminished plasma clearance of epinephrine. 
6. Normal plasma norepinephrine concentrations in patients with mild hypertension 
are due to normal spillover and normal clearance of norepinephrine, suggesting 
normal sympathoneural activity in mild primary hypertension. 
7. During treatment with the OL\-selective adrenoceptor antagonist doxazosin, sym­
pathoneural outflow is increased without a concomitant adrenomedullary activation, 
indicating vasodilation-induced and baroreflex-mediated sympathoneural activa­
tion. The absence of adrenomedullary activation might explain the paradoxal absence 
of reflex tachycardia. 
8. The selective β ι -adrenoceptor antagonist atenolol has no effect on the plasma nor­
epinephrine concentration or on total body spillover of norepinephrine, but it 
reduces plasma epinephrine levels by reducing total body epinephrine spillover. It is 
unclear whether this selective effect of atenolol on epinephrine secretion contributes 
to its hypotensive action and to its cardioprotective effects on the longterm. 
Chapter 9 
Algemene discussie en conclusies 
De laatste decennia is er veel onderzoek verricht naar de rol van het sympatisch 
zenuwstelsel in de pathogenese van verhoogde bloeddruk ofwel primaire hypertensie. 
Het sympatisch zenuwstelsel speelt een belangrijke rol bij de regulatie van de bloeddruk 
en het is dus niet verwonderlijk dat men veronderstelde dat een verhoogde activiteit of 
reactiviteit van het sympatisch zenuwstelsel zou kunnen bijdragen aan het ontstaan of 
zelfs de oorzaak zou kunnen zijn van een verhoogde bloeddruk. In de loop der jaren zijn 
er inderdaad nog al wat aanwijzingen gevonden dat er mogelijk iets mis is met de functie 
van het sympatisch zenuwstelsel, met name bij jonge patiënten met een verhoogde 
bloeddruk. Er zijn twee belangrijke redenen waarom het nog steeds onduidelijk is of een 
abnormale sympaticusactiviteit wel een directe oorzaak is van een verhoogde bloeddruk. 
In de eerste plaats is het praktisch onmogelijk om bij de mens een oorzaak-gevolg relatie 
onomstotelijk vast te stellen. Het is niet uitgesloten dat een abnormale sympaticus-ac-
tiviteit niet de oorzaak maar een gevolg is van de verhoogde bloeddruk. In de tweede 
plaats is de activiteit van het sympatische zenuwstelsel buitengewoon variabel waarbij er 
bovendien geen gelijke activiteitsverdeling is over de verschillende organen. Sympa-
ticusactiviteit wordt gegenereerd in het centrale zenuwstelsel en de meeste beschikbare 
meet-methoden richten zich juist op de activiteit in het perifere deel van het zenuwstel-
sel. Het is derhalve moeilijk om een representatieve maat te vinden voor de globale 
activiteit van het systeem. 
In dit proefschrift staat één biochemische onderzoeksmethode om sympaticusactiviteit 
te meten centraal, namelijk de zogenaamde isotoopdilutie methode. Bij deze techniek 
wordt gebruik gemaakt van 'steady-state' infusies van radioactief-gemerkte catecholami-
nes. Met behulp van een gevoelige bepalingsmethode kunnen zowel endogene als 
radioactief-gemerkte catecholamines gemeten worden, waarna het mogelijk is om zowel 
de klaring als de spillover van catecholamines in de bloedbaan te berekenen. Zo kunnen 
als kinetische parameters niet alleen de totale lichaamsklaring en spillover berekend 
worden, maar is het ook mogelijk deze parameters te berekenen voor een specifiek 
orgaan, indien zowel arteriële als veneuze bloedmonsters afgenomen worden en de 
doorbloeding van dit orgaan gemeten wordt. In dit proefschrift zijn deze parameters 
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gemeten in het onderarmsvaatbed. Als radioactief-gemerkte catecholamines zijn ^ - n o r -
adrenaline en 3H-adrenaline gebruikt. De noradrenaline-kinetiek geeft specifieke infor-
matie over de activiteit van het sympatische zenuwstelsel terwijl de adrenaline-kinetiek 
specifieke informatie geeft over de activiteit van het bijniermerg. 
Om niet alleen de basale activiteit, maar ook de reactiviteit van het sympatisch zenuwstel-
sel inclusief bijniermerg te kunnen meten moet het sympatische zenuwstelsel ge-
stimuleerd worden. In het onderzoek dat in dit proefschrift beschreven is hebben wij als 
stimulus van het sympatische zenuwstelsel gebruik gemaakt van de LBNP ("lower body 
negative pressure")-methode. Hierbij wordt een negatieve druk aangebracht rond het 
onderlichaam, waardoor er een redistributie van het bloed plaatsvindt: bloed verplaatst 
zich van de bovenste naar de onderste lichaamshelft. Door de verminderde veneuze 
terugstroom van bloed naar het hart zullen, afhankelijk van de intensiteit van de 
negatieve druk, de cardiopulmonale of cardiopulmonale en arterièle baroreceptoren 
gedeactiveerd worden. Dit leidt tot een toename van sympaticusactiviteit en de hierdoor 
teweeggebrachte vasoconstrictie zal helpen de bloeddruk te stabiliseren. Bij een negatieve 
druk van lager dan -20 mmHg zullen specifiek de cardiopulmonale baroreceptoren 
gedeactiveerd worden, terwijl bij een negatieve druk van hoger dan -20 mmHg zowel 
cardiopulmonale als arteriole baroreceptoren gedeactiveerd worden. Toepassing van 
LBNP met verschillende graden van intensiteit maakt het dus mogelijk om selectief het 
effect van deactivatie van cardiopulmonale baroreceptoren te onderzoeken. 
In hoofdstuk 2 beschrijven wij een modificatie van een specifieke en sensitieve HPLC-
bepaling met fluorimetrische detectie om lage plasma concentraties van endogene en 
radioactief-gemerkte catecholamines gelijktijdig te kunnen meten. De detectiegrens 
voor endogeen (ongemerkt) noradrenaline en adrenaline is respectievelijk 2.2 en 3.2 
pmol/L. In het bijzonder voor adrenaline is dit een beduidend betere gevoeligheid dan 
die bereikt kan worden met HPLC met electrochemische detectie. De detectiegrens van 
radioactief-gemerkte plasma catecholamines is 6 dpm. Deze bepalingsmethodiek is dus 
bijzonder geschikt voor onderzoek naar de kinetiek van catecholamines. 
In hoofdstuk 3 worden de effecten beschreven van LBNP op de catecholaminekinetiek 
bij normotensieve personen. In het bijzonder werd onderzocht of de veranderingen in 
catecholaminekinetiek door LBNP afhankelijk zijn van de intensiteit van de toegepaste 
stimulus. Selectieve deactivatie van cardiopulmonale baroreceptoren door middel van 
LBNP (-15 mmHg) veroorzaakte een toename van de noradrenaline spillover in de 
onderarm met ongeveer 50%, zonder toename van de totale lichaamsspillover van 
noradrenaline. Kennelijk leidt selectieve deactivatie van de cardiopulmonale barorecep-
toren tot een selectieve sympaticusactivatie van de skeletspieren in de onderarm, zonder 
gegeneraliseerde toename van sympaticusactiviteit. Blijkens een toename van de totale 
lichaamsspillover van adrenaline van ongeveer 30% neemt hierbij ook selectief de 
secretie van adrenaline door de bijnieren toe. Effecten op de klaring van beide catechol-
amines werden niet waargenomen tijdens deze LBNP fase. Gecombineerde deactivatie 
van de cardiopulmonale en arterièle baroreceptoren tijdens LBNP van -40 mmHg leidde 
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wel tot een toename van de totale lichaamsspillover van noradrenaline met een verdere 
toename van de lokale noradrenaline spillover in de onderarm. Ook de totale lichaams-
spillover van adrenaline nam verder toe terwijl de klaringen van adrenaline en noradre-
naline daalden bij deze intensiteit van LBNP. Deze gegevens wijzen er op dat de arteriële 
baroreceptoren even belangrijk zijn voor de baroreflexcontrole van skelet-spiercirculatie 
als de cardiopulmonale baroreceptoren. 
Tijdens de onderzoeken waarbij LBNP werd toegepast gedurende 30 minuten hadden 
sommige gezonde normotensieve personen een neiging tot collaberen tijdens LBNP van 
-40 mmHg. Deze collapsneiging had een duidelijk vasovagaal karakter: duizeligheid, 
misselijkheid, lage bloeddruk en polsfrequentievertraging. In hoofdstuk 4 worden de 
personen die wel en die geen collapsneiging hadden met elkaar vergeleken. Onze 
aandacht ging speciaal uit naar de catecholaminekinetiek tijdens de fase van LBNP van 
-15 mmHg. Bij deze lichte intensiteit van de LBNP had geen enkele proefpersoon 
klachten en werden ook geen afwijkingen in bloeddruk of hartfrequentie vastgesteld. 
Toch bleek dat de personen die later bijna collabeerden tijdens LBNP van -40 mmHg 
ook al afwijkingen vertoonden in de catecholaminekinetiek tijdens LBNP van -15 
mmHg. Zo hadden degenen die bijna collabeerden een sterkere stijging van het plasma 
adrenaline tijdens LBNP van -15 mmHg dan diegenen die niet collabeerden. Het plasma 
noradrenaline en de lokale noradrenaline spillover in de onderarm stegen daarentegen 
bijna niet bij diegenen die later bijna collabeerden. Dit zou kunnen betekenen dat, 
voorafgaand aan een vasovagale collaps, de combinatie van een toegenomen ad-
renomedullaire activiteit en een verminderde sympaticusactiviteit mogelijk een rol speelt 
bij het ontstaan van deze reactie. Het is goed mogelijk dat de toegenomen adrenomedul-
laire activiteit een centrale oorzaak heeft. Verder onderzoek moet duidelijk maken of er 
inderdaad sprake is van een causale relatie tussen de toegenomen adrenomedullaire 
activiteit en het ontstaan van de collaps. 
In hoofdstuk 5 worden de resultaten besproken van een onderzoek bij een grote groep 
patiënten met een lichte primaire hypertensie. Deze patiënten hadden basaal een hogere 
plasma adrenaline concentratie dan de normotensieve controlegroep. Dit bleek te 
berusten op een toegenomen secretie van adrenaline door de bijnieren en niet op een 
verminderde klaring van adrenaline. Verhoogde plasma adrenaline concentraties zijn al 
eerder beschreven en dit gegeven zou kunnen passen bij de door anderen geformuleerde 
"adrenaline-hypothese". Deze hypothese veronderstelt dat een, al dan niet intermitte-
rend, verhoogde plasma adrenaline concentratie leidt tot stimulering van presynaptische 
ß2-adrenoreceptoren waardoor er een facilitatie optreedt van de neuronale noradrenaline 
afgifte met als uiteindelijk resultaat een toename van vasoconstrictie. Het circulerend 
adrenaline wordt bovendien ook opgenomen door het terminale deel van de sympatische 
neuronen om vervolgens weer samen met noradrenaline afgegeven te worden in de 
synaps waar opnieuw presynaptische ß2-adrenoreceptor stimulatie plaatsvindt. Deze 
vicieuze cirkel zou volgens deze hypothese dus leiden tot hypertensie. Alhoewel er sterke 
aanwijzingen zijn voor bepaalde delen van deze hypothese is het bewijs bij de mens nog 
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niet geleverd. De gevonden verhoogde plasma adrenaline concentraties bij de patiënten 
met hypertensie zouden deze hypothese echter kunnen steunen. Wij vonden echter geen 
belangrijke verschillen in noradrenalinekinetiek tussen beide groepen hetgeen suggereert 
dat er géén sprake is van een gegeneraliseerde of lokaal verhoogde sympaticusactiviteit 
in de door ons bestudeerde patiënten met hypertensie. Het ontbreken van een toename 
van de noradrenaline spillover in de onderarm ondergraaft de "adrenaline-hypothese" 
overigens niet, omdat de noradrenaline spillover in het bloed niet gelijk is aan de 
neuronale noradrenaline afgifte in de synaps. 
In hoofdstuk 6 beschrijven wij de effecten van 3 maanden behandeling van een kleine 
groep hypertensiepatiënten met de selectieve (Xi-adrenoreceptor antagonist doxazosine 
met betrekking tot de catecholaminekinetiek. Doxazosine verlaagde, zoals verwacht, de 
bloeddruk zonder dat er een reflectoire tachycardie werd waargenomen. Toch moet er 
sprake zijn van activatie van het sympatisch zenuwstelsel tijdens deze therapie, omdat 
na 3 maanden behandeling de plasma noradrenaline concentratie was toegenomen, 
hetgeen bleek te berusten op een toename van de noradrenaline spillover in zowel 
onderarm als in het gehele lichaam en niet op een verminderde klaring. Er was echter 
géén toename van de adrenomedullaire activiteit, hetgeen mogelijk verklaart waarom er 
geen reflectoire tachycardie werd waargenomen. Blijkbaar leidt vasodilatatie door een 
Oti-adrenoreceptor antagonist tot een selectieve reflectoire toename van sympaticusac-
tiviteit maar niet van adrenomedullaire activiteit. Het is de vraag of de toegenomen 
plasma noradrenaline concentraties tijdens behandeling met een OCi-adrenoreceptor 
antagonist op de lange termijn onschadelijk zijn. 
Een andere groep hypertensiepatiënten werd gedurende 3 maanden behandeld met de 
selectieve ßj-adrenoreceptor antagonist atenolol. In tegenstelling tot de behandeling met 
de (Xi-adrenoreceptor antagonist doxazosine werd geen effect van atenolol waargeno-
men op de totale lichaamsspillover en onderarmsspillover van noradrenaline. Daaren-
tegen bleek de plasma adrenaline concentratie gedaald, hetgeen bleek te berusten op een 
gedaalde adrenomedullaire secretie van adrenaline. Het is de vraag of dit selectieve effect 
van atenolol op de adrenalinesecretie bijdraagt aan het hypotensieve effect van deze 
ßi-blokker en aan het cardioprotectieve effect op de lange termijn. 
Conclusies 
1. De hoge sensitiviteit en specificiteit van de HPLC met fluorimetrische detectie 
maken deze techniek uitermate geschikt voor het meten van lage fysiologische plasma 
concentraties van catecholamines. In combinatie met de mogelijkheid om simultaan 
radioactief-gemerkte catecholamines te meten schept dit de mogelijkheid om met 
name kinetiekstudies van adrenaline betrouwbaar uit te voeren. 
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2. Cardiopulmonale baroreceptordeactivatie leidt tot selectieve sympaticusactivatie van 
skeletspieren en bijniermerg. 
3. Simultane deactivatie van cardiopulmonale en arteriële baroreceptoren leidt tot een 
meer gegeneraliseerde sympaticusactivatie in het gehele lichaam. 
4. Gezonde normotensieve proefpersonen die neigen tot vasovagale reacties tonen reeds 
een abnormale neurohumorale regulatie vóórdat er enig symptoom van een collaps 
aanwezig is. De abnormaal sterke stijging van de plasma adrenaline concentratie in 
combinatie met een verminderde sympaticusactivatie speelt mogelijk een rol bij de 
totstandkoming van de vasovagale reactie. 
5. Patiënten met een primaire hypertensie hebben licht verhoogde plasma adrenaline 
concentraties en dit is het gevolg van een toegenomen adrenomedullaire adrenaline-
secretie en niet van een verminderde klaring van adrenaline. 
6. Patiënten met een primaire hypertensie hebben niet alleen normale plasma norad-
renaline concentraties maar ook de spillover en de klaring van noradrenaline zijn 
ongestoord. Dit suggereert dat er bij patiënten met een primaire hypertensie sprake 
is van een normale sympaticusactiviteit. 
7. Behandeling van hypertensiepatiënten met de CCi-adrenoreceptor antagonist doxa-
zosine leidt tot toename van de sympatoneuronale activiteit maar niet tot toename 
van de adrenomedullaire activiteit. Dit verklaart mogelijk het ontbreken van een 
reflectoire tachycardie tijdens langdurige behandeling met dit antihypertensivum. 
8. Behandeling van hypertensiepatiënten met de ßi-adrenoreceptor antagonist atenolol 
leidt niet tot verandering van sympatoneuronale activiteit maar wel tot afname van 
de adrenomedullaire activiteit. Het is onduidelijk of dit selectieve effect van atenolol 
op de secretie van adrenaline bijdraagt aan de hypotensieve werking en aan het 
cardioprotectieve effect op de lange termijn. 
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STELLINGEN 
behorende bij het proefschrift 
Catecholamine Kinetics 
in 
Primary Hypertension 

1. Catecholamine-kinetiek studies kunnen alleen betrouwbaar uitgevoerd worden met 
een zeer specifieke en sensitieve methode voor het bepalen van plasma concentraties 
van endogene en tritium-gelabelde catecholamines, (dit proefschrift) 
2. Een verhoogde secretie van adrenaline kan voorafgaan aan een vasovagale collaps 
en is niet alleen een gevolg hiervan. Mogelijk speelt adrenaline een rol in de 
Pathogenese van de vasovagale collaps, (dit proefschrift) 
3. Deactivatie van cardiopulmonale baroreceptoren veroorzaakt een toename van de 
adrenalinesecretie door de bijnieren, (dit proefschrift) 
4. Patiënten met een primaire hypertensic hebben een toegenomen adrenalinesecretie. 
(dit proefschrift) 
5. Behandeling van primaire hypertensie met de ai-adrenoceptor antagonist doxazo-
sine veroorzaakt een toename van sympaticusactiviteit. (dit proefschrift) 
6. Door behandeling van primaire hypertensie met de β ι-adrenoceptor antagonist 
atenolol neemt de secretie van adrenaline door de bijnieren af, hetgeen mogelijk 
bijdraagt aan het bloeddrukverlagend en cardioprotectieve effect van β ι-adrenocep­
tor antagonisten, (dit proefschrift) 
7. Alvorens de OCi-adrenoceptor antagonisten een vaste plaats toe te kennen bij de 
behandeling van benigne prostaathypertrofie, dient er meer bekend te zijn over hun 
effecten op de bloeddruk bij de overgang van liggen of zitten naar staan. 
8. In de wetenschap is het net zo belangrijk om een probleem te ontdekken, als om 
het op te lossen. 
9. Toen Jacobus I van Engeland in 1603 uitriep: roken is een gruwel voor het oog, 
een walging voor de neus, schadelijk voor het verstand en gevaarlijk voor hart en 
longen, kon hij nog niet weten dat rokers mogelijk minder kans hebben op het 
krijgen van de ziekte van Alzheimer. 
10. Gezien de toename van het aantal ouderen op de fiets en het verminderd waarnemen 
van hoge tonen bij het ouder worden, zouden racefietsen moeten worden uitgerust 
met een fietsbel met lage frequentie. 
11. Neem nu de wetenschap; die gaat alsmaar vooruit, zodat wij steeds verder achter­
blijven. Olivier В. Bommel 
12. Isotopenjaren tellen dubbel. 
Marie-Cécile Jacobs 10 december 1996 



